[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fRat-ZKvbcWNxPPSU0gZCVbfSPKPfJNO2km_bfpE098M":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Chinese PLA General Hospital",[4],537,false,155,13,1275044,111,269,[14,17,19,22,25,28,31,33],{"name":15,"count":16},"Sepsis",20,{"name":18,"count":9},"Hepatocellular Carcinoma",{"name":20,"count":21},"Gastric Cancer",12,{"name":23,"count":24},"Solid Tumor",9,{"name":26,"count":27},"Anxiety",8,{"name":29,"count":30},"Pancreatic Cancer",7,{"name":32,"count":30},"Depression",{"name":34,"count":30},"Lymphoma",[36,41,46,51,56,60,65,70,75,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02259556","CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas","2018-10","CART30",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04483076","Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer","2022-12","Chemotherapy drug",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05218889","Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","2024-12-16","surufatinib + camrelizumab + nab-paclitaxel + S-1",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06339216","A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.","2024-12-30","Adebrelimab+Apatinib+Paclitaxel for",{"nctId":57,"briefTitle":58,"date":54,"intervention":59},"NCT06572462","ATG Individualized Dosing Model in URD-PBSCT.","individualized ATG dosing strategy",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT06798376","Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer","2025-01-31","≤4 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05403242","RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2","2025-09","RC48-ADC",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06014073","TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r\u002Fr B-NHL","2025-09-01","TRAC and Power3",{"nctId":76,"briefTitle":77,"date":73,"intervention":78},"NCT06928376","A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid\u002FHigh-Risk AML Patients","Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06439628","ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine","2025-09-28","Rimegepant",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,136,154,186,204,222,250,280,298,316,341,368,386,404,432,450,468,490,684,766,793,837,871,906,928,956,1016,1059,1081,1122,1153,1171,1196,1214,1232,1250,1276,1294,1312,1330,1355,1373,1397,1415,1433,1460,1478,1496,1514,1532,1550,1568,1592,1617,1643,1668,1686,1704,1732,1750,1768,1786,1808,1834,1852,1871,1898,1916,1941,1959,1984,2011,2029,2047,2070,2088,2114,2132,2150,2168,2186,2204,2254,2308,2338,2369,2391,2413,2436,2461,2479,2497,2526,2626,2659,2681,2703,2725,2755,2789,2813,2837,2863,2887,2908,2926,2944,2968,2994,3012,3033,3051,3084,3125,3147,3179,3201,3226,3244,3271,3297,3315,3341,3359,3383,3405,3430,3448,3472,3490,3515,3540,3558,3584,3612,3636,3664,3682,3700,3724,3753,3771,3789,3807,3825,3850,3876,3894,3912,3930,3960,3978,4005,4023,4048,4075,4093,4111,4129,4156,4174,4199,4279,4338,4372,4406,4437,4473,4491,4513,4537,4555,4573,4600,4618,4636,4676,4725,4754,4780,4811,4833,4855,4885,4911,4933,4962,4987,5005,5030,5048,5075,5093,5114,5137,5163,5181,5205,5230,5248,5273,5291,5319,5365,5390,5416,5443,5461,5479,5503,5529,5550,5568,5590,5613,5639,5657,5678,5702,5728,5752,5770,5788,5811,5834,5856,5874,5892,5915,5933,5956,5974,5992,6016,6042,6064,6082,6109,6127,6145,6169,6187,6205,6223,6249,6267,6285,6303,6321,6344,6369,6391,6414,6432,6450,6473,6498,6516,6537,6561,6584,6608,6626,6644,6669,6687,6705,6730,6748,6772,6795,6819,6837,6855,6873,6896,6919,6937,6955,6973,6995,7028,7061,7084,7110,7135,7161,7179,7202,7224,7242,7264,7291,7313,7335,7359,7381,7407,7425,7443,7467,7485,7503,7528,7549,7571,7596,7643,7672,7706,7740,7762,7788,7820,7843,7861,7885,7908,7935,7953,7975,8000,8018,8036,8061,8079,8102,8127,8145,8170,8192,8210,8234,8257,8275,8297,8315,8339,8357,8380,8398,8416,8434,8458,8483,8507,8525,8551,8569,8591,8616,8640,8661,8686,8711],{"intervention":93,"totalTrials":94,"cells":95},"Saline",2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":134},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":114,"soonestReadout":106},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"NCT06963112","Intraoperative Midazolam on Delirium Outcome of Elderly Patients","RECRUITING",[86],"2026-07-01","2026-08-01","2025-04-01",612,[111,26],"Delirium",[113,93],"Midazolam",1,{"trials":116,"activeCount":98},[],{"trials":118,"activeCount":98},[],{"trials":120,"activeCount":114,"soonestReadout":126},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT07063108","Efficacy and Safety of S-ketamine in Elderly Patients Undergoing Non-cardiac Surgery: a RCT（ESSENCE）","NOT_YET_RECRUITING",[89],"2026-06-30","2026-12-31","2025-12-01",276,[131],"Postoperative Pain",[133,93],"Esketamine hydrochloride",{"trials":135,"activeCount":98},[],{"intervention":133,"totalTrials":114,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":152},{"trials":139,"activeCount":98},[],{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":114,"soonestReadout":126},[148],{"nctId":122,"briefTitle":123,"status":124,"phases":149,"primaryCompletion":126,"completion":127,"start":128,"enrollment":129,"conditions":150,"interventions":151},[89],[131],[133,93],{"trials":153,"activeCount":98},[],{"intervention":155,"totalTrials":114,"cells":156},"The rHuEPO Monotherapy Group",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":184},{"trials":158,"activeCount":98},[],{"trials":160,"activeCount":98},[],{"trials":162,"activeCount":98},[],{"trials":164,"activeCount":98},[],{"trials":166,"activeCount":114,"soonestReadout":171},[167],{"nctId":168,"briefTitle":169,"status":104,"phases":170,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":181},"NCT07045155","Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis",[89],"2027-12-30","2028-12-30","2025-08-01",240,[176,177,178,179,180],"Dialysis; Complications","Chronic Kidney Disease 5D","Renal Anemia of Chronic Kidney Disease","Renal Anaemia","Renal Anemia, Chronic",[155,182,183],"The Pegmolesatide and Roxadustat Combination Therapy Group","The Pegmolesatide Monotherapy Group",{"trials":185,"activeCount":98},[],{"intervention":182,"totalTrials":114,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":202},{"trials":189,"activeCount":98},[],{"trials":191,"activeCount":98},[],{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":98},[],{"trials":197,"activeCount":114,"soonestReadout":171},[198],{"nctId":168,"briefTitle":169,"status":104,"phases":199,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":200,"interventions":201},[89],[176,177,178,179,180],[155,182,183],{"trials":203,"activeCount":98},[],{"intervention":183,"totalTrials":114,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":220},{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":98},[],{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":98},[],{"trials":215,"activeCount":114,"soonestReadout":171},[216],{"nctId":168,"briefTitle":169,"status":104,"phases":217,"primaryCompletion":171,"completion":172,"start":173,"enrollment":174,"conditions":218,"interventions":219},[89],[176,177,178,179,180],[155,182,183],{"trials":221,"activeCount":98},[],{"intervention":223,"totalTrials":114,"cells":224},"Acemetacin",{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":248},{"trials":226,"activeCount":98},[],{"trials":228,"activeCount":98},[],{"trials":230,"activeCount":98},[],{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":114,"soonestReadout":239},[235],{"nctId":236,"briefTitle":237,"status":124,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":247},"NCT07582146","Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study",[89],"2026-09","2026-12","2026-04",150,[244,245,246],"Axial Spondyloarthritis","Axial Spondyloarthritis, Non-Radiographic","Ankylosing Spondylitis (AS) \u002F Radiographic Axial SpA (r-axSpA)",[223],{"trials":249,"activeCount":98},[],{"intervention":251,"totalTrials":114,"cells":252},"Huaier granule",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":278},{"trials":254,"activeCount":98},[],{"trials":256,"activeCount":98},[],{"trials":258,"activeCount":98},[],{"trials":260,"activeCount":98},[],{"trials":262,"activeCount":114,"soonestReadout":267},[263],{"nctId":264,"briefTitle":265,"status":104,"phases":266,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":275},"NCT05839314","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy",[89],"2027-05-03","2027-07-01","2023-05-09",480,[272,273,274],"Nephropathy","Glomerular Diseases","Idiopathic Membranous Nephropathy",[251,276,277],"Renin-angiotensin-aldosterone system inhibitors","Ciclosporin soft",{"trials":279,"activeCount":98},[],{"intervention":276,"totalTrials":114,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":288,"PHASE4":290,"NA":296},{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":98},[],{"trials":287,"activeCount":98},[],{"trials":289,"activeCount":98},[],{"trials":291,"activeCount":114,"soonestReadout":267},[292],{"nctId":264,"briefTitle":265,"status":104,"phases":293,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":294,"interventions":295},[89],[272,273,274],[251,276,277],{"trials":297,"activeCount":98},[],{"intervention":277,"totalTrials":114,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":306,"PHASE4":308,"NA":314},{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":98},[],{"trials":309,"activeCount":114,"soonestReadout":267},[310],{"nctId":264,"briefTitle":265,"status":104,"phases":311,"primaryCompletion":267,"completion":268,"start":269,"enrollment":270,"conditions":312,"interventions":313},[89],[272,273,274],[251,276,277],{"trials":315,"activeCount":98},[],{"intervention":317,"totalTrials":114,"cells":318},"Ruxolitinib, Decitabine",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":339},{"trials":320,"activeCount":98},[],{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":114,"soonestReadout":333},[329],{"nctId":330,"briefTitle":331,"status":104,"phases":332,"primaryCompletion":333,"completion":172,"start":334,"enrollment":335,"conditions":336,"interventions":338},"NCT07101588","Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial",[89],"2028-01-01","2025-01-01",200,[337],"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[317],{"trials":340,"activeCount":98},[],{"intervention":342,"totalTrials":114,"cells":343},"Eculizumab+IVMP",{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":366},{"trials":345,"activeCount":98},[],{"trials":347,"activeCount":98},[],{"trials":349,"activeCount":98},[],{"trials":351,"activeCount":98},[],{"trials":353,"activeCount":114,"soonestReadout":358},[354],{"nctId":355,"briefTitle":356,"status":104,"phases":357,"primaryCompletion":358,"completion":359,"start":360,"enrollment":335,"conditions":361,"interventions":363},"NCT07410039","Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study",[89],"2027-06-30","2029-06-30","2026-02-01",[362],"Neuromyelitis Optica Spectrum Disorder Attack",[342,364,365],"IVIG+IVMP","IVMP",{"trials":367,"activeCount":98},[],{"intervention":364,"totalTrials":114,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":384},{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":98},[],{"trials":375,"activeCount":98},[],{"trials":377,"activeCount":98},[],{"trials":379,"activeCount":114,"soonestReadout":358},[380],{"nctId":355,"briefTitle":356,"status":104,"phases":381,"primaryCompletion":358,"completion":359,"start":360,"enrollment":335,"conditions":382,"interventions":383},[89],[362],[342,364,365],{"trials":385,"activeCount":98},[],{"intervention":365,"totalTrials":114,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":394,"PHASE4":396,"NA":402},{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":98},[],{"trials":393,"activeCount":98},[],{"trials":395,"activeCount":98},[],{"trials":397,"activeCount":114,"soonestReadout":358},[398],{"nctId":355,"briefTitle":356,"status":104,"phases":399,"primaryCompletion":358,"completion":359,"start":360,"enrollment":335,"conditions":400,"interventions":401},[89],[362],[342,364,365],{"trials":403,"activeCount":98},[],{"intervention":405,"totalTrials":114,"cells":406},"Keluoxin",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":415,"NA":430},{"trials":408,"activeCount":98},[],{"trials":410,"activeCount":98},[],{"trials":412,"activeCount":98},[],{"trials":414,"activeCount":98},[],{"trials":416,"activeCount":114,"soonestReadout":421},[417],{"nctId":418,"briefTitle":419,"status":124,"phases":420,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":427},"NCT06660940","Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy",[89],"2027-10","2024-10",460,[425,426],"Diabetic Kidney Disease","Diabetic Retinopathy",[405,428,429],"Keluoxin Capsule Simulants","Irbesartan",{"trials":431,"activeCount":98},[],{"intervention":428,"totalTrials":114,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":448},{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":98},[],{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":114,"soonestReadout":421},[444],{"nctId":418,"briefTitle":419,"status":124,"phases":445,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":446,"interventions":447},[89],[425,426],[405,428,429],{"trials":449,"activeCount":98},[],{"intervention":429,"totalTrials":114,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":466},{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[],{"trials":461,"activeCount":114,"soonestReadout":421},[462],{"nctId":418,"briefTitle":419,"status":124,"phases":463,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":464,"interventions":465},[89],[425,426],[405,428,429],{"trials":467,"activeCount":98},[],{"intervention":45,"totalTrials":114,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":486,"NA":488},{"trials":471,"activeCount":98},[],{"trials":473,"activeCount":98},[],{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":114,"soonestReadout":44},[478],{"nctId":42,"briefTitle":43,"status":104,"phases":479,"primaryCompletion":44,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":485},[88],"2028-12","2021-01-13",524,[20,484],"Chemotherapy Effect",[45],{"trials":487,"activeCount":98},[],{"trials":489,"activeCount":98},[],{"intervention":491,"totalTrials":492,"cells":493},"Cyclophosphamide",16,{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":531,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":495,"activeCount":98},[],{"trials":497,"activeCount":94,"soonestReadout":520},[498,516],{"nctId":499,"briefTitle":500,"status":501,"phases":502,"primaryCompletion":126,"completion":503,"start":504,"enrollment":24,"conditions":505,"interventions":511},"NCT05631899","CAR-DC Vaccine and ICIs in Local Advanced\u002FMetastatic Solid Tumors","ACTIVE_NOT_RECRUITING",[86],"2026-12-30","2023-04-03",[506,507,508,509,510],"Solid Tumor, Adult","EphA2 Overexpression","KRAS G12V","KRAS G12C","KRAS G12D",[512,513,491,514,515],"KRAS-EphA-2-CAR-DC","Abraxane","Anti-PD-1 antibody","Anti-CTLA4 Monoclonal Antibody",{"nctId":517,"briefTitle":518,"status":104,"phases":519,"primaryCompletion":520,"completion":503,"start":521,"enrollment":522,"conditions":523,"interventions":528},"NCT05631886","Combination of CAR-DC Vaccine and ICIs in Malignant Tumors",[86],"2025-12-30","2023-07-04",10,[506,34,507,524,525,526,527],"TP53 R273H","TP53 R175H","TP53 R248Q","TP53 R249S",[529,513,491,530,515],"TP53-EphA-2-CAR-DC","anti-PD-1 antibody",{"trials":532,"activeCount":9,"soonestReadout":73},[533,546,553,564,574,585,596,607,616,622,634,644,655,666],{"nctId":534,"briefTitle":535,"status":104,"phases":536,"primaryCompletion":537,"completion":127,"start":538,"enrollment":539,"conditions":540,"interventions":542},"NCT05681650","HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors",[86,87],"2025-12-31","2023-10-11",30,[541],"HER2 Positive Advanced Solid Tumors",[543,544,491,545],"HypoSti.CAR-HER2 T cells","Albumin-bound paclitaxel","Fludarabine",{"nctId":71,"briefTitle":72,"status":104,"phases":547,"primaryCompletion":73,"completion":548,"start":549,"enrollment":539,"conditions":550,"interventions":552},[86,87],"2026-09-01","2023-09-06",[551],"Non Hodgkin's Lymphoma",[74,545,491],{"nctId":554,"briefTitle":555,"status":104,"phases":556,"primaryCompletion":557,"completion":558,"start":559,"enrollment":539,"conditions":560,"interventions":562},"NCT06321289","Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r\u002Fr B-NHL",[86,87],"2026-03-20","2027-03-20","2024-03-20",[561],"Non-hodgkin Lymphoma,B Cell",[563,545,491],"Allogeneic CD19-STAR T cell",{"nctId":565,"briefTitle":566,"status":104,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":539,"conditions":571,"interventions":572},"NCT06838832","Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r\u002Fr NHL",[86,87],"2027-03-01","2028-03-01","2025-07-27",[561],[573,545,491],"Allogenic CD19-CAR-γδT cell",{"nctId":575,"briefTitle":576,"status":104,"phases":577,"primaryCompletion":578,"completion":579,"start":580,"enrollment":539,"conditions":581,"interventions":583},"NCT06481735","TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r\u002Fr B-ALL",[86,87],"2027-02-15","2028-02-15","2025-02-15",[582],"Acute Lymphocytic Leukemia",[584,545,491],"TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell",{"nctId":586,"briefTitle":587,"status":104,"phases":588,"primaryCompletion":589,"completion":590,"start":591,"enrollment":539,"conditions":592,"interventions":594},"NCT06323525","TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r\u002Fr B Cell Lymphoma",[86,87],"2026-04-25","2027-04-25","2024-04-17",[593],"Non-hodgkin Lymphoma",[595,545,491],"TCR reserved and Power3",{"nctId":597,"briefTitle":598,"status":104,"phases":599,"primaryCompletion":600,"completion":601,"start":602,"enrollment":539,"conditions":603,"interventions":605},"NCT07009002","BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r\u002Fr B Cell Lymphoma",[86,87],"2026-05-31","2027-05-31","2025-06-20",[604],"B Cell Lymphoma",[606,545,491],"CAR19TIF cells",{"nctId":608,"briefTitle":609,"status":104,"phases":610,"primaryCompletion":127,"completion":611,"start":612,"enrollment":539,"conditions":613,"interventions":614},"NCT05554939","Allogenic CD19-targeting CAR-γδT Cell Therapy in R\u002FR NHL",[86,87],"2027-12-31","2022-12-11",[551],[615,545,491],"Allogenic CD19 CAR-γδT cell",{"nctId":617,"briefTitle":618,"status":104,"phases":619,"primaryCompletion":600,"completion":601,"start":602,"enrollment":539,"conditions":620,"interventions":621},"NCT07008885","BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r\u002Fr B-ALL",[86,87],[582],[606,545,491],{"nctId":623,"briefTitle":624,"status":625,"phases":626,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT05631912","TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r\u002Fr B-NHL","UNKNOWN",[86,87],"2024-12-15","2025-12-15","2023-06-30",38,[561],[633,545,491],"Autologous CD19-STAR-T cell",{"nctId":635,"briefTitle":636,"status":104,"phases":637,"primaryCompletion":537,"completion":127,"start":638,"enrollment":639,"conditions":640,"interventions":642},"NCT05693844","Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced\u002FMetastatic Solid Tumors",[86,87],"2023-01-20",15,[641],"Advanced or Metastatic Solid Tumors",[643,544,491,545],"Pan-T booster co-expressing MSLN CAR T cell",{"nctId":645,"briefTitle":646,"status":124,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":539,"conditions":651,"interventions":652},"NCT06939270","CD73\u002FAXL Targeted HypoSti.CAR-T Cells in CD73\u002FAXL Positive Advanced\u002FMetastatic Solid Tumors",[86,87],"2027-05-01","2028-05-01","2025-05-01",[23],[653,654,491,545],"CD73\u002FAXL.HypoSti.CAR-T cells","Albumin-Bound Paclitaxel",{"nctId":656,"briefTitle":657,"status":104,"phases":658,"primaryCompletion":359,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT07570563","Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors.",[86,87],"2031-12-31","2026-05-15",24,[663,23],"Hematologic Malignancy",[665,491,545],"QH101 Cell",{"nctId":667,"briefTitle":668,"status":104,"phases":669,"primaryCompletion":537,"completion":127,"start":670,"enrollment":671,"conditions":672,"interventions":674},"NCT05699811","IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced\u002FMetastatic Solid Tumors",[86,87],"2023-02-23",40,[673],"Locally Advanced or Metastatic Solid Tumors",[675,676,491,677],"MSC-IFNα","Nab paclitaxel","Anti-PD-1 monoclonal antibody",{"trials":679,"activeCount":98},[],{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"intervention":545,"totalTrials":685,"cells":686},14,{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":745,"PHASE4":747,"NA":764},{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":21,"soonestReadout":73},[693,697,701,705,709,713,717,721,725,729,733,737,741],{"nctId":534,"briefTitle":535,"status":104,"phases":694,"primaryCompletion":537,"completion":127,"start":538,"enrollment":539,"conditions":695,"interventions":696},[86,87],[541],[543,544,491,545],{"nctId":71,"briefTitle":72,"status":104,"phases":698,"primaryCompletion":73,"completion":548,"start":549,"enrollment":539,"conditions":699,"interventions":700},[86,87],[551],[74,545,491],{"nctId":554,"briefTitle":555,"status":104,"phases":702,"primaryCompletion":557,"completion":558,"start":559,"enrollment":539,"conditions":703,"interventions":704},[86,87],[561],[563,545,491],{"nctId":565,"briefTitle":566,"status":104,"phases":706,"primaryCompletion":568,"completion":569,"start":570,"enrollment":539,"conditions":707,"interventions":708},[86,87],[561],[573,545,491],{"nctId":575,"briefTitle":576,"status":104,"phases":710,"primaryCompletion":578,"completion":579,"start":580,"enrollment":539,"conditions":711,"interventions":712},[86,87],[582],[584,545,491],{"nctId":586,"briefTitle":587,"status":104,"phases":714,"primaryCompletion":589,"completion":590,"start":591,"enrollment":539,"conditions":715,"interventions":716},[86,87],[593],[595,545,491],{"nctId":597,"briefTitle":598,"status":104,"phases":718,"primaryCompletion":600,"completion":601,"start":602,"enrollment":539,"conditions":719,"interventions":720},[86,87],[604],[606,545,491],{"nctId":608,"briefTitle":609,"status":104,"phases":722,"primaryCompletion":127,"completion":611,"start":612,"enrollment":539,"conditions":723,"interventions":724},[86,87],[551],[615,545,491],{"nctId":617,"briefTitle":618,"status":104,"phases":726,"primaryCompletion":600,"completion":601,"start":602,"enrollment":539,"conditions":727,"interventions":728},[86,87],[582],[606,545,491],{"nctId":623,"briefTitle":624,"status":625,"phases":730,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":731,"interventions":732},[86,87],[561],[633,545,491],{"nctId":635,"briefTitle":636,"status":104,"phases":734,"primaryCompletion":537,"completion":127,"start":638,"enrollment":639,"conditions":735,"interventions":736},[86,87],[641],[643,544,491,545],{"nctId":645,"briefTitle":646,"status":124,"phases":738,"primaryCompletion":648,"completion":649,"start":650,"enrollment":539,"conditions":739,"interventions":740},[86,87],[23],[653,654,491,545],{"nctId":656,"briefTitle":657,"status":104,"phases":742,"primaryCompletion":359,"completion":659,"start":660,"enrollment":661,"conditions":743,"interventions":744},[86,87],[663,23],[665,491,545],{"trials":746,"activeCount":98},[],{"trials":748,"activeCount":98},[749],{"nctId":750,"briefTitle":751,"status":625,"phases":752,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT02784561","Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation",[89],"2019-07","2020-07","2016-07",80,[758],"Leukemia",[760,761,545,762,763],"Busulfan","Cytarabine","granulocyte colony-stimulating factor","rabbit ATG（Sanofi\u002FGenzyme）",{"trials":765,"activeCount":98},[],{"intervention":544,"totalTrials":767,"cells":768},3,{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"trials":774,"activeCount":767,"soonestReadout":537},[775,779,783],{"nctId":534,"briefTitle":535,"status":104,"phases":776,"primaryCompletion":537,"completion":127,"start":538,"enrollment":539,"conditions":777,"interventions":778},[86,87],[541],[543,544,491,545],{"nctId":635,"briefTitle":636,"status":104,"phases":780,"primaryCompletion":537,"completion":127,"start":638,"enrollment":639,"conditions":781,"interventions":782},[86,87],[641],[643,544,491,545],{"nctId":645,"briefTitle":646,"status":124,"phases":784,"primaryCompletion":648,"completion":649,"start":650,"enrollment":539,"conditions":785,"interventions":786},[86,87],[23],[653,654,491,545],{"trials":788,"activeCount":98},[],{"trials":790,"activeCount":98},[],{"trials":792,"activeCount":98},[],{"intervention":78,"totalTrials":767,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":796,"activeCount":98},[],{"trials":798,"activeCount":98},[],{"trials":800,"activeCount":94,"soonestReadout":73},[801,812,821],{"nctId":802,"briefTitle":803,"status":104,"phases":804,"primaryCompletion":805,"completion":806,"start":807,"enrollment":335,"conditions":808,"interventions":810},"NCT06084819","Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed\u002FRefractory Acute Myeloid Leukemia",[87],"2029-01-31","2030-01-31","2023-08-01",[809],"Relapsed\u002FRefractory Acute Myeloid Leukemia",[78,811],"Best-Available Therapy(BAT) Regimen",{"nctId":76,"briefTitle":77,"status":104,"phases":813,"primaryCompletion":73,"completion":548,"start":814,"enrollment":815,"conditions":816,"interventions":819},[87],"2024-04-18",160,[817,818],"Acute Myeloid Leukemia","First Line Therapy",[78,820],"\"3+7\"",{"nctId":822,"briefTitle":823,"status":824,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":335,"conditions":829,"interventions":830},"NCT06068621","Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","COMPLETED",[87],"2024-05-31","2025-08-31","2023-03-01",[817],[78,820],{"trials":832,"activeCount":98},[],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"intervention":838,"totalTrials":94,"cells":839},"Amimestrocel",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":865,"PHASE4":867,"NA":869},{"trials":841,"activeCount":98},[],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":94,"soonestReadout":660},[846,856],{"nctId":847,"briefTitle":848,"status":104,"phases":849,"primaryCompletion":660,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT06969807","Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease",[87],"2028-05-15","2025-06-09",120,[854],"Diabetic Kidney Disease (DKD)",[838],{"nctId":857,"briefTitle":858,"status":104,"phases":859,"primaryCompletion":660,"completion":850,"start":860,"enrollment":861,"conditions":862,"interventions":864},"NCT06954740","Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury",[87],"2025-06-10",50,[863],"Acute Kidney Injury",[838],{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[],{"trials":870,"activeCount":98},[],{"intervention":872,"totalTrials":94,"cells":873},"Chidamide; Decitabine; Anti-PD-1 Antibody",{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"trials":879,"activeCount":94,"soonestReadout":548},[880,891],{"nctId":881,"briefTitle":882,"status":104,"phases":883,"primaryCompletion":884,"completion":884,"start":885,"enrollment":886,"conditions":887,"interventions":889},"NCT06393361","Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R\u002FR cHL Who Are Transplant-ineligible or Refused Transplant.",[87],"2027-06-01","2024-06-01",100,[888],"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma",[872,890],"Brentuximab Vedotin, anti-PD-1 antibody.",{"nctId":892,"briefTitle":893,"status":124,"phases":894,"primaryCompletion":548,"completion":895,"start":896,"enrollment":886,"conditions":897,"interventions":898},"NCT06563778","Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R\u002FR cHL Who Are Transplant-ineligible or Refused Transplant.",[87],"2028-09-01","2024-09-01",[888],[872,899],"Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody",{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[],{"intervention":606,"totalTrials":94,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":94,"soonestReadout":600},[914,918],{"nctId":597,"briefTitle":598,"status":104,"phases":915,"primaryCompletion":600,"completion":601,"start":602,"enrollment":539,"conditions":916,"interventions":917},[86,87],[604],[606,545,491],{"nctId":617,"briefTitle":618,"status":104,"phases":919,"primaryCompletion":600,"completion":601,"start":602,"enrollment":539,"conditions":920,"interventions":921},[86,87],[582],[606,545,491],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[],{"trials":927,"activeCount":98},[],{"intervention":929,"totalTrials":94,"cells":930},"CD70-targeting CAR-T cells",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":950,"PHASE4":952,"NA":954},{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":94,"soonestReadout":537},[937,944],{"nctId":938,"briefTitle":939,"status":104,"phases":940,"primaryCompletion":537,"completion":127,"start":941,"enrollment":539,"conditions":942,"interventions":943},"NCT05948033","CD70 Targeted CAR-T Cells in CD70 Positive Relapsed\u002FRefractory Lymphoma",[86,87],"2023-07-15",[34],[929],{"nctId":945,"briefTitle":946,"status":104,"phases":947,"primaryCompletion":537,"completion":127,"start":941,"enrollment":539,"conditions":948,"interventions":949},"NCT05947487","CD70 Targeted CAR-T Cells in CD70 Positive Advanced\u002FMetastatic Solid Tumors",[86,87],[506],[929],{"trials":951,"activeCount":98},[],{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":98},[],{"intervention":957,"totalTrials":958,"cells":959},"Camrelizumab",4,{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":961,"activeCount":98},[],{"trials":963,"activeCount":98},[],{"trials":965,"activeCount":114,"soonestReadout":992},[966,978,988,998],{"nctId":967,"briefTitle":968,"status":625,"phases":969,"primaryCompletion":970,"completion":971,"start":972,"enrollment":886,"conditions":973,"interventions":975},"NCT04233294","Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant\u002FRelapsed Patients With Classical Hodgkin Lymphoma",[87],"2024-02","2026-02","2020-02-02",[974],"Hodgkin Lymphoma",[976,957,977],"Chidamide","Decitabine",{"nctId":979,"briefTitle":980,"status":625,"phases":981,"primaryCompletion":982,"completion":983,"start":984,"enrollment":886,"conditions":985,"interventions":987},"NCT04337606","Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor",[86,87],"2024-04-04","2026-04-04","2020-04-04",[986],"Non Hodgkin Lymphoma",[976,977,957],{"nctId":989,"briefTitle":990,"status":104,"phases":991,"primaryCompletion":992,"completion":993,"start":360,"enrollment":994,"conditions":995,"interventions":997},"NCT07527026","A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR\u002FMSS Rectal Cancer",[87],"2028-02-01","2029-02-01",44,[996],"Locally Advanced Rectal Cancer",[957],{"nctId":999,"briefTitle":1000,"status":625,"phases":1001,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1007},"NCT04367025","Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer",[87],"2022-05","2023-05","2020-05",70,[20],[957,1008,1009],"Oxaliplatin","S1",{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"trials":1015,"activeCount":98},[],{"intervention":1017,"totalTrials":767,"cells":1018},"S-1",{"EARLY_PHASE1":1019,"PHASE1":1021,"PHASE2":1023,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1020,"activeCount":98},[],{"trials":1022,"activeCount":98},[],{"trials":1024,"activeCount":114,"soonestReadout":68},[1025,1032,1044],{"nctId":66,"briefTitle":67,"status":104,"phases":1026,"primaryCompletion":68,"completion":239,"start":1027,"enrollment":1028,"conditions":1029,"interventions":1031},[86,87],"2022-09-20",42,[1030],"Advanced Gastroesophageal Adenocarcinoma",[69,1017],{"nctId":1033,"briefTitle":1034,"status":625,"phases":1035,"primaryCompletion":1036,"completion":1037,"start":1038,"enrollment":1039,"conditions":1040,"interventions":1042},"NCT02124317","Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer",[87],"2016-12","2017-05","2014-04",60,[1041],"Advanced Pancreatic Cancer",[1043,1017],"nanoparticle albumin-bound paclitaxel",{"nctId":1045,"briefTitle":1046,"status":625,"phases":1047,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":16,"conditions":1050,"interventions":1051},"NCT03007446","The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer",[87],"2018-11","2016-11",[20],[1052,1008,1017],"Apatinib",{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"intervention":820,"totalTrials":94,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1062,"activeCount":98},[],{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":114,"soonestReadout":73},[1067,1071],{"nctId":76,"briefTitle":77,"status":104,"phases":1068,"primaryCompletion":73,"completion":548,"start":814,"enrollment":815,"conditions":1069,"interventions":1070},[87],[817,818],[78,820],{"nctId":822,"briefTitle":823,"status":824,"phases":1072,"primaryCompletion":826,"completion":827,"start":828,"enrollment":335,"conditions":1073,"interventions":1074},[87],[817],[78,820],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[],{"trials":1080,"activeCount":98},[],{"intervention":1082,"totalTrials":94,"cells":1083},"Rituximab",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1085,"activeCount":98},[],{"trials":1087,"activeCount":98},[],{"trials":1089,"activeCount":114,"soonestReadout":503},[1090,1105],{"nctId":1091,"briefTitle":1092,"status":104,"phases":1093,"primaryCompletion":503,"completion":884,"start":1094,"enrollment":539,"conditions":1095,"interventions":1102},"NCT06471738","Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma",[87],"2024-07-10",[1096,1097,1098,1099,1100,1101],"Ann Arbor Stage II Follicular Lymphoma","Grade 1 Follicular Lymphoma","Ann Arbor Stage III Follicular Lymphoma","Ann Arbor Stage IV Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma",[1103,1082,1104],"Zanubrutinib","Venetoclax",{"nctId":1106,"briefTitle":1107,"status":625,"phases":1108,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":671,"conditions":1112,"interventions":1114},"NCT05073250","IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.",[87],"2023-12-31","2024-11-01","2021-12-31",[1113],"Inert Non Hodgkin's Lymphoma",[1115,1082],"IBI376",{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[],{"trials":1121,"activeCount":98},[],{"intervention":676,"totalTrials":94,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"trials":1129,"activeCount":114,"soonestReadout":537},[1130,1143],{"nctId":1131,"briefTitle":1132,"status":625,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT05327582","An Open-label, Phase I\u002FII Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC",[86,87],"2023-04-30","2024-04-30","2022-04-12",65,[29,1139],"Biliary Tract Cancer",[1141,1142,676],"Durvalumab","Lenvatinib",{"nctId":667,"briefTitle":668,"status":104,"phases":1144,"primaryCompletion":537,"completion":127,"start":670,"enrollment":671,"conditions":1145,"interventions":1146},[86,87],[673],[675,676,491,677],{"trials":1148,"activeCount":98},[],{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[],{"intervention":69,"totalTrials":114,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1165,"PHASE4":1167,"NA":1169},{"trials":1156,"activeCount":98},[],{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":114,"soonestReadout":68},[1161],{"nctId":66,"briefTitle":67,"status":104,"phases":1162,"primaryCompletion":68,"completion":239,"start":1027,"enrollment":1028,"conditions":1163,"interventions":1164},[86,87],[1030],[69,1017],{"trials":1166,"activeCount":98},[],{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"intervention":50,"totalTrials":114,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1174,"activeCount":98},[],{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":114,"soonestReadout":49},[1179],{"nctId":47,"briefTitle":48,"status":104,"phases":1180,"primaryCompletion":49,"completion":1181,"start":1182,"enrollment":1183,"conditions":1184,"interventions":1188},[86,87],"2025-06","2021-08-04",90,[29,1185,1186,1187],"PDAC - Pancreatic Ductal Adenocarcinoma","Pancreas Cancer","Pancreatic Neoplasms",[50,1189],"nab-paclitaxel + gemcitabine",{"trials":1191,"activeCount":98},[],{"trials":1193,"activeCount":98},[],{"trials":1195,"activeCount":98},[],{"intervention":1189,"totalTrials":114,"cells":1197},{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1199,"activeCount":98},[],{"trials":1201,"activeCount":98},[],{"trials":1203,"activeCount":114,"soonestReadout":49},[1204],{"nctId":47,"briefTitle":48,"status":104,"phases":1205,"primaryCompletion":49,"completion":1181,"start":1182,"enrollment":1183,"conditions":1206,"interventions":1207},[86,87],[29,1185,1186,1187],[50,1189],{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"intervention":543,"totalTrials":114,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":98},[],{"trials":1219,"activeCount":98},[],{"trials":1221,"activeCount":114,"soonestReadout":537},[1222],{"nctId":534,"briefTitle":535,"status":104,"phases":1223,"primaryCompletion":537,"completion":127,"start":538,"enrollment":539,"conditions":1224,"interventions":1225},[86,87],[541],[543,544,491,545],{"trials":1227,"activeCount":98},[],{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[],{"intervention":74,"totalTrials":114,"cells":1233},{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1235,"activeCount":98},[],{"trials":1237,"activeCount":98},[],{"trials":1239,"activeCount":114,"soonestReadout":73},[1240],{"nctId":71,"briefTitle":72,"status":104,"phases":1241,"primaryCompletion":73,"completion":548,"start":549,"enrollment":539,"conditions":1242,"interventions":1243},[86,87],[551],[74,545,491],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"intervention":1251,"totalTrials":114,"cells":1252},"Regorafenib+Immune checkpoint inhibitor",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":114,"soonestReadout":568},[1259],{"nctId":1260,"briefTitle":1261,"status":104,"phases":1262,"primaryCompletion":568,"completion":1263,"start":1264,"enrollment":852,"conditions":1265,"interventions":1267},"NCT06558773","GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and\u002For Regorafenib in Previously Treated pMMR\u002FMSS CRC.",[87],"2029-03-31","2026-03-01",[1266],"Colorectal Cancer",[1251,1268,1269],"Eliglustat+Immune checkpoint inhibitor","Eliglustat+Immune checkpoint inhibitor +Regorafenib",{"trials":1271,"activeCount":98},[],{"trials":1273,"activeCount":98},[],{"trials":1275,"activeCount":98},[],{"intervention":1268,"totalTrials":114,"cells":1277},{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1288,"PHASE4":1290,"NA":1292},{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":114,"soonestReadout":568},[1284],{"nctId":1260,"briefTitle":1261,"status":104,"phases":1285,"primaryCompletion":568,"completion":1263,"start":1264,"enrollment":852,"conditions":1286,"interventions":1287},[87],[1266],[1251,1268,1269],{"trials":1289,"activeCount":98},[],{"trials":1291,"activeCount":98},[],{"trials":1293,"activeCount":98},[],{"intervention":1269,"totalTrials":114,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1297,"activeCount":98},[],{"trials":1299,"activeCount":98},[],{"trials":1301,"activeCount":114,"soonestReadout":568},[1302],{"nctId":1260,"briefTitle":1261,"status":104,"phases":1303,"primaryCompletion":568,"completion":1263,"start":1264,"enrollment":852,"conditions":1304,"interventions":1305},[87],[1266],[1251,1268,1269],{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":98},[],{"trials":1311,"activeCount":98},[],{"intervention":563,"totalTrials":114,"cells":1313},{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1324,"PHASE4":1326,"NA":1328},{"trials":1315,"activeCount":98},[],{"trials":1317,"activeCount":98},[],{"trials":1319,"activeCount":114,"soonestReadout":557},[1320],{"nctId":554,"briefTitle":555,"status":104,"phases":1321,"primaryCompletion":557,"completion":558,"start":559,"enrollment":539,"conditions":1322,"interventions":1323},[86,87],[561],[563,545,491],{"trials":1325,"activeCount":98},[],{"trials":1327,"activeCount":98},[],{"trials":1329,"activeCount":98},[],{"intervention":1331,"totalTrials":114,"cells":1332},"the standard \"3+7\" regimen",{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1349,"PHASE4":1351,"NA":1353},{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":98},[],{"trials":1338,"activeCount":114,"soonestReadout":171},[1339],{"nctId":1340,"briefTitle":1341,"status":104,"phases":1342,"primaryCompletion":171,"completion":611,"start":1343,"enrollment":852,"conditions":1344,"interventions":1347},"NCT07514936","Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia",[87],"2024-11-18",[1345,1346],"Newly Diagnosed Acute Myeloid Leukemia (AML)","Elderly Patients",[1331,1348],"Azacytidine; Cytarabine; Aclacinomycin; Chidamide; Venetoclax; Granulocyte",{"trials":1350,"activeCount":98},[],{"trials":1352,"activeCount":98},[],{"trials":1354,"activeCount":98},[],{"intervention":1348,"totalTrials":114,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1367,"PHASE4":1369,"NA":1371},{"trials":1358,"activeCount":98},[],{"trials":1360,"activeCount":98},[],{"trials":1362,"activeCount":114,"soonestReadout":171},[1363],{"nctId":1340,"briefTitle":1341,"status":104,"phases":1364,"primaryCompletion":171,"completion":611,"start":1343,"enrollment":852,"conditions":1365,"interventions":1366},[87],[1345,1346],[1331,1348],{"trials":1368,"activeCount":98},[],{"trials":1370,"activeCount":98},[],{"trials":1372,"activeCount":98},[],{"intervention":1374,"totalTrials":114,"cells":1375},"Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1377,"activeCount":98},[],{"trials":1379,"activeCount":98},[],{"trials":1381,"activeCount":114,"soonestReadout":1386},[1382],{"nctId":1383,"briefTitle":1384,"status":104,"phases":1385,"primaryCompletion":1386,"completion":1387,"start":896,"enrollment":539,"conditions":1388,"interventions":1390},"NCT07044921","Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.",[87],"2026-07-31","2027-07-31",[1389],"Colorectal Cancer Metastatic",[1374],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":98},[],{"intervention":573,"totalTrials":114,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":98},[],{"trials":1402,"activeCount":98},[],{"trials":1404,"activeCount":114,"soonestReadout":568},[1405],{"nctId":565,"briefTitle":566,"status":104,"phases":1406,"primaryCompletion":568,"completion":569,"start":570,"enrollment":539,"conditions":1407,"interventions":1408},[86,87],[561],[573,545,491],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":98},[],{"trials":1414,"activeCount":98},[],{"intervention":584,"totalTrials":114,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1427,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":114,"soonestReadout":578},[1423],{"nctId":575,"briefTitle":576,"status":104,"phases":1424,"primaryCompletion":578,"completion":579,"start":580,"enrollment":539,"conditions":1425,"interventions":1426},[86,87],[582],[584,545,491],{"trials":1428,"activeCount":98},[],{"trials":1430,"activeCount":98},[],{"trials":1432,"activeCount":98},[],{"intervention":1434,"totalTrials":114,"cells":1435},"One tablet of NB001 plus three tablets of placebo",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1454,"PHASE4":1456,"NA":1458},{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":98},[],{"trials":1441,"activeCount":114,"soonestReadout":1446},[1442],{"nctId":1443,"briefTitle":1444,"status":124,"phases":1445,"primaryCompletion":1446,"completion":127,"start":1447,"enrollment":852,"conditions":1448,"interventions":1450},"NCT07577050","A Phase II Study of NB001 for Acute Migraine Treatment",[87],"2026-09-30","2026-04-20",[1449],"Migraine",[1434,1451,1452,1453],"Two tablets of NB001 plus two tablets of placebo","Four tablets of NB001","Four tablets of placebo",{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":98},[],{"trials":1459,"activeCount":98},[],{"intervention":1451,"totalTrials":114,"cells":1461},{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1472,"PHASE4":1474,"NA":1476},{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":114,"soonestReadout":1446},[1468],{"nctId":1443,"briefTitle":1444,"status":124,"phases":1469,"primaryCompletion":1446,"completion":127,"start":1447,"enrollment":852,"conditions":1470,"interventions":1471},[87],[1449],[1434,1451,1452,1453],{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":98},[],{"trials":1477,"activeCount":98},[],{"intervention":1452,"totalTrials":114,"cells":1479},{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1490,"PHASE4":1492,"NA":1494},{"trials":1481,"activeCount":98},[],{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":114,"soonestReadout":1446},[1486],{"nctId":1443,"briefTitle":1444,"status":124,"phases":1487,"primaryCompletion":1446,"completion":127,"start":1447,"enrollment":852,"conditions":1488,"interventions":1489},[87],[1449],[1434,1451,1452,1453],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[],{"trials":1495,"activeCount":98},[],{"intervention":1453,"totalTrials":114,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":114,"soonestReadout":1446},[1504],{"nctId":1443,"briefTitle":1444,"status":124,"phases":1505,"primaryCompletion":1446,"completion":127,"start":1447,"enrollment":852,"conditions":1506,"interventions":1507},[87],[1449],[1434,1451,1452,1453],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":98},[],{"trials":1513,"activeCount":98},[],{"intervention":811,"totalTrials":114,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":98},[],{"trials":1519,"activeCount":98},[],{"trials":1521,"activeCount":114,"soonestReadout":805},[1522],{"nctId":802,"briefTitle":803,"status":104,"phases":1523,"primaryCompletion":805,"completion":806,"start":807,"enrollment":335,"conditions":1524,"interventions":1525},[87],[809],[78,811],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"intervention":890,"totalTrials":114,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":98},[],{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":114,"soonestReadout":884},[1540],{"nctId":881,"briefTitle":882,"status":104,"phases":1541,"primaryCompletion":884,"completion":884,"start":885,"enrollment":886,"conditions":1542,"interventions":1543},[87],[888],[872,890],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":98},[],{"intervention":595,"totalTrials":114,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":98},[],{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":114,"soonestReadout":589},[1558],{"nctId":586,"briefTitle":587,"status":104,"phases":1559,"primaryCompletion":589,"completion":590,"start":591,"enrollment":539,"conditions":1560,"interventions":1561},[86,87],[593],[595,545,491],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":98},[],{"intervention":1569,"totalTrials":114,"cells":1570},"Eliglustat, CD30 target immunotherapy",{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1586,"PHASE4":1588,"NA":1590},{"trials":1572,"activeCount":98},[],{"trials":1574,"activeCount":98},[],{"trials":1576,"activeCount":114,"soonestReadout":1581},[1577],{"nctId":1578,"briefTitle":1579,"status":104,"phases":1580,"primaryCompletion":1581,"completion":1582,"start":1583,"enrollment":671,"conditions":1584,"interventions":1585},"NCT07138547","GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma",[86,87],"2028-08-31","2029-08-31","2025-12-26",[34],[1569],{"trials":1587,"activeCount":98},[],{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"intervention":1593,"totalTrials":114,"cells":1594},"SCRT+targeted therapy+immunotherapy+chemotherapy",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1611,"PHASE4":1613,"NA":1615},{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"trials":1600,"activeCount":114,"soonestReadout":1605},[1601],{"nctId":1602,"briefTitle":1603,"status":124,"phases":1604,"primaryCompletion":1605,"completion":1606,"start":1607,"enrollment":1039,"conditions":1608,"interventions":1610},"NCT07581626","Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer",[87],"2027-04-01","2028-04-01","2026-05-01",[1609],"Locally Advanced Rectal Cancer (LARC)",[1593],{"trials":1612,"activeCount":98},[],{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[],{"intervention":1618,"totalTrials":114,"cells":1619},"Anti-BCMA-CD19 CAR-T cells",{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1637,"PHASE4":1639,"NA":1641},{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":114,"soonestReadout":1630},[1626],{"nctId":1627,"briefTitle":1628,"status":104,"phases":1629,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":24,"conditions":1633,"interventions":1636},"NCT07148791","Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease",[87],"2027-09-01","2029-12-31","2025-09-05",[1634,1635],"IgG4 Related Disease","B-cell Mediated Autoimmune Disorders",[1618],{"trials":1638,"activeCount":98},[],{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"intervention":1644,"totalTrials":114,"cells":1645},"Ruxolitinib combined with Chidamide.",{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1662,"PHASE4":1664,"NA":1666},{"trials":1647,"activeCount":98},[],{"trials":1649,"activeCount":98},[],{"trials":1651,"activeCount":114,"soonestReadout":1656},[1652],{"nctId":1653,"briefTitle":1654,"status":104,"phases":1655,"primaryCompletion":1656,"completion":1657,"start":1658,"enrollment":861,"conditions":1659,"interventions":1661},"NCT05088226","Ruxolitinib and Chidamide Intensified Bu\u002FCY Conditioning Regimen",[87],"2030-06-01","2031-06-01","2021-12-01",[1660],"Peripheral Blood Stem Cell Transplantation",[1644],{"trials":1663,"activeCount":98},[],{"trials":1665,"activeCount":98},[],{"trials":1667,"activeCount":98},[],{"intervention":1103,"totalTrials":114,"cells":1669},{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1680,"PHASE4":1682,"NA":1684},{"trials":1671,"activeCount":98},[],{"trials":1673,"activeCount":98},[],{"trials":1675,"activeCount":114,"soonestReadout":503},[1676],{"nctId":1091,"briefTitle":1092,"status":104,"phases":1677,"primaryCompletion":503,"completion":884,"start":1094,"enrollment":539,"conditions":1678,"interventions":1679},[87],[1096,1097,1098,1099,1100,1101],[1103,1082,1104],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"intervention":1104,"totalTrials":114,"cells":1687},{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[],{"trials":1693,"activeCount":114,"soonestReadout":503},[1694],{"nctId":1091,"briefTitle":1092,"status":104,"phases":1695,"primaryCompletion":503,"completion":884,"start":1094,"enrollment":539,"conditions":1696,"interventions":1697},[87],[1096,1097,1098,1099,1100,1101],[1103,1082,1104],{"trials":1699,"activeCount":98},[],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"intervention":1705,"totalTrials":114,"cells":1706},"Colorectal cancer: Tunlametinib + cetuximab β",{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1708,"activeCount":98},[],{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":114,"soonestReadout":1717},[1713],{"nctId":1714,"briefTitle":1715,"status":124,"phases":1716,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1183,"conditions":1720,"interventions":1723},"NCT07446270","Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies",[87],"2027-10-30","2028-10-30","2026-03-03",[1721,1722],"Treatment for Advanced Colorectal Cancer","Treatment for Advanced Pancreatic Cancer",[1705,1724,1725],"Pancreatic cancer: Tunlametinib + cetuximab β","Pancreatic cancer: Tunlametinib +Nimotuzumab",{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"trials":1731,"activeCount":98},[],{"intervention":1724,"totalTrials":114,"cells":1733},{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1744,"PHASE4":1746,"NA":1748},{"trials":1735,"activeCount":98},[],{"trials":1737,"activeCount":98},[],{"trials":1739,"activeCount":114,"soonestReadout":1717},[1740],{"nctId":1714,"briefTitle":1715,"status":124,"phases":1741,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1183,"conditions":1742,"interventions":1743},[87],[1721,1722],[1705,1724,1725],{"trials":1745,"activeCount":98},[],{"trials":1747,"activeCount":98},[],{"trials":1749,"activeCount":98},[],{"intervention":1725,"totalTrials":114,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1762,"PHASE4":1764,"NA":1766},{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":114,"soonestReadout":1717},[1758],{"nctId":1714,"briefTitle":1715,"status":124,"phases":1759,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1183,"conditions":1760,"interventions":1761},[87],[1721,1722],[1705,1724,1725],{"trials":1763,"activeCount":98},[],{"trials":1765,"activeCount":98},[],{"trials":1767,"activeCount":98},[],{"intervention":615,"totalTrials":114,"cells":1769},{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1774,"PHASE3":1780,"PHASE4":1782,"NA":1784},{"trials":1771,"activeCount":98},[],{"trials":1773,"activeCount":98},[],{"trials":1775,"activeCount":114,"soonestReadout":127},[1776],{"nctId":608,"briefTitle":609,"status":104,"phases":1777,"primaryCompletion":127,"completion":611,"start":612,"enrollment":539,"conditions":1778,"interventions":1779},[86,87],[551],[615,545,491],{"trials":1781,"activeCount":98},[],{"trials":1783,"activeCount":98},[],{"trials":1785,"activeCount":98},[],{"intervention":40,"totalTrials":114,"cells":1787},{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1789,"activeCount":98},[],{"trials":1791,"activeCount":98},[],{"trials":1793,"activeCount":114,"soonestReadout":39},[1794],{"nctId":37,"briefTitle":38,"status":104,"phases":1795,"primaryCompletion":39,"completion":1796,"start":1797,"enrollment":539,"conditions":1798,"interventions":1801},[86,87],"2029-10","2014-10",[1799,1800],"Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma",[40],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[],{"intervention":1809,"totalTrials":114,"cells":1810},"CACAG+VEN",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1828,"PHASE4":1830,"NA":1832},{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":114,"soonestReadout":1821},[1817],{"nctId":1818,"briefTitle":1819,"status":104,"phases":1820,"primaryCompletion":1821,"completion":1822,"start":73,"enrollment":1823,"conditions":1824,"interventions":1826},"NCT07512700","Venetoclax Combined With CACAG Regimen Versus \"3+7\" Regimen in the Treatment of Acute Monocytic Leukemia",[87],"2028-09-30","2029-10-31",204,[1825],"Acute Monocytic Leukemia",[1809,1827],"3+7",{"trials":1829,"activeCount":98},[],{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"intervention":1827,"totalTrials":114,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"trials":1841,"activeCount":114,"soonestReadout":1821},[1842],{"nctId":1818,"briefTitle":1819,"status":104,"phases":1843,"primaryCompletion":1821,"completion":1822,"start":73,"enrollment":1823,"conditions":1844,"interventions":1845},[87],[1825],[1809,1827],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"intervention":55,"totalTrials":114,"cells":1853},{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1855,"activeCount":98},[],{"trials":1857,"activeCount":98},[],{"trials":1859,"activeCount":114,"soonestReadout":54},[1860],{"nctId":52,"briefTitle":53,"status":124,"phases":1861,"primaryCompletion":54,"completion":1862,"start":559,"enrollment":539,"conditions":1863,"interventions":1864},[87],"2026-11-30",[20],[55],{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"intervention":1872,"totalTrials":114,"cells":1873},"RetroNectin active Killer cells",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1875,"activeCount":98},[],{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":114,"soonestReadout":611},[1880],{"nctId":1881,"briefTitle":1882,"status":104,"phases":1883,"primaryCompletion":611,"completion":1884,"start":1885,"enrollment":1183,"conditions":1886,"interventions":1890},"NCT07212933","The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial",[87],"2028-06-30","2025-07-01",[1887,1888,1889],"Gastric (Stomach) Cancer","Biological Therapy","Immunotherapy",[1872,1891],"TAS-102",{"trials":1893,"activeCount":98},[],{"trials":1895,"activeCount":98},[],{"trials":1897,"activeCount":98},[],{"intervention":1891,"totalTrials":114,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1901,"activeCount":98},[],{"trials":1903,"activeCount":98},[],{"trials":1905,"activeCount":114,"soonestReadout":611},[1906],{"nctId":1881,"briefTitle":1882,"status":104,"phases":1907,"primaryCompletion":611,"completion":1884,"start":1885,"enrollment":1183,"conditions":1908,"interventions":1909},[87],[1887,1888,1889],[1872,1891],{"trials":1911,"activeCount":98},[],{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":98},[],{"intervention":1917,"totalTrials":114,"cells":1918},"XPO1 inhibitor",{"EARLY_PHASE1":1919,"PHASE1":1921,"PHASE2":1923,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":114,"soonestReadout":537},[1925],{"nctId":1926,"briefTitle":1927,"status":104,"phases":1928,"primaryCompletion":537,"completion":127,"start":1929,"enrollment":522,"conditions":1930,"interventions":1934},"NCT05833893","Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK\u002FT-cell Lymphoma",[87],"2023-05-01",[1931,1932,1933],"nk\u002FT-cell Lymphoma","Newly Diagnosed","Advanced Lymphoma",[1917],{"trials":1936,"activeCount":98},[],{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"intervention":643,"totalTrials":114,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1944,"activeCount":98},[],{"trials":1946,"activeCount":98},[],{"trials":1948,"activeCount":114,"soonestReadout":537},[1949],{"nctId":635,"briefTitle":636,"status":104,"phases":1950,"primaryCompletion":537,"completion":127,"start":638,"enrollment":639,"conditions":1951,"interventions":1952},[86,87],[641],[643,544,491,545],{"trials":1954,"activeCount":98},[],{"trials":1956,"activeCount":98},[],{"trials":1958,"activeCount":98},[],{"intervention":1960,"totalTrials":114,"cells":1961},"mFOLFOX\u002FFOLFIRI",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1963,"activeCount":98},[],{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":114,"soonestReadout":480},[1968],{"nctId":1969,"briefTitle":1970,"status":104,"phases":1971,"primaryCompletion":480,"completion":1972,"start":1973,"enrollment":1974,"conditions":1975,"interventions":1977},"NCT07391618","Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU",[87],"2029-12","2025-05-15",583,[1976],"Advanced Colorectal Cancer",[1960],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[],{"intervention":1985,"totalTrials":114,"cells":1986},"GPC3-CART cells",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1991,"PHASE3":2005,"PHASE4":2007,"NA":2009},{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":114,"soonestReadout":1997},[1993],{"nctId":1994,"briefTitle":1995,"status":124,"phases":1996,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":539,"conditions":2000,"interventions":2002},"NCT06641453","CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma",[86,87],"2027-11-15","2028-11-15","2024-11-15",[2001],"Hepatocellular Carcinoma (HCC)",[1985,2003,2004],"Fludarabine Phosphate for","Cyclophosphamide for",{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[],{"trials":2010,"activeCount":98},[],{"intervention":2003,"totalTrials":114,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2014,"activeCount":98},[],{"trials":2016,"activeCount":98},[],{"trials":2018,"activeCount":114,"soonestReadout":1997},[2019],{"nctId":1994,"briefTitle":1995,"status":124,"phases":2020,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":539,"conditions":2021,"interventions":2022},[86,87],[2001],[1985,2003,2004],{"trials":2024,"activeCount":98},[],{"trials":2026,"activeCount":98},[],{"trials":2028,"activeCount":98},[],{"intervention":2004,"totalTrials":114,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2041,"PHASE4":2043,"NA":2045},{"trials":2032,"activeCount":98},[],{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":114,"soonestReadout":1997},[2037],{"nctId":1994,"briefTitle":1995,"status":124,"phases":2038,"primaryCompletion":1997,"completion":1998,"start":1999,"enrollment":539,"conditions":2039,"interventions":2040},[86,87],[2001],[1985,2003,2004],{"trials":2042,"activeCount":98},[],{"trials":2044,"activeCount":98},[],{"trials":2046,"activeCount":98},[],{"intervention":59,"totalTrials":114,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2064,"PHASE4":2066,"NA":2068},{"trials":2050,"activeCount":98},[],{"trials":2052,"activeCount":98},[],{"trials":2054,"activeCount":114,"soonestReadout":54},[2055],{"nctId":57,"briefTitle":58,"status":104,"phases":2056,"primaryCompletion":54,"completion":2057,"start":2058,"enrollment":539,"conditions":2059,"interventions":2063},[87],"2025-06-30","2020-12-31",[2060,2061,2062],"Cytomegalovirus Infections","Infection Reactivation","Stem Cell Transplant Complications",[59],{"trials":2065,"activeCount":98},[],{"trials":2067,"activeCount":98},[],{"trials":2069,"activeCount":98},[],{"intervention":653,"totalTrials":114,"cells":2071},{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":114,"soonestReadout":648},[2078],{"nctId":645,"briefTitle":646,"status":124,"phases":2079,"primaryCompletion":648,"completion":649,"start":650,"enrollment":539,"conditions":2080,"interventions":2081},[86,87],[23],[653,654,491,545],{"trials":2083,"activeCount":98},[],{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":98},[],{"intervention":2089,"totalTrials":114,"cells":2090},"3D hypoxia-preconditioned UC-MSC group",{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":114,"soonestReadout":127},[2097],{"nctId":2098,"briefTitle":2099,"status":2100,"phases":2101,"primaryCompletion":127,"completion":127,"start":807,"enrollment":671,"conditions":2102,"interventions":2106},"NCT07299123","Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA","ENROLLING_BY_INVITATION",[86,87],[2103,2104,2105],"Severe Aplastic Anemia (SAA)","Severe Aplastic Anemia, Refractory","Severe Aplastic Anemia",[2089,2107],"2D UC-MSC group",{"trials":2109,"activeCount":98},[],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"intervention":2107,"totalTrials":114,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":98},[],{"trials":2119,"activeCount":98},[],{"trials":2121,"activeCount":114,"soonestReadout":127},[2122],{"nctId":2098,"briefTitle":2099,"status":2100,"phases":2123,"primaryCompletion":127,"completion":127,"start":807,"enrollment":671,"conditions":2124,"interventions":2125},[86,87],[2103,2104,2105],[2089,2107],{"trials":2127,"activeCount":98},[],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"intervention":665,"totalTrials":114,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":98},[],{"trials":2137,"activeCount":98},[],{"trials":2139,"activeCount":114,"soonestReadout":359},[2140],{"nctId":656,"briefTitle":657,"status":104,"phases":2141,"primaryCompletion":359,"completion":659,"start":660,"enrollment":661,"conditions":2142,"interventions":2143},[86,87],[663,23],[665,491,545],{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"intervention":899,"totalTrials":114,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":98},[],{"trials":2155,"activeCount":98},[],{"trials":2157,"activeCount":114,"soonestReadout":548},[2158],{"nctId":892,"briefTitle":893,"status":124,"phases":2159,"primaryCompletion":548,"completion":895,"start":896,"enrollment":886,"conditions":2160,"interventions":2161},[87],[888],[872,899],{"trials":2163,"activeCount":98},[],{"trials":2165,"activeCount":98},[],{"trials":2167,"activeCount":98},[],{"intervention":675,"totalTrials":114,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2180,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":98},[],{"trials":2173,"activeCount":98},[],{"trials":2175,"activeCount":114,"soonestReadout":537},[2176],{"nctId":667,"briefTitle":668,"status":104,"phases":2177,"primaryCompletion":537,"completion":127,"start":670,"enrollment":671,"conditions":2178,"interventions":2179},[86,87],[673],[675,676,491,677],{"trials":2181,"activeCount":98},[],{"trials":2183,"activeCount":98},[],{"trials":2185,"activeCount":98},[],{"intervention":677,"totalTrials":114,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":114,"soonestReadout":537},[2194],{"nctId":667,"briefTitle":668,"status":104,"phases":2195,"primaryCompletion":537,"completion":127,"start":670,"enrollment":671,"conditions":2196,"interventions":2197},[86,87],[673],[675,676,491,677],{"trials":2199,"activeCount":98},[],{"trials":2201,"activeCount":98},[],{"trials":2203,"activeCount":98},[],{"intervention":2205,"totalTrials":958,"cells":2206},"KSVCBD",{"EARLY_PHASE1":2207,"PHASE1":2226,"PHASE2":2246,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2208,"activeCount":94,"soonestReadout":2213},[2209,2218],{"nctId":2210,"briefTitle":2211,"status":124,"phases":2212,"primaryCompletion":2213,"completion":1263,"start":2214,"enrollment":1039,"conditions":2215,"interventions":2217},"NCT07613411","Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases",[85],"2028-12-31","2026-06-01",[2216],"Autoimmune Diseases",[2205],{"nctId":2219,"briefTitle":2220,"status":124,"phases":2221,"primaryCompletion":2213,"completion":1263,"start":660,"enrollment":2222,"conditions":2223,"interventions":2225},"NCT07592754","The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.",[85],18,[2224],"Neuromyelitis Optica Spectrum Disease (NMOSD)",[2205],{"trials":2227,"activeCount":94,"soonestReadout":2232},[2228,2238],{"nctId":2229,"briefTitle":2230,"status":104,"phases":2231,"primaryCompletion":2232,"completion":2233,"start":2234,"enrollment":24,"conditions":2235,"interventions":2237},"NCT07620275","Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and\u002For BCMA",[86],"2028-12-15","2029-03-15","2026-06-10",[2236],"Multiple Myeloma",[2205],{"nctId":2239,"briefTitle":2240,"status":104,"phases":2241,"primaryCompletion":172,"completion":2242,"start":2243,"enrollment":24,"conditions":2244,"interventions":2245},"NCT07620314","Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and\u002For BCMA",[86],"2029-03-30","2026-06-15",[1800],[2205],{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[],{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"intervention":530,"totalTrials":2255,"cells":2256},5,{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2280,"PHASE3":2302,"PHASE4":2304,"NA":2306},{"trials":2258,"activeCount":98},[],{"trials":2260,"activeCount":94,"soonestReadout":520},[2261,2272,2276],{"nctId":2262,"briefTitle":2263,"status":625,"phases":2264,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":16,"conditions":2268,"interventions":2269},"NCT03991559","A Safety Study of the Pan-immunotherapy in Patients With Unresectable\u002FMetastatic Solid Tumors or Lymphomas",[86],"2019-12-31","2020-05-31","2018-11-01",[23,34],[2270,514,2271],"Manganese Chloride","Systemic therapy",{"nctId":499,"briefTitle":500,"status":501,"phases":2273,"primaryCompletion":126,"completion":503,"start":504,"enrollment":24,"conditions":2274,"interventions":2275},[86],[506,507,508,509,510],[512,513,491,514,515],{"nctId":517,"briefTitle":518,"status":104,"phases":2277,"primaryCompletion":520,"completion":503,"start":521,"enrollment":522,"conditions":2278,"interventions":2279},[86],[506,34,507,524,525,526,527],[529,513,491,530,515],{"trials":2281,"activeCount":98},[2282,2293],{"nctId":2283,"briefTitle":2284,"status":625,"phases":2285,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":861,"conditions":2289,"interventions":2290},"NCT03989310","An Open-label, Phase I\u002FII Study of the Pan-immunotherapy in Patients With Local Advanced\u002FMetastatic Pancreatic Cancer",[86,87],"2021-05-31","2022-03-31","2019-03-01",[29],[2270,2291,2292,530],"nab-paclitaxel","Gemcitabine",{"nctId":2294,"briefTitle":2295,"status":625,"phases":2296,"primaryCompletion":2297,"completion":2298,"start":2288,"enrollment":16,"conditions":2299,"interventions":2301},"NCT04004234","A Phase I\u002FII Study of the Pan-immunotherapy in Patients With Local Advanced\u002FMetastatic BTC",[86,87],"2020-08-31","2021-08-31",[2300],"Biliary Tract Cancer (BTC)",[2270,2291,2292,530],{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[],{"trials":2307,"activeCount":98},[],{"intervention":2309,"totalTrials":94,"cells":2310},"EBV-TCR-T cells",{"EARLY_PHASE1":2311,"PHASE1":2313,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2312,"activeCount":98},[],{"trials":2314,"activeCount":94,"soonestReadout":127},[2315,2323],{"nctId":2316,"briefTitle":2317,"status":104,"phases":2318,"primaryCompletion":127,"completion":127,"start":807,"enrollment":24,"conditions":2319,"interventions":2322},"NCT06135922","Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection",[86],[2320,2321],"EBV-associated Hemophagocytic Lymphohistiocytosis","EBV Infection",[2309],{"nctId":2324,"briefTitle":2325,"status":104,"phases":2326,"primaryCompletion":611,"completion":2213,"start":807,"enrollment":21,"conditions":2327,"interventions":2329},"NCT06119256","Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT",[86],[2328],"EBV Infection After Allogenic HSCT",[2309],{"trials":2331,"activeCount":98},[],{"trials":2333,"activeCount":98},[],{"trials":2335,"activeCount":98},[],{"trials":2337,"activeCount":98},[],{"intervention":2339,"totalTrials":94,"cells":2340},"PIN +anti-PD1",{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2361,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2342,"activeCount":98},[],{"trials":2344,"activeCount":94,"soonestReadout":126},[2345,2355],{"nctId":2346,"briefTitle":2347,"status":104,"phases":2348,"primaryCompletion":126,"completion":2349,"start":2350,"enrollment":2351,"conditions":2352,"interventions":2354},"NCT06883149","PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor",[86],"2030-12-01","2025-03-19",25,[23,2353],"Adult",[2339],{"nctId":2356,"briefTitle":2357,"status":104,"phases":2358,"primaryCompletion":1386,"completion":2349,"start":602,"enrollment":2351,"conditions":2359,"interventions":2360},"NCT07018518","PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma",[86],[18,2353],[2339],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[],{"trials":2366,"activeCount":98},[],{"trials":2368,"activeCount":98},[],{"intervention":513,"totalTrials":94,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2389},{"trials":2372,"activeCount":98},[],{"trials":2374,"activeCount":94,"soonestReadout":520},[2375,2379],{"nctId":499,"briefTitle":500,"status":501,"phases":2376,"primaryCompletion":126,"completion":503,"start":504,"enrollment":24,"conditions":2377,"interventions":2378},[86],[506,507,508,509,510],[512,513,491,514,515],{"nctId":517,"briefTitle":518,"status":104,"phases":2380,"primaryCompletion":520,"completion":503,"start":521,"enrollment":522,"conditions":2381,"interventions":2382},[86],[506,34,507,524,525,526,527],[529,513,491,530,515],{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[],{"intervention":515,"totalTrials":94,"cells":2392},{"EARLY_PHASE1":2393,"PHASE1":2395,"PHASE2":2405,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":94,"soonestReadout":520},[2397,2401],{"nctId":499,"briefTitle":500,"status":501,"phases":2398,"primaryCompletion":126,"completion":503,"start":504,"enrollment":24,"conditions":2399,"interventions":2400},[86],[506,507,508,509,510],[512,513,491,514,515],{"nctId":517,"briefTitle":518,"status":104,"phases":2402,"primaryCompletion":520,"completion":503,"start":521,"enrollment":522,"conditions":2403,"interventions":2404},[86],[506,34,507,524,525,526,527],[529,513,491,530,515],{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":98},[],{"trials":2410,"activeCount":98},[],{"trials":2412,"activeCount":98},[],{"intervention":2414,"totalTrials":114,"cells":2415},"PIN+sintilimab",{"EARLY_PHASE1":2416,"PHASE1":2418,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2417,"activeCount":98},[],{"trials":2419,"activeCount":114,"soonestReadout":2424},[2420],{"nctId":2421,"briefTitle":2422,"status":124,"phases":2423,"primaryCompletion":2424,"completion":2425,"start":1264,"enrollment":2351,"conditions":2426,"interventions":2427},"NCT07411781","PIN in Combination With Sintilimab in Previously Treated pMMR\u002FMSS CRC With Hepatic Metastases",[86],"2027-03-31","2031-03-01",[1266,2353],[2414],{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[],{"trials":2433,"activeCount":98},[],{"trials":2435,"activeCount":98},[],{"intervention":2437,"totalTrials":114,"cells":2438},"Recognized pharmacological treatments for AD.",{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2453,"PHASE3":2455,"PHASE4":2457,"NA":2459},{"trials":2440,"activeCount":98},[],{"trials":2442,"activeCount":114,"soonestReadout":2447},[2443],{"nctId":2444,"briefTitle":2445,"status":104,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":334,"enrollment":2449,"conditions":2450,"interventions":2452},"NCT07094438","Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease",[86],"2026-06","2027-07",98,[2451],"Alzheimer Disease",[2437],{"trials":2454,"activeCount":98},[],{"trials":2456,"activeCount":98},[],{"trials":2458,"activeCount":98},[],{"trials":2460,"activeCount":98},[],{"intervention":512,"totalTrials":114,"cells":2462},{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2477},{"trials":2464,"activeCount":98},[],{"trials":2466,"activeCount":114,"soonestReadout":126},[2467],{"nctId":499,"briefTitle":500,"status":501,"phases":2468,"primaryCompletion":126,"completion":503,"start":504,"enrollment":24,"conditions":2469,"interventions":2470},[86],[506,507,508,509,510],[512,513,491,514,515],{"trials":2472,"activeCount":98},[],{"trials":2474,"activeCount":98},[],{"trials":2476,"activeCount":98},[],{"trials":2478,"activeCount":98},[],{"intervention":529,"totalTrials":114,"cells":2480},{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2482,"activeCount":98},[],{"trials":2484,"activeCount":114,"soonestReadout":520},[2485],{"nctId":517,"briefTitle":518,"status":104,"phases":2486,"primaryCompletion":520,"completion":503,"start":521,"enrollment":522,"conditions":2487,"interventions":2488},[86],[506,34,507,524,525,526,527],[529,513,491,530,515],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[],{"intervention":113,"totalTrials":94,"cells":2498},{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":114,"soonestReadout":106},[2503],{"nctId":102,"briefTitle":103,"status":104,"phases":2504,"primaryCompletion":106,"completion":107,"start":108,"enrollment":109,"conditions":2505,"interventions":2506},[86],[111,26],[113,93],{"trials":2508,"activeCount":98},[],{"trials":2510,"activeCount":98},[],{"trials":2512,"activeCount":98},[],{"trials":2514,"activeCount":98},[2515],{"nctId":2516,"briefTitle":2517,"status":824,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2525},"NCT05456230","Comparison of Postoperative Delirium in Elders Anaesthetised With Midazolam and Without Midazolam",[],"2022-04-30","2022-07-11","2020-04-01",11927,[2524],"Postoperative Delirium",[113],{"intervention":2527,"totalTrials":27,"cells":2528},"normal saline",{"EARLY_PHASE1":2529,"PHASE1":2544,"PHASE2":2546,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2530,"activeCount":114,"soonestReadout":2535},[2531],{"nctId":2532,"briefTitle":2533,"status":124,"phases":2534,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":2539,"interventions":2541},"NCT06485648","Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis",[85],"2026-10-01","2029-10-01","2024-10-01",96,[2540],"Lupus Nephritis",[2542,2543],"Umbilical cord mesenchymal stem cells","Normal saline",{"trials":2545,"activeCount":98},[],{"trials":2547,"activeCount":98},[],{"trials":2549,"activeCount":98},[],{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":958,"soonestReadout":2582},[2554,2565,2578,2586,2596,2607,2620],{"nctId":2555,"briefTitle":2556,"status":824,"phases":2557,"primaryCompletion":2558,"completion":2559,"start":2560,"enrollment":861,"conditions":2561,"interventions":2563},"NCT03024801","Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury",[90],"2014-05","2016-05","2012-02",[2562],"Cartilage Injury",[2564,2527],"autologous platelet-rich plasma",{"nctId":2566,"briefTitle":2567,"status":124,"phases":2568,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":2571,"conditions":2572,"interventions":2575},"NCT07367542","Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery",[90],"2027-02-01","2026-01-17",218,[32,26,2573,2574],"S-ketamine","Breast Cancer",[2576,2577],"Esketamine 0.3mg\u002Fkg","Normal Saline",{"nctId":2579,"briefTitle":2580,"status":124,"phases":2581,"primaryCompletion":2582,"completion":2569,"start":2582,"enrollment":2583,"conditions":2584,"interventions":2585},"NCT07374211","Effect of Esketamine on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Severe Depression",[90],"2026-01-18",242,[32,26,2573,2574],[2576,2527],{"nctId":2587,"briefTitle":2588,"status":124,"phases":2589,"primaryCompletion":648,"completion":884,"start":1447,"enrollment":2590,"conditions":2591,"interventions":2593},"NCT07294755","The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery",[90],300,[2592],"Postoperative Analgesia",[2527,2594,2595],"Investigational drug 20 mL of 0.5% ropivacaine","0.5% ropivacaine + 25 mg tetracaine, made up to a total volume of 20 mL",{"nctId":2597,"briefTitle":2598,"status":625,"phases":2599,"primaryCompletion":2600,"completion":2559,"start":2560,"enrollment":886,"conditions":2601,"interventions":2603},"NCT02721940","Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis",[90],"2015-01",[2602],"Osteonecrosis",[2604,2605,2606,2543],"Mononuclear Cells","Platelets","Zoledronic Acid",{"nctId":2608,"briefTitle":2609,"status":824,"phases":2610,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":2614,"conditions":2615,"interventions":2618},"NCT06608030","Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery",[90],"2025-04-07","2025-04-30","2024-09-23",142,[2616,2617,2573],"Depression, Anxiety","Cardiac Surgery",[2619,2527],"Esketamine",{"nctId":2621,"briefTitle":2622,"status":124,"phases":2623,"primaryCompletion":2582,"completion":2569,"start":2582,"enrollment":2614,"conditions":2624,"interventions":2625},"NCT07374198","Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression",[90],[32,26,2573,2574],[2576,2527],{"intervention":2627,"totalTrials":94,"cells":2628},"YHDF placebo",{"EARLY_PHASE1":2629,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2630,"activeCount":94,"soonestReadout":2213},[2631,2642],{"nctId":2632,"briefTitle":2633,"status":124,"phases":2634,"primaryCompletion":2213,"completion":1631,"start":2214,"enrollment":2635,"conditions":2636,"interventions":2638},"NCT07612605","Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia",[85],250,[2637],"Pneumonia",[2627,2639,2640,2641],"Bacteriophage Placebo","YHDF Drug","Bacteriophage",{"nctId":2643,"briefTitle":2644,"status":124,"phases":2645,"primaryCompletion":2213,"completion":1582,"start":360,"enrollment":174,"conditions":2646,"interventions":2647},"NCT07338123","A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli",[85],[2637],[2640,2648,2641,2639],"YHDF Placebo",{"trials":2650,"activeCount":98},[],{"trials":2652,"activeCount":98},[],{"trials":2654,"activeCount":98},[],{"trials":2656,"activeCount":98},[],{"trials":2658,"activeCount":98},[],{"intervention":2639,"totalTrials":94,"cells":2660},{"EARLY_PHASE1":2661,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2662,"activeCount":94,"soonestReadout":2213},[2663,2667],{"nctId":2632,"briefTitle":2633,"status":124,"phases":2664,"primaryCompletion":2213,"completion":1631,"start":2214,"enrollment":2635,"conditions":2665,"interventions":2666},[85],[2637],[2627,2639,2640,2641],{"nctId":2643,"briefTitle":2644,"status":124,"phases":2668,"primaryCompletion":2213,"completion":1582,"start":360,"enrollment":174,"conditions":2669,"interventions":2670},[85],[2637],[2640,2648,2641,2639],{"trials":2672,"activeCount":98},[],{"trials":2674,"activeCount":98},[],{"trials":2676,"activeCount":98},[],{"trials":2678,"activeCount":98},[],{"trials":2680,"activeCount":98},[],{"intervention":2640,"totalTrials":94,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2693,"PHASE2":2695,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2684,"activeCount":94,"soonestReadout":2213},[2685,2689],{"nctId":2632,"briefTitle":2633,"status":124,"phases":2686,"primaryCompletion":2213,"completion":1631,"start":2214,"enrollment":2635,"conditions":2687,"interventions":2688},[85],[2637],[2627,2639,2640,2641],{"nctId":2643,"briefTitle":2644,"status":124,"phases":2690,"primaryCompletion":2213,"completion":1582,"start":360,"enrollment":174,"conditions":2691,"interventions":2692},[85],[2637],[2640,2648,2641,2639],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[],{"trials":2698,"activeCount":98},[],{"trials":2700,"activeCount":98},[],{"trials":2702,"activeCount":98},[],{"intervention":2641,"totalTrials":94,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2715,"PHASE2":2717,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2706,"activeCount":94,"soonestReadout":2213},[2707,2711],{"nctId":2632,"briefTitle":2633,"status":124,"phases":2708,"primaryCompletion":2213,"completion":1631,"start":2214,"enrollment":2635,"conditions":2709,"interventions":2710},[85],[2637],[2627,2639,2640,2641],{"nctId":2643,"briefTitle":2644,"status":124,"phases":2712,"primaryCompletion":2213,"completion":1582,"start":360,"enrollment":174,"conditions":2713,"interventions":2714},[85],[2637],[2640,2648,2641,2639],{"trials":2716,"activeCount":98},[],{"trials":2718,"activeCount":98},[],{"trials":2720,"activeCount":98},[],{"trials":2722,"activeCount":98},[],{"trials":2724,"activeCount":98},[],{"intervention":2542,"totalTrials":94,"cells":2726},{"EARLY_PHASE1":2727,"PHASE1":2733,"PHASE2":2735,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2728,"activeCount":114,"soonestReadout":2535},[2729],{"nctId":2532,"briefTitle":2533,"status":124,"phases":2730,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":2731,"interventions":2732},[85],[2540],[2542,2543],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[2737],{"nctId":2738,"briefTitle":2739,"status":824,"phases":2740,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":2743,"conditions":2744,"interventions":2747},"NCT02302599","Mesenchymal Stem Cells to Treat Type 2 Diabetes",[87],"2020-12","2013-01",103,[2745,2746],"Type 2 Diabetes","Mesenchymal Stem Cells",[2542,2748],"Controlled suspension liquid",{"trials":2750,"activeCount":98},[],{"trials":2752,"activeCount":98},[],{"trials":2754,"activeCount":98},[],{"intervention":2756,"totalTrials":94,"cells":2757},"Eliglustat",{"EARLY_PHASE1":2758,"PHASE1":2769,"PHASE2":2781,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2759,"activeCount":114,"soonestReadout":2764},[2760],{"nctId":2761,"briefTitle":2762,"status":124,"phases":2763,"primaryCompletion":2764,"completion":2765,"start":173,"enrollment":522,"conditions":2766,"interventions":2768},"NCT07090538","GSL Synthetase Inhibitor Plus GM-CSF and\u002F or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.",[85],"2026-08-31","2027-08-31",[2767],"Neuroblastoma",[2756],{"trials":2770,"activeCount":98},[2771],{"nctId":2772,"briefTitle":2773,"status":824,"phases":2774,"primaryCompletion":2775,"completion":2775,"start":2776,"enrollment":2777,"conditions":2778,"interventions":2779},"NCT04944888","GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor",[86],"2023-11-30","2021-07-01",31,[23,663],[2756,2780],"Immune checkpoint inhibitor",{"trials":2782,"activeCount":98},[],{"trials":2784,"activeCount":98},[],{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[],{"intervention":2790,"totalTrials":114,"cells":2791},"CAR-T cell",{"EARLY_PHASE1":2792,"PHASE1":2803,"PHASE2":2805,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2793,"activeCount":114,"soonestReadout":2798},[2794],{"nctId":2795,"briefTitle":2796,"status":124,"phases":2797,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":21,"conditions":2801,"interventions":2802},"NCT07040917","A Study of CAR-T Cells in Subjects With Autoimmune Diseases",[85],"2027-11-30","2028-04-30","2025-09-30",[2216],[2790],{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[],{"trials":2808,"activeCount":98},[],{"trials":2810,"activeCount":98},[],{"trials":2812,"activeCount":98},[],{"intervention":2814,"totalTrials":114,"cells":2815},"68Ga-XT771",{"EARLY_PHASE1":2816,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2833,"NA":2835},{"trials":2817,"activeCount":114,"soonestReadout":2822},[2818],{"nctId":2819,"briefTitle":2820,"status":104,"phases":2821,"primaryCompletion":2822,"completion":2214,"start":2823,"enrollment":639,"conditions":2824,"interventions":2826},"NCT07067905","Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma",[85],"2026-04-01","2025-06-27",[2825],"Clear Cell Renal Cell Carcinoma and Glioblastoma",[2814],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"trials":2836,"activeCount":98},[],{"intervention":2576,"totalTrials":767,"cells":2838},{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"trials":2844,"activeCount":98},[],{"trials":2846,"activeCount":98},[],{"trials":2848,"activeCount":98},[],{"trials":2850,"activeCount":767,"soonestReadout":2582},[2851,2855,2859],{"nctId":2566,"briefTitle":2567,"status":124,"phases":2852,"primaryCompletion":2569,"completion":2569,"start":2570,"enrollment":2571,"conditions":2853,"interventions":2854},[90],[32,26,2573,2574],[2576,2577],{"nctId":2579,"briefTitle":2580,"status":124,"phases":2856,"primaryCompletion":2582,"completion":2569,"start":2582,"enrollment":2583,"conditions":2857,"interventions":2858},[90],[32,26,2573,2574],[2576,2527],{"nctId":2621,"briefTitle":2622,"status":124,"phases":2860,"primaryCompletion":2582,"completion":2569,"start":2582,"enrollment":2614,"conditions":2861,"interventions":2862},[90],[32,26,2573,2574],[2576,2527],{"intervention":2864,"totalTrials":114,"cells":2865},"NBP Softgel",{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2872,"PHASE4":2874,"NA":2876},{"trials":2867,"activeCount":98},[],{"trials":2869,"activeCount":98},[],{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[],{"trials":2875,"activeCount":98},[],{"trials":2877,"activeCount":114,"soonestReadout":2882},[2878],{"nctId":2879,"briefTitle":2880,"status":124,"phases":2881,"primaryCompletion":2882,"completion":480,"start":2883,"enrollment":2884,"conditions":2885,"interventions":2886},"NCT06968429","Efficacy and Safety of Oral NBP Soft Capsules for the Prevention of Episode Migraine Attacks in Adult Migraine Patients",[90],"2027-12","2025-05",500,[1449],[2864],{"intervention":83,"totalTrials":114,"cells":2888},{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2895,"PHASE4":2897,"NA":2899},{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[],{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":114,"soonestReadout":82},[2901],{"nctId":80,"briefTitle":81,"status":501,"phases":2902,"primaryCompletion":82,"completion":2903,"start":2904,"enrollment":2905,"conditions":2906,"interventions":2907},[],"2027-06-28","2024-08-27",3000,[1449],[83],{"intervention":2594,"totalTrials":114,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2911,"activeCount":98},[],{"trials":2913,"activeCount":98},[],{"trials":2915,"activeCount":98},[],{"trials":2917,"activeCount":98},[],{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":114,"soonestReadout":648},[2922],{"nctId":2587,"briefTitle":2588,"status":124,"phases":2923,"primaryCompletion":648,"completion":884,"start":1447,"enrollment":2590,"conditions":2924,"interventions":2925},[90],[2592],[2527,2594,2595],{"intervention":2595,"totalTrials":114,"cells":2927},{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2932,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":98},[],{"trials":2933,"activeCount":98},[],{"trials":2935,"activeCount":98},[],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":114,"soonestReadout":648},[2940],{"nctId":2587,"briefTitle":2588,"status":124,"phases":2941,"primaryCompletion":648,"completion":884,"start":1447,"enrollment":2590,"conditions":2942,"interventions":2943},[90],[2592],[2527,2594,2595],{"intervention":2945,"totalTrials":114,"cells":2946},"NEFECON",{"EARLY_PHASE1":2947,"PHASE1":2949,"PHASE2":2951,"PHASE3":2953,"PHASE4":2955,"NA":2957},{"trials":2948,"activeCount":98},[],{"trials":2950,"activeCount":98},[],{"trials":2952,"activeCount":98},[],{"trials":2954,"activeCount":98},[],{"trials":2956,"activeCount":98},[],{"trials":2958,"activeCount":114,"soonestReadout":2963},[2959],{"nctId":2960,"briefTitle":2961,"status":104,"phases":2962,"primaryCompletion":2963,"completion":2963,"start":2964,"enrollment":539,"conditions":2965,"interventions":2967},"NCT07585981","Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.",[],"2027-10-01","2025-10-20",[2966],"IgA Glomerulonephritis",[2945],{"intervention":2969,"totalTrials":114,"cells":2970},"Phage cocktail administered via nebulization",{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2977,"PHASE4":2979,"NA":2981},{"trials":2972,"activeCount":98},[],{"trials":2974,"activeCount":98},[],{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[],{"trials":2980,"activeCount":98},[],{"trials":2982,"activeCount":114,"soonestReadout":2987},[2983],{"nctId":2984,"briefTitle":2985,"status":124,"phases":2986,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2989,"conditions":2990,"interventions":2992},"NCT07202234","Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia",[90],"2028-05-31","2025-11-01",248,[2991],"VAP - Ventilator Associated Pneumonia",[2969,2993],"Nebulized normal saline inhalation therapy",{"intervention":2993,"totalTrials":114,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3002,"PHASE4":3004,"NA":3006},{"trials":2997,"activeCount":98},[],{"trials":2999,"activeCount":98},[],{"trials":3001,"activeCount":98},[],{"trials":3003,"activeCount":98},[],{"trials":3005,"activeCount":98},[],{"trials":3007,"activeCount":114,"soonestReadout":2987},[3008],{"nctId":2984,"briefTitle":2985,"status":124,"phases":3009,"primaryCompletion":2987,"completion":2987,"start":2988,"enrollment":2989,"conditions":3010,"interventions":3011},[90],[2991],[2969,2993],{"intervention":64,"totalTrials":114,"cells":3013},{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3015,"activeCount":98},[],{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[],{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":114,"soonestReadout":63},[3026],{"nctId":61,"briefTitle":62,"status":104,"phases":3027,"primaryCompletion":63,"completion":63,"start":3028,"enrollment":2590,"conditions":3029,"interventions":3031},[],"2025-01-16",[3030],"Gastric Adenocarcinoma",[64,3032],"≥5 cycles of neoadjuvant PD-1 Inhibitors combined with chemotherapy",{"intervention":3032,"totalTrials":114,"cells":3034},{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3036,"activeCount":98},[],{"trials":3038,"activeCount":98},[],{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[],{"trials":3046,"activeCount":114,"soonestReadout":63},[3047],{"nctId":61,"briefTitle":62,"status":104,"phases":3048,"primaryCompletion":63,"completion":63,"start":3028,"enrollment":2590,"conditions":3049,"interventions":3050},[],[3030],[64,3032],{"intervention":3052,"totalTrials":94,"cells":3053},"chemotherapy",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3058,"PHASE3":3068,"PHASE4":3070,"NA":3082},{"trials":3055,"activeCount":98},[],{"trials":3057,"activeCount":98},[],{"trials":3059,"activeCount":98},[3060],{"nctId":3061,"briefTitle":3062,"status":625,"phases":3063,"primaryCompletion":2265,"completion":2058,"start":3064,"enrollment":852,"conditions":3065,"interventions":3067},"NCT03453255","DCHA as Postremission Therapy for AML With t(8;21)",[86,87],"2018-01-01",[3066],"Chemotherapy",[3066],{"trials":3069,"activeCount":98},[],{"trials":3071,"activeCount":98},[3072],{"nctId":3073,"briefTitle":3074,"status":625,"phases":3075,"primaryCompletion":3076,"completion":3077,"start":1797,"enrollment":522,"conditions":3078,"interventions":3080},"NCT02283424","Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation",[89],"2017-10","2017-12",[3079],"Neoplasms, Therapy-Associated",[3081,3052],"Icotinib",{"trials":3083,"activeCount":98},[],{"intervention":3085,"totalTrials":94,"cells":3086},"Conventional therapy + S (+)-Ketamine",{"EARLY_PHASE1":3087,"PHASE1":3089,"PHASE2":3091,"PHASE3":3093,"PHASE4":3095,"NA":3123},{"trials":3088,"activeCount":98},[],{"trials":3090,"activeCount":98},[],{"trials":3092,"activeCount":98},[],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[3097,3110],{"nctId":3098,"briefTitle":3099,"status":625,"phases":3100,"primaryCompletion":3101,"completion":3102,"start":3103,"enrollment":3104,"conditions":3105,"interventions":3108},"NCT04837170","Safety and Efficacy Evaluation of S (+) - Ketamine in Adults",[89],"2022-06-01","2022-06-30","2021-05-01",12000,[131,3106,3107],"Adults","Anesthesia",[3085,3109],"Conventional therapy",{"nctId":3111,"briefTitle":3112,"status":625,"phases":3113,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":2905,"conditions":3117,"interventions":3122},"NCT04834427","Safety and Efficacy Evaluation of S (+) - Ketamine in Children",[89],"2024-12-01","2024-12-04","2022-04-20",[2573,2619,3118,131,3119,3120,111,2616,3121],"Acute Pain","Analgesia","Hyperalgesia","Children",[3085,3109],{"trials":3124,"activeCount":98},[],{"intervention":3109,"totalTrials":94,"cells":3126},{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3131,"PHASE3":3133,"PHASE4":3135,"NA":3145},{"trials":3128,"activeCount":98},[],{"trials":3130,"activeCount":98},[],{"trials":3132,"activeCount":98},[],{"trials":3134,"activeCount":98},[],{"trials":3136,"activeCount":98},[3137,3141],{"nctId":3098,"briefTitle":3099,"status":625,"phases":3138,"primaryCompletion":3101,"completion":3102,"start":3103,"enrollment":3104,"conditions":3139,"interventions":3140},[89],[131,3106,3107],[3085,3109],{"nctId":3111,"briefTitle":3112,"status":625,"phases":3142,"primaryCompletion":3114,"completion":3115,"start":3116,"enrollment":2905,"conditions":3143,"interventions":3144},[89],[2573,2619,3118,131,3119,3120,111,2616,3121],[3085,3109],{"trials":3146,"activeCount":98},[],{"intervention":761,"totalTrials":94,"cells":3148},{"EARLY_PHASE1":3149,"PHASE1":3151,"PHASE2":3153,"PHASE3":3169,"PHASE4":3171,"NA":3177},{"trials":3150,"activeCount":98},[],{"trials":3152,"activeCount":98},[],{"trials":3154,"activeCount":98},[3155],{"nctId":3156,"briefTitle":3157,"status":824,"phases":3158,"primaryCompletion":3159,"completion":3160,"start":3161,"enrollment":3162,"conditions":3163,"interventions":3166},"NCT01690507","Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）",[86,87],"2015-05","2016-01","2012-11",29,[3164,3165],"MDS","AML",[977,761,3167,3168],"aclacinomycin","Granulocyte colony-stimulating factor",{"trials":3170,"activeCount":98},[],{"trials":3172,"activeCount":98},[3173],{"nctId":750,"briefTitle":751,"status":625,"phases":3174,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":3175,"interventions":3176},[89],[758],[760,761,545,762,763],{"trials":3178,"activeCount":98},[],{"intervention":3168,"totalTrials":94,"cells":3180},{"EARLY_PHASE1":3181,"PHASE1":3183,"PHASE2":3185,"PHASE3":3191,"PHASE4":3193,"NA":3199},{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[3187],{"nctId":3156,"briefTitle":3157,"status":824,"phases":3188,"primaryCompletion":3159,"completion":3160,"start":3161,"enrollment":3162,"conditions":3189,"interventions":3190},[86,87],[3164,3165],[977,761,3167,3168],{"trials":3192,"activeCount":98},[],{"trials":3194,"activeCount":98},[3195],{"nctId":750,"briefTitle":751,"status":625,"phases":3196,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":3197,"interventions":3198},[89],[758],[760,761,545,762,763],{"trials":3200,"activeCount":98},[],{"intervention":3202,"totalTrials":114,"cells":3203},"0.9% sodium chloride",{"EARLY_PHASE1":3204,"PHASE1":3206,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3224},{"trials":3205,"activeCount":98},[],{"trials":3207,"activeCount":98},[],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[],{"trials":3213,"activeCount":98},[3214],{"nctId":3215,"briefTitle":3216,"status":824,"phases":3217,"primaryCompletion":3218,"completion":3218,"start":3219,"enrollment":1005,"conditions":3220,"interventions":3222},"NCT02833688","Effects of Dexmedetomidine on the Liver Injury After Hepatectomy",[89],"2017-01-26","2016-08-02",[3221],"Ischemia-reperfusion Injury",[3223,3202],"dexmedetomidine",{"trials":3225,"activeCount":98},[],{"intervention":3081,"totalTrials":114,"cells":3227},{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3234,"PHASE4":3236,"NA":3242},{"trials":3229,"activeCount":98},[],{"trials":3231,"activeCount":98},[],{"trials":3233,"activeCount":98},[],{"trials":3235,"activeCount":98},[],{"trials":3237,"activeCount":98},[3238],{"nctId":3073,"briefTitle":3074,"status":625,"phases":3239,"primaryCompletion":3076,"completion":3077,"start":1797,"enrollment":522,"conditions":3240,"interventions":3241},[89],[3079],[3081,3052],{"trials":3243,"activeCount":98},[],{"intervention":3245,"totalTrials":114,"cells":3246},"Nicorandil",{"EARLY_PHASE1":3247,"PHASE1":3249,"PHASE2":3251,"PHASE3":3253,"PHASE4":3255,"NA":3269},{"trials":3248,"activeCount":98},[],{"trials":3250,"activeCount":98},[],{"trials":3252,"activeCount":98},[],{"trials":3254,"activeCount":98},[],{"trials":3256,"activeCount":98},[3257],{"nctId":3258,"briefTitle":3259,"status":824,"phases":3260,"primaryCompletion":3261,"completion":3262,"start":3263,"enrollment":3264,"conditions":3265,"interventions":3268},"NCT03445728","China-Administration of Nicorandil Group（CHANGE）",[89],"2020-07-31","2021-10-01","2018-02-24",238,[3266,3267,3245],"Myocardial Infarction","Percutaneous Coronary Intervention",[3245],{"trials":3270,"activeCount":98},[],{"intervention":3272,"totalTrials":114,"cells":3273},"Prednisone",{"EARLY_PHASE1":3274,"PHASE1":3276,"PHASE2":3278,"PHASE3":3280,"PHASE4":3282,"NA":3295},{"trials":3275,"activeCount":98},[],{"trials":3277,"activeCount":98},[],{"trials":3279,"activeCount":98},[],{"trials":3281,"activeCount":98},[],{"trials":3283,"activeCount":98},[3284],{"nctId":3285,"briefTitle":3286,"status":824,"phases":3287,"primaryCompletion":3288,"completion":3288,"start":3289,"enrollment":3290,"conditions":3291,"interventions":3293},"NCT02703194","Leflunomide for Maintenance of Remission in IgG4 Related Disease",[89],"2019-01","2016-03",68,[3292],"Immunoglobulin G4 Related Sclerosing Disease",[3272,3294],"Leflunomide",{"trials":3296,"activeCount":98},[],{"intervention":3294,"totalTrials":114,"cells":3298},{"EARLY_PHASE1":3299,"PHASE1":3301,"PHASE2":3303,"PHASE3":3305,"PHASE4":3307,"NA":3313},{"trials":3300,"activeCount":98},[],{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":98},[],{"trials":3306,"activeCount":98},[],{"trials":3308,"activeCount":98},[3309],{"nctId":3285,"briefTitle":3286,"status":824,"phases":3310,"primaryCompletion":3288,"completion":3288,"start":3289,"enrollment":3290,"conditions":3311,"interventions":3312},[89],[3292],[3272,3294],{"trials":3314,"activeCount":98},[],{"intervention":3316,"totalTrials":114,"cells":3317},"Intra-articular Tocilizumab",{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3324,"PHASE4":3326,"NA":3339},{"trials":3319,"activeCount":98},[],{"trials":3321,"activeCount":98},[],{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[],{"trials":3327,"activeCount":98},[3328],{"nctId":3329,"briefTitle":3330,"status":625,"phases":3331,"primaryCompletion":3332,"completion":3333,"start":3334,"enrollment":1039,"conditions":3335,"interventions":3337},"NCT03215407","The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone",[89],"2017-12-12","2018-03-03","2017-08-01",[3336],"Rheumatoid Arthritis of Knee",[3316,3338],"Intra-articular Compound Betamethasone",{"trials":3340,"activeCount":98},[],{"intervention":3338,"totalTrials":114,"cells":3342},{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3349,"PHASE4":3351,"NA":3357},{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[],{"trials":3352,"activeCount":98},[3353],{"nctId":3329,"briefTitle":3330,"status":625,"phases":3354,"primaryCompletion":3332,"completion":3333,"start":3334,"enrollment":1039,"conditions":3355,"interventions":3356},[89],[3336],[3316,3338],{"trials":3358,"activeCount":98},[],{"intervention":3360,"totalTrials":114,"cells":3361},"Abelmoschus manihot",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3368,"PHASE4":3370,"NA":3381},{"trials":3363,"activeCount":98},[],{"trials":3365,"activeCount":98},[],{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"trials":3371,"activeCount":98},[3372],{"nctId":3373,"briefTitle":3374,"status":625,"phases":3375,"primaryCompletion":3160,"completion":1036,"start":3376,"enrollment":3377,"conditions":3378,"interventions":3380},"NCT02231138","Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease",[89],"2014-09",1600,[3379],"Chronic Kidney Disease",[3360],{"trials":3382,"activeCount":98},[],{"intervention":3384,"totalTrials":114,"cells":3385},"modified Tian Wang Bu Xin Dan hydrogel patch",{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3390,"PHASE3":3392,"PHASE4":3394,"NA":3403},{"trials":3387,"activeCount":98},[],{"trials":3389,"activeCount":98},[],{"trials":3391,"activeCount":98},[],{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[3396],{"nctId":3397,"briefTitle":3398,"status":625,"phases":3399,"primaryCompletion":44,"completion":44,"start":3400,"enrollment":335,"conditions":3401,"interventions":3402},"NCT04947761","Modified Tian Wang Bu Xin Dan Hydrogel Patch in Preventing Postoperative Delirium in Elderly Patients",[89],"2021-07-13",[2524],[3384],{"trials":3404,"activeCount":98},[],{"intervention":3406,"totalTrials":114,"cells":3407},"Olmesartan medoxomil",{"EARLY_PHASE1":3408,"PHASE1":3410,"PHASE2":3412,"PHASE3":3414,"PHASE4":3416,"NA":3428},{"trials":3409,"activeCount":98},[],{"trials":3411,"activeCount":98},[],{"trials":3413,"activeCount":98},[],{"trials":3415,"activeCount":98},[],{"trials":3417,"activeCount":98},[3418],{"nctId":3419,"briefTitle":3420,"status":625,"phases":3421,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":886,"conditions":3424,"interventions":3426},"NCT02360956","Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)",[89],"2016-06","2014-12",[3425],"Coronary Atherosclerosis",[3406,3427],"Antihypertensive medication",{"trials":3429,"activeCount":98},[],{"intervention":3427,"totalTrials":114,"cells":3431},{"EARLY_PHASE1":3432,"PHASE1":3434,"PHASE2":3436,"PHASE3":3438,"PHASE4":3440,"NA":3446},{"trials":3433,"activeCount":98},[],{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[],{"trials":3439,"activeCount":98},[],{"trials":3441,"activeCount":98},[3442],{"nctId":3419,"briefTitle":3420,"status":625,"phases":3443,"primaryCompletion":3422,"completion":3422,"start":3423,"enrollment":886,"conditions":3444,"interventions":3445},[89],[3425],[3406,3427],{"trials":3447,"activeCount":98},[],{"intervention":3449,"totalTrials":114,"cells":3450},"bivalirudin",{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3455,"PHASE3":3457,"PHASE4":3459,"NA":3470},{"trials":3452,"activeCount":98},[],{"trials":3454,"activeCount":98},[],{"trials":3456,"activeCount":98},[],{"trials":3458,"activeCount":98},[],{"trials":3460,"activeCount":98},[3461],{"nctId":3462,"briefTitle":3463,"status":625,"phases":3464,"primaryCompletion":3076,"completion":1048,"start":2559,"enrollment":3465,"conditions":3466,"interventions":3468},"NCT02787317","Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI",[89],1770,[3467],"Coronary Disease",[3449,3469],"Heparin",{"trials":3471,"activeCount":98},[],{"intervention":3469,"totalTrials":114,"cells":3473},{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3482,"NA":3488},{"trials":3475,"activeCount":98},[],{"trials":3477,"activeCount":98},[],{"trials":3479,"activeCount":98},[],{"trials":3481,"activeCount":98},[],{"trials":3483,"activeCount":98},[3484],{"nctId":3462,"briefTitle":3463,"status":625,"phases":3485,"primaryCompletion":3076,"completion":1048,"start":2559,"enrollment":3465,"conditions":3486,"interventions":3487},[89],[3467],[3449,3469],{"trials":3489,"activeCount":98},[],{"intervention":3491,"totalTrials":114,"cells":3492},"Nimotuzumab plus S1",{"EARLY_PHASE1":3493,"PHASE1":3495,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3513},{"trials":3494,"activeCount":98},[],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"trials":3500,"activeCount":98},[],{"trials":3502,"activeCount":98},[3503],{"nctId":3504,"briefTitle":3505,"status":625,"phases":3506,"primaryCompletion":3507,"completion":3508,"start":3509,"enrollment":1039,"conditions":3510,"interventions":3512},"NCT02945267","Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer",[89],"2018-12","2019-12","2016-09",[3511],"Unresectable Pancreatic Cancer",[3491],{"trials":3514,"activeCount":98},[],{"intervention":3516,"totalTrials":114,"cells":3517},"Valsartan",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3524,"PHASE4":3526,"NA":3538},{"trials":3519,"activeCount":98},[],{"trials":3521,"activeCount":98},[],{"trials":3523,"activeCount":98},[],{"trials":3525,"activeCount":98},[],{"trials":3527,"activeCount":98},[3528],{"nctId":3529,"briefTitle":3530,"status":625,"phases":3531,"primaryCompletion":3532,"completion":3533,"start":3534,"enrollment":1039,"conditions":3535,"interventions":3536},"NCT02299310","Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease",[89],"2015-11","2015-12","2014-11",[3379],[3516,3537],"Perindopril",{"trials":3539,"activeCount":98},[],{"intervention":3537,"totalTrials":114,"cells":3541},{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3556},{"trials":3543,"activeCount":98},[],{"trials":3545,"activeCount":98},[],{"trials":3547,"activeCount":98},[],{"trials":3549,"activeCount":98},[],{"trials":3551,"activeCount":98},[3552],{"nctId":3529,"briefTitle":3530,"status":625,"phases":3553,"primaryCompletion":3532,"completion":3533,"start":3534,"enrollment":1039,"conditions":3554,"interventions":3555},[89],[3379],[3516,3537],{"trials":3557,"activeCount":98},[],{"intervention":3559,"totalTrials":114,"cells":3560},"physiological saline",{"EARLY_PHASE1":3561,"PHASE1":3563,"PHASE2":3565,"PHASE3":3567,"PHASE4":3569,"NA":3582},{"trials":3562,"activeCount":98},[],{"trials":3564,"activeCount":98},[],{"trials":3566,"activeCount":98},[],{"trials":3568,"activeCount":98},[],{"trials":3570,"activeCount":98},[3571],{"nctId":3572,"briefTitle":3573,"status":824,"phases":3574,"primaryCompletion":3575,"completion":3576,"start":3577,"enrollment":335,"conditions":3578,"interventions":3581},"NCT06551259","Effect of Dexmedetomidine on Central Nervous System Complications in Patients Undergoing Cardiac Surgery",[89],"2024-07-30","2024-08-30","2024-01-01",[3579,3580],"Randomized Controlled Trial","Dexmedetomidine",[3580,3559],{"trials":3583,"activeCount":98},[],{"intervention":3585,"totalTrials":114,"cells":3586},"Total Intravenous Anesthesia and Peripheral nerve blocks",{"EARLY_PHASE1":3587,"PHASE1":3589,"PHASE2":3591,"PHASE3":3593,"PHASE4":3595,"NA":3610},{"trials":3588,"activeCount":98},[],{"trials":3590,"activeCount":98},[],{"trials":3592,"activeCount":98},[],{"trials":3594,"activeCount":98},[],{"trials":3596,"activeCount":98},[3597],{"nctId":3598,"briefTitle":3599,"status":625,"phases":3600,"primaryCompletion":3601,"completion":3602,"start":3603,"enrollment":756,"conditions":3604,"interventions":3609},"NCT01934049","Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty",[89],"2014-02","2014-06","2013-09",[3605,3606,3607,2524,3608],"Femoral Neck Fractures","Postoperative Complications","Inflammatory Response","Postoperative Cognitive Dysfunction",[3585],{"trials":3611,"activeCount":98},[],{"intervention":3613,"totalTrials":114,"cells":3614},"cardiomyopeptidin",{"EARLY_PHASE1":3615,"PHASE1":3617,"PHASE2":3619,"PHASE3":3621,"PHASE4":3623,"NA":3634},{"trials":3616,"activeCount":98},[],{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"trials":3622,"activeCount":98},[],{"trials":3624,"activeCount":98},[3625],{"nctId":3626,"briefTitle":3627,"status":824,"phases":3628,"primaryCompletion":3629,"completion":650,"start":3630,"enrollment":815,"conditions":3631,"interventions":3633},"NCT06155110","A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI",[89],"2025-03-01","2019-11-01",[3632],"Cardiovascular Diseases",[3613],{"trials":3635,"activeCount":98},[],{"intervention":3637,"totalTrials":114,"cells":3638},"Avatrombopag maleate",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3662},{"trials":3640,"activeCount":98},[],{"trials":3642,"activeCount":98},[],{"trials":3644,"activeCount":98},[],{"trials":3646,"activeCount":98},[],{"trials":3648,"activeCount":98},[3649],{"nctId":3650,"briefTitle":3651,"status":625,"phases":3652,"primaryCompletion":629,"completion":3653,"start":3654,"enrollment":3655,"conditions":3656,"interventions":3659},"NCT04915287","Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure",[89],"2023-07-31","2021-06-06",476,[3657,3658],"Thrombocytopenia; Drugs","Chronic Liver Disease",[3637,3660,3661],"Platelet transfusion","Medicine",{"trials":3663,"activeCount":98},[],{"intervention":3660,"totalTrials":114,"cells":3665},{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3674,"NA":3680},{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[3676],{"nctId":3650,"briefTitle":3651,"status":625,"phases":3677,"primaryCompletion":629,"completion":3653,"start":3654,"enrollment":3655,"conditions":3678,"interventions":3679},[89],[3657,3658],[3637,3660,3661],{"trials":3681,"activeCount":98},[],{"intervention":3661,"totalTrials":114,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3690,"PHASE4":3692,"NA":3698},{"trials":3685,"activeCount":98},[],{"trials":3687,"activeCount":98},[],{"trials":3689,"activeCount":98},[],{"trials":3691,"activeCount":98},[],{"trials":3693,"activeCount":98},[3694],{"nctId":3650,"briefTitle":3651,"status":625,"phases":3695,"primaryCompletion":629,"completion":3653,"start":3654,"enrollment":3655,"conditions":3696,"interventions":3697},[89],[3657,3658],[3637,3660,3661],{"trials":3699,"activeCount":98},[],{"intervention":3701,"totalTrials":114,"cells":3702},"Xuebijing",{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3709,"PHASE4":3711,"NA":3722},{"trials":3704,"activeCount":98},[],{"trials":3706,"activeCount":98},[],{"trials":3708,"activeCount":98},[],{"trials":3710,"activeCount":98},[],{"trials":3712,"activeCount":98},[3713],{"nctId":3714,"briefTitle":3715,"status":625,"phases":3716,"primaryCompletion":3507,"completion":3507,"start":3717,"enrollment":3718,"conditions":3719,"interventions":3721},"NCT02937974","Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD",[89],"2016-10",254,[3720],"Pulmonary Disease, Chronic Obstructive",[3701],{"trials":3723,"activeCount":98},[],{"intervention":3725,"totalTrials":114,"cells":3726},"Shenyankangfu",{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3731,"PHASE3":3733,"PHASE4":3735,"NA":3751},{"trials":3728,"activeCount":98},[],{"trials":3730,"activeCount":98},[],{"trials":3732,"activeCount":98},[],{"trials":3734,"activeCount":98},[],{"trials":3736,"activeCount":98},[3737],{"nctId":3738,"briefTitle":3739,"status":625,"phases":3740,"primaryCompletion":3741,"start":3601,"enrollment":3742,"conditions":3743,"interventions":3746},"NCT02063100","Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis",[89],"2015-07",720,[3744,3745],"Glomerulonephritis","Proteinuria",[3725,3747,3748,3749,3750],"Losartan potassium 50mg","Shenyankangfu tablets and Losartan potassium 50mg","Shenyankangfu tablets and Losartan potassium 100mg","Losartan potassium 100mg",{"trials":3752,"activeCount":98},[],{"intervention":3747,"totalTrials":114,"cells":3754},{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3763,"NA":3769},{"trials":3756,"activeCount":98},[],{"trials":3758,"activeCount":98},[],{"trials":3760,"activeCount":98},[],{"trials":3762,"activeCount":98},[],{"trials":3764,"activeCount":98},[3765],{"nctId":3738,"briefTitle":3739,"status":625,"phases":3766,"primaryCompletion":3741,"start":3601,"enrollment":3742,"conditions":3767,"interventions":3768},[89],[3744,3745],[3725,3747,3748,3749,3750],{"trials":3770,"activeCount":98},[],{"intervention":3748,"totalTrials":114,"cells":3772},{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3779,"PHASE4":3781,"NA":3787},{"trials":3774,"activeCount":98},[],{"trials":3776,"activeCount":98},[],{"trials":3778,"activeCount":98},[],{"trials":3780,"activeCount":98},[],{"trials":3782,"activeCount":98},[3783],{"nctId":3738,"briefTitle":3739,"status":625,"phases":3784,"primaryCompletion":3741,"start":3601,"enrollment":3742,"conditions":3785,"interventions":3786},[89],[3744,3745],[3725,3747,3748,3749,3750],{"trials":3788,"activeCount":98},[],{"intervention":3749,"totalTrials":114,"cells":3790},{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3795,"PHASE3":3797,"PHASE4":3799,"NA":3805},{"trials":3792,"activeCount":98},[],{"trials":3794,"activeCount":98},[],{"trials":3796,"activeCount":98},[],{"trials":3798,"activeCount":98},[],{"trials":3800,"activeCount":98},[3801],{"nctId":3738,"briefTitle":3739,"status":625,"phases":3802,"primaryCompletion":3741,"start":3601,"enrollment":3742,"conditions":3803,"interventions":3804},[89],[3744,3745],[3725,3747,3748,3749,3750],{"trials":3806,"activeCount":98},[],{"intervention":3750,"totalTrials":114,"cells":3808},{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3813,"PHASE3":3815,"PHASE4":3817,"NA":3823},{"trials":3810,"activeCount":98},[],{"trials":3812,"activeCount":98},[],{"trials":3814,"activeCount":98},[],{"trials":3816,"activeCount":98},[],{"trials":3818,"activeCount":98},[3819],{"nctId":3738,"briefTitle":3739,"status":625,"phases":3820,"primaryCompletion":3741,"start":3601,"enrollment":3742,"conditions":3821,"interventions":3822},[89],[3744,3745],[3725,3747,3748,3749,3750],{"trials":3824,"activeCount":98},[],{"intervention":3826,"totalTrials":114,"cells":3827},"Nirmatrelvir\u002Fritonavir",{"EARLY_PHASE1":3828,"PHASE1":3830,"PHASE2":3832,"PHASE3":3834,"PHASE4":3836,"NA":3848},{"trials":3829,"activeCount":98},[],{"trials":3831,"activeCount":98},[],{"trials":3833,"activeCount":98},[],{"trials":3835,"activeCount":98},[],{"trials":3837,"activeCount":98},[3838],{"nctId":3839,"briefTitle":3840,"status":625,"phases":3841,"primaryCompletion":3842,"completion":3842,"start":3843,"enrollment":539,"conditions":3844,"interventions":3847},"NCT05938140","Efficiency and Safety of Paxlovid for COVID-19 Patients With Severe Chronic Kidney Disease",[89],"2025-05-30","2023-06-22",[3845,3846],"COVID-19","Renal Insufficiency, Chronic",[3826],{"trials":3849,"activeCount":98},[],{"intervention":3851,"totalTrials":114,"cells":3852},"Sitagliptin",{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3859,"PHASE4":3861,"NA":3874},{"trials":3854,"activeCount":98},[],{"trials":3856,"activeCount":98},[],{"trials":3858,"activeCount":98},[],{"trials":3860,"activeCount":98},[],{"trials":3862,"activeCount":98},[3863],{"nctId":3864,"briefTitle":3865,"status":625,"phases":3866,"primaryCompletion":3867,"completion":3868,"start":3869,"enrollment":2590,"conditions":3870,"interventions":3872},"NCT03602638","Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes",[89],"2019-05-01","2020-12-01","2018-10-01",[3871],"Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1",[3851,3873],"Acarbose",{"trials":3875,"activeCount":98},[],{"intervention":3873,"totalTrials":114,"cells":3877},{"EARLY_PHASE1":3878,"PHASE1":3880,"PHASE2":3882,"PHASE3":3884,"PHASE4":3886,"NA":3892},{"trials":3879,"activeCount":98},[],{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[],{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[3888],{"nctId":3864,"briefTitle":3865,"status":625,"phases":3889,"primaryCompletion":3867,"completion":3868,"start":3869,"enrollment":2590,"conditions":3890,"interventions":3891},[89],[3871],[3851,3873],{"trials":3893,"activeCount":98},[],{"intervention":760,"totalTrials":114,"cells":3895},{"EARLY_PHASE1":3896,"PHASE1":3898,"PHASE2":3900,"PHASE3":3902,"PHASE4":3904,"NA":3910},{"trials":3897,"activeCount":98},[],{"trials":3899,"activeCount":98},[],{"trials":3901,"activeCount":98},[],{"trials":3903,"activeCount":98},[],{"trials":3905,"activeCount":98},[3906],{"nctId":750,"briefTitle":751,"status":625,"phases":3907,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":3908,"interventions":3909},[89],[758],[760,761,545,762,763],{"trials":3911,"activeCount":98},[],{"intervention":763,"totalTrials":114,"cells":3913},{"EARLY_PHASE1":3914,"PHASE1":3916,"PHASE2":3918,"PHASE3":3920,"PHASE4":3922,"NA":3928},{"trials":3915,"activeCount":98},[],{"trials":3917,"activeCount":98},[],{"trials":3919,"activeCount":98},[],{"trials":3921,"activeCount":98},[],{"trials":3923,"activeCount":98},[3924],{"nctId":750,"briefTitle":751,"status":625,"phases":3925,"primaryCompletion":753,"completion":754,"start":755,"enrollment":756,"conditions":3926,"interventions":3927},[89],[758],[760,761,545,762,763],{"trials":3929,"activeCount":98},[],{"intervention":3931,"totalTrials":114,"cells":3932},"sodium bicarbonate Ringer",{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3939,"PHASE4":3941,"NA":3958},{"trials":3934,"activeCount":98},[],{"trials":3936,"activeCount":98},[],{"trials":3938,"activeCount":98},[],{"trials":3940,"activeCount":98},[],{"trials":3942,"activeCount":98},[3943],{"nctId":3944,"briefTitle":3945,"status":625,"phases":3946,"primaryCompletion":3947,"completion":3948,"start":3949,"enrollment":3950,"conditions":3951,"interventions":3956},"NCT04596956","Safety and Efficacy of Sodium Bicarbonate Ringer Injection",[89],"2025-08","2025-12","2020-10",5000,[3952,3953,3954,3955],"Ringer Bicarbonate","Elderly Abdominal Surgery","Safety","Effectiveness",[3931,3957],"Lactated Ringer's solution",{"trials":3959,"activeCount":98},[],{"intervention":3957,"totalTrials":114,"cells":3961},{"EARLY_PHASE1":3962,"PHASE1":3964,"PHASE2":3966,"PHASE3":3968,"PHASE4":3970,"NA":3976},{"trials":3963,"activeCount":98},[],{"trials":3965,"activeCount":98},[],{"trials":3967,"activeCount":98},[],{"trials":3969,"activeCount":98},[],{"trials":3971,"activeCount":98},[3972],{"nctId":3944,"briefTitle":3945,"status":625,"phases":3973,"primaryCompletion":3947,"completion":3948,"start":3949,"enrollment":3950,"conditions":3974,"interventions":3975},[89],[3952,3953,3954,3955],[3931,3957],{"trials":3977,"activeCount":98},[],{"intervention":3979,"totalTrials":114,"cells":3980},"Iopromide",{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3987,"PHASE4":3989,"NA":4003},{"trials":3982,"activeCount":98},[],{"trials":3984,"activeCount":98},[],{"trials":3986,"activeCount":98},[],{"trials":3988,"activeCount":98},[],{"trials":3990,"activeCount":98},[3991],{"nctId":3992,"briefTitle":3993,"status":824,"phases":3994,"primaryCompletion":3995,"completion":3996,"start":3997,"enrollment":3998,"conditions":3999,"interventions":4001},"NCT00926562","A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients",[89],"2010-12","2011-05","2009-02",592,[4000],"Kidney Failure, Chronic",[3979,4002],"Iodixanol",{"trials":4004,"activeCount":98},[],{"intervention":4002,"totalTrials":114,"cells":4006},{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4013,"PHASE4":4015,"NA":4021},{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"trials":4012,"activeCount":98},[],{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[4017],{"nctId":3992,"briefTitle":3993,"status":824,"phases":4018,"primaryCompletion":3995,"completion":3996,"start":3997,"enrollment":3998,"conditions":4019,"interventions":4020},[89],[4000],[3979,4002],{"trials":4022,"activeCount":98},[],{"intervention":4024,"totalTrials":114,"cells":4025},"Melatonin 3 mg",{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4046},{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"trials":4031,"activeCount":98},[],{"trials":4033,"activeCount":98},[],{"trials":4035,"activeCount":98},[4036],{"nctId":4037,"briefTitle":4038,"status":625,"phases":4039,"primaryCompletion":4040,"completion":4040,"start":4041,"enrollment":4042,"conditions":4043,"interventions":4045},"NCT03966235","Melatonin on Coronary Artery Calcification",[89],"2021-06-01","2019-06-01",74,[4044],"Coronary Artery Calcification",[4024],{"trials":4047,"activeCount":98},[],{"intervention":4049,"totalTrials":114,"cells":4050},"ATG",{"EARLY_PHASE1":4051,"PHASE1":4053,"PHASE2":4055,"PHASE3":4057,"PHASE4":4059,"NA":4073},{"trials":4052,"activeCount":98},[],{"trials":4054,"activeCount":98},[],{"trials":4056,"activeCount":98},[],{"trials":4058,"activeCount":98},[],{"trials":4060,"activeCount":98},[4061],{"nctId":4062,"briefTitle":4063,"status":824,"phases":4064,"primaryCompletion":4065,"completion":4066,"start":3160,"enrollment":886,"conditions":4067,"interventions":4069},"NCT02677181","Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT",[89],"2020-01","2022-04",[4068],"aGVHD",[4049,4070,4071,4072],"CsA","mycophenolate mofetil","Methotrexate",{"trials":4074,"activeCount":98},[],{"intervention":4070,"totalTrials":114,"cells":4076},{"EARLY_PHASE1":4077,"PHASE1":4079,"PHASE2":4081,"PHASE3":4083,"PHASE4":4085,"NA":4091},{"trials":4078,"activeCount":98},[],{"trials":4080,"activeCount":98},[],{"trials":4082,"activeCount":98},[],{"trials":4084,"activeCount":98},[],{"trials":4086,"activeCount":98},[4087],{"nctId":4062,"briefTitle":4063,"status":824,"phases":4088,"primaryCompletion":4065,"completion":4066,"start":3160,"enrollment":886,"conditions":4089,"interventions":4090},[89],[4068],[4049,4070,4071,4072],{"trials":4092,"activeCount":98},[],{"intervention":4071,"totalTrials":114,"cells":4094},{"EARLY_PHASE1":4095,"PHASE1":4097,"PHASE2":4099,"PHASE3":4101,"PHASE4":4103,"NA":4109},{"trials":4096,"activeCount":98},[],{"trials":4098,"activeCount":98},[],{"trials":4100,"activeCount":98},[],{"trials":4102,"activeCount":98},[],{"trials":4104,"activeCount":98},[4105],{"nctId":4062,"briefTitle":4063,"status":824,"phases":4106,"primaryCompletion":4065,"completion":4066,"start":3160,"enrollment":886,"conditions":4107,"interventions":4108},[89],[4068],[4049,4070,4071,4072],{"trials":4110,"activeCount":98},[],{"intervention":4072,"totalTrials":114,"cells":4112},{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4117,"PHASE3":4119,"PHASE4":4121,"NA":4127},{"trials":4114,"activeCount":98},[],{"trials":4116,"activeCount":98},[],{"trials":4118,"activeCount":98},[],{"trials":4120,"activeCount":98},[],{"trials":4122,"activeCount":98},[4123],{"nctId":4062,"briefTitle":4063,"status":824,"phases":4124,"primaryCompletion":4065,"completion":4066,"start":3160,"enrollment":886,"conditions":4125,"interventions":4126},[89],[4068],[4049,4070,4071,4072],{"trials":4128,"activeCount":98},[],{"intervention":4130,"totalTrials":114,"cells":4131},"Huaren Peritoneal Dialysate",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4154},{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[],{"trials":4137,"activeCount":98},[],{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[4142],{"nctId":4143,"briefTitle":4144,"status":824,"phases":4145,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":4149,"conditions":4150,"interventions":4152},"NCT01779557","Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate",[89],"2019-10","2021-09","2013-02",750,[4151],"Kidney Failure,Chronic",[4130,4153],"Baxter Peritoneal Dialysate",{"trials":4155,"activeCount":98},[],{"intervention":4153,"totalTrials":114,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4172},{"trials":4159,"activeCount":98},[],{"trials":4161,"activeCount":98},[],{"trials":4163,"activeCount":98},[],{"trials":4165,"activeCount":98},[],{"trials":4167,"activeCount":98},[4168],{"nctId":4143,"briefTitle":4144,"status":824,"phases":4169,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":4149,"conditions":4170,"interventions":4171},[89],[4151],[4130,4153],{"trials":4173,"activeCount":98},[],{"intervention":4175,"totalTrials":114,"cells":4176},"Rosuvastatin",{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4181,"PHASE3":4183,"PHASE4":4185,"NA":4197},{"trials":4178,"activeCount":98},[],{"trials":4180,"activeCount":98},[],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[4187],{"nctId":4188,"briefTitle":4189,"status":625,"phases":4190,"primaryCompletion":4191,"completion":4191,"start":4192,"enrollment":1039,"conditions":4193,"interventions":4196},"NCT00885872","Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)",[89],"2012-03","2009-03",[4194,4195],"Hyperlipidemia","Atherosclerosis",[4175],{"trials":4198,"activeCount":98},[],{"intervention":977,"totalTrials":27,"cells":4200},{"EARLY_PHASE1":4201,"PHASE1":4203,"PHASE2":4205,"PHASE3":4263,"PHASE4":4275,"NA":4277},{"trials":4202,"activeCount":98},[],{"trials":4204,"activeCount":98},[],{"trials":4206,"activeCount":98},[4207,4218,4222,4233,4245,4255,4259],{"nctId":4208,"briefTitle":4209,"status":625,"phases":4210,"primaryCompletion":2288,"completion":4211,"start":4212,"enrollment":539,"conditions":4213,"interventions":4215},"NCT03346642","Two Stage Study of Combination of Chemotherapy, SHR-1210 and\u002For Decitabine for Relapsed\u002FRefractory PMBCLs",[86,87],"2019-10-01","2017-05-01",[4214],"Primary Mediastinal Large B-cell Lymphoma",[977,4216,4217],"GVD chemotherapy","SHR-1210",{"nctId":967,"briefTitle":968,"status":625,"phases":4219,"primaryCompletion":970,"completion":971,"start":972,"enrollment":886,"conditions":4220,"interventions":4221},[87],[974],[976,957,977],{"nctId":4223,"briefTitle":4224,"status":625,"phases":4225,"primaryCompletion":4226,"completion":108,"start":4227,"enrollment":886,"conditions":4228,"interventions":4231},"NCT05320640","Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R\u002FR NHL and Advanced Solid Tumors",[86,87],"2024-04-01","2022-03-30",[4229,4230],"Relapsed\u002FRefractory Non-Hodgkin Lymphoma","Advanced Solid Tumors",[976,977,4232],"Immune checkpoint inhibitors（anti-PD1\u002FPD-L1\u002FCTLA4 antibodies）",{"nctId":4234,"briefTitle":4235,"status":625,"phases":4236,"primaryCompletion":4237,"completion":4238,"start":4239,"enrollment":756,"conditions":4240,"interventions":4242},"NCT04553393","Decitabine-primed Tandem CD19\u002FCD20 CAR T Cells Plus Epigenetic Agents in Aggressive r\u002Fr B-NHL With Huge Tumor Burden",[86,87],"2021-09-08","2022-09-08","2020-09-09",[4241],"Refractory or Relapsed Aggressive r\u002Fr B-NHL With Huge Tumor Burden",[976,977,4243,4244],"Chidamide and Decitabine","Decitabine-primed Tandem CAR19\u002F20 engineered T cells",{"nctId":4246,"briefTitle":4247,"status":625,"phases":4248,"primaryCompletion":4249,"completion":4250,"start":4251,"enrollment":4252,"conditions":4253,"interventions":4254},"NCT03250962","SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma",[87],"2022-07-21","2025-03-21","2017-09-11",280,[974],[4217,977],{"nctId":3156,"briefTitle":3157,"status":824,"phases":4256,"primaryCompletion":3159,"completion":3160,"start":3161,"enrollment":3162,"conditions":4257,"interventions":4258},[86,87],[3164,3165],[977,761,3167,3168],{"nctId":979,"briefTitle":980,"status":625,"phases":4260,"primaryCompletion":982,"completion":983,"start":984,"enrollment":886,"conditions":4261,"interventions":4262},[86,87],[986],[976,977,957],{"trials":4264,"activeCount":98},[4265],{"nctId":4266,"briefTitle":4267,"status":625,"phases":4268,"primaryCompletion":4269,"completion":4269,"start":3602,"enrollment":2884,"conditions":4270,"interventions":4273},"NCT02159820","Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer",[87,88],"2024-06",[4271,4272],"Primary Malignant Neoplasm of Ovary","FIGO Stages II to IV",[977,4274],"Paclitaxel and Carboplatin",{"trials":4276,"activeCount":98},[],{"trials":4278,"activeCount":98},[],{"intervention":4280,"totalTrials":958,"cells":4281},"Bevacizumab",{"EARLY_PHASE1":4282,"PHASE1":4284,"PHASE2":4286,"PHASE3":4320,"PHASE4":4334,"NA":4336},{"trials":4283,"activeCount":98},[],{"trials":4285,"activeCount":98},[],{"trials":4287,"activeCount":98},[4288,4298,4309],{"nctId":4289,"briefTitle":4290,"status":824,"phases":4291,"primaryCompletion":4292,"completion":4292,"start":3997,"enrollment":4293,"conditions":4294,"interventions":4296},"NCT02048540","Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell",[86,87],"2013-12",86,[4295],"Locally Advanced Gastric Carcinoma",[4280,4297],"docetaxel oxaliplatin 5-FU CF",{"nctId":4299,"briefTitle":4300,"status":625,"phases":4301,"primaryCompletion":4302,"start":4303,"enrollment":4304,"conditions":4305,"interventions":4307},"NCT01838538","Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy",[87],"2013-06","2011-06",54,[4306],"Ovarian Cancer With Malignant Ascites",[4280,4308],"TC:paclitaxel + carboplatin",{"nctId":4310,"briefTitle":4311,"status":625,"phases":4312,"primaryCompletion":4313,"completion":4313,"start":4314,"enrollment":1005,"conditions":4315,"interventions":4317},"NCT03095001","Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion",[87],"2020-06-01","2017-06-01",[4316],"Peritoneal Adhesion",[4280,4318,4319],"Carboplatin","paclitaxel",{"trials":4321,"activeCount":98},[4322],{"nctId":4323,"briefTitle":4324,"status":824,"phases":4325,"primaryCompletion":4326,"completion":4327,"start":4328,"enrollment":4329,"conditions":4330,"interventions":4332},"NCT01661790","Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer",[88],"2012-06","2012-10","2009-08",72,[4331],"Malignant Pleural Effusion",[4280,4333],"Cisplatin",{"trials":4335,"activeCount":98},[],{"trials":4337,"activeCount":98},[],{"intervention":4339,"totalTrials":94,"cells":4340},"Temozolomide",{"EARLY_PHASE1":4341,"PHASE1":4343,"PHASE2":4345,"PHASE3":4355,"PHASE4":4368,"NA":4370},{"trials":4342,"activeCount":98},[],{"trials":4344,"activeCount":98},[],{"trials":4346,"activeCount":98},[4347],{"nctId":4348,"briefTitle":4349,"status":625,"phases":4350,"primaryCompletion":4351,"completion":3422,"start":2742,"enrollment":1039,"conditions":4352,"interventions":4354},"NCT01900951","Temozolomide as Maintenance Therapy in Small Cell Lung Cancer",[87],"2016-02",[4353],"Carcinoma, Small Cell",[4339],{"trials":4356,"activeCount":98},[4357],{"nctId":4358,"briefTitle":4359,"status":625,"phases":4360,"primaryCompletion":4361,"completion":4362,"start":3533,"enrollment":4363,"conditions":4364,"interventions":4366},"NCT02772107","Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer",[87,88],"2017-06","2018-01",132,[4365],"Extensive-stage Small Cell Lung Cancer",[4339,4367],"first-line chemotherapy",{"trials":4369,"activeCount":98},[],{"trials":4371,"activeCount":98},[],{"intervention":4373,"totalTrials":94,"cells":4374},"adoptive immunotherapy",{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4379,"PHASE3":4391,"PHASE4":4402,"NA":4404},{"trials":4376,"activeCount":98},[],{"trials":4378,"activeCount":98},[],{"trials":4380,"activeCount":98},[4381],{"nctId":4382,"briefTitle":4383,"status":824,"phases":4384,"primaryCompletion":4361,"completion":4361,"start":4385,"enrollment":522,"conditions":4386,"interventions":4389},"NCT01894373","Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis",[86,87],"2015-06",[4387,4388],"Psoriasis","Adoptive Immunotherapy",[4388,4390],"CIK",{"trials":4392,"activeCount":98},[4393],{"nctId":4394,"briefTitle":4395,"status":824,"phases":4396,"primaryCompletion":4397,"completion":4398,"start":4399,"enrollment":671,"conditions":4400,"interventions":4401},"NCT02851784","Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma",[87,88],"2020-07-30","2021-03-01","2009-12",[18],[4373],{"trials":4403,"activeCount":98},[],{"trials":4405,"activeCount":98},[],{"intervention":4333,"totalTrials":94,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4427,"PHASE4":4433,"NA":4435},{"trials":4409,"activeCount":98},[],{"trials":4411,"activeCount":98},[],{"trials":4413,"activeCount":98},[4414],{"nctId":4415,"briefTitle":4416,"status":625,"phases":4417,"primaryCompletion":4302,"completion":4385,"start":4418,"enrollment":1039,"conditions":4419,"interventions":4424},"NCT01131429","A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel\u002FCisplatin in Previously Untreated Stage IIIB\u002FIV Lung Adenocarcinoma With EGFR Mutations",[87],"2010-06",[4420,4421,4422,4423],"Neoplasms, Lung","Carcinoma, Non-Small Cell Lung","Drug Therapy","Genes, EGFR",[4425,4426,4333,4426,4333,4425],"Erlotinib","Docetaxel",{"trials":4428,"activeCount":98},[4429],{"nctId":4323,"briefTitle":4324,"status":824,"phases":4430,"primaryCompletion":4326,"completion":4327,"start":4328,"enrollment":4329,"conditions":4431,"interventions":4432},[88],[4331],[4280,4333],{"trials":4434,"activeCount":98},[],{"trials":4436,"activeCount":98},[],{"intervention":4438,"totalTrials":94,"cells":4439},"Antithymocyte Globulin",{"EARLY_PHASE1":4440,"PHASE1":4442,"PHASE2":4444,"PHASE3":4456,"PHASE4":4469,"NA":4471},{"trials":4441,"activeCount":98},[],{"trials":4443,"activeCount":98},[],{"trials":4445,"activeCount":98},[4446],{"nctId":4447,"briefTitle":4448,"status":625,"phases":4449,"primaryCompletion":4450,"completion":4451,"start":3868,"enrollment":4452,"conditions":4453,"interventions":4455},"NCT04778618","Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation",[87],"2022-07-31","2024-01-14",63,[4454],"Haploidentical Hematopoietic Stem Cell Transplantation",[4438],{"trials":4457,"activeCount":98},[4458],{"nctId":4459,"briefTitle":4460,"status":824,"phases":4461,"primaryCompletion":4462,"completion":4463,"start":4464,"enrollment":1823,"conditions":4465,"interventions":4466},"NCT05166967","Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation",[88],"2024-02-16","2025-07-29","2022-01-01",[4454],[4467,4468],"Individual Antithymocyte globulin","Antithymocyte globulin",{"trials":4470,"activeCount":98},[],{"trials":4472,"activeCount":98},[],{"intervention":4367,"totalTrials":114,"cells":4474},{"EARLY_PHASE1":4475,"PHASE1":4477,"PHASE2":4479,"PHASE3":4481,"PHASE4":4487,"NA":4489},{"trials":4476,"activeCount":98},[],{"trials":4478,"activeCount":98},[],{"trials":4480,"activeCount":98},[],{"trials":4482,"activeCount":98},[4483],{"nctId":4358,"briefTitle":4359,"status":625,"phases":4484,"primaryCompletion":4361,"completion":4362,"start":3533,"enrollment":4363,"conditions":4485,"interventions":4486},[87,88],[4365],[4339,4367],{"trials":4488,"activeCount":98},[],{"trials":4490,"activeCount":98},[],{"intervention":4492,"totalTrials":114,"cells":4493},"Camrelizumab and Decitabine",{"EARLY_PHASE1":4494,"PHASE1":4496,"PHASE2":4498,"PHASE3":4500,"PHASE4":4509,"NA":4511},{"trials":4495,"activeCount":98},[],{"trials":4497,"activeCount":98},[],{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[4502],{"nctId":4503,"briefTitle":4504,"status":625,"phases":4505,"primaryCompletion":4464,"completion":334,"start":4506,"enrollment":886,"conditions":4507,"interventions":4508},"NCT04510610","Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed\u002FRefractory Classical Hodgkin Lymphoma",[87,88],"2019-09-01",[974],[4492],{"trials":4510,"activeCount":98},[],{"trials":4512,"activeCount":98},[],{"intervention":4514,"totalTrials":114,"cells":4515},"genotyping guided therapy Ticagrelor, Clopidogrel",{"EARLY_PHASE1":4516,"PHASE1":4518,"PHASE2":4520,"PHASE3":4522,"PHASE4":4533,"NA":4535},{"trials":4517,"activeCount":98},[],{"trials":4519,"activeCount":98},[],{"trials":4521,"activeCount":98},[],{"trials":4523,"activeCount":98},[4524],{"nctId":4525,"briefTitle":4526,"status":625,"phases":4527,"primaryCompletion":3289,"completion":4528,"start":1797,"enrollment":335,"conditions":4529,"interventions":4531},"NCT02048228","Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS",[87,88],"2016-08",[4530],"CLOPIDOGREL, POOR METABOLISM of (Disorder)",[4514,4532],"standard therapy clopidogrel",{"trials":4534,"activeCount":98},[],{"trials":4536,"activeCount":98},[],{"intervention":4532,"totalTrials":114,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4545,"PHASE4":4551,"NA":4553},{"trials":4540,"activeCount":98},[],{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[],{"trials":4546,"activeCount":98},[4547],{"nctId":4525,"briefTitle":4526,"status":625,"phases":4548,"primaryCompletion":3289,"completion":4528,"start":1797,"enrollment":335,"conditions":4549,"interventions":4550},[87,88],[4530],[4514,4532],{"trials":4552,"activeCount":98},[],{"trials":4554,"activeCount":98},[],{"intervention":4467,"totalTrials":114,"cells":4556},{"EARLY_PHASE1":4557,"PHASE1":4559,"PHASE2":4561,"PHASE3":4563,"PHASE4":4569,"NA":4571},{"trials":4558,"activeCount":98},[],{"trials":4560,"activeCount":98},[],{"trials":4562,"activeCount":98},[],{"trials":4564,"activeCount":98},[4565],{"nctId":4459,"briefTitle":4460,"status":824,"phases":4566,"primaryCompletion":4462,"completion":4463,"start":4464,"enrollment":1823,"conditions":4567,"interventions":4568},[88],[4454],[4467,4468],{"trials":4570,"activeCount":98},[],{"trials":4572,"activeCount":98},[],{"intervention":4574,"totalTrials":114,"cells":4575},"Anlotinib and TQB2450 solution",{"EARLY_PHASE1":4576,"PHASE1":4578,"PHASE2":4580,"PHASE3":4582,"PHASE4":4596,"NA":4598},{"trials":4577,"activeCount":98},[],{"trials":4579,"activeCount":98},[],{"trials":4581,"activeCount":98},[],{"trials":4583,"activeCount":98},[4584],{"nctId":4585,"briefTitle":4586,"status":625,"phases":4587,"primaryCompletion":4588,"completion":1109,"start":4589,"enrollment":756,"conditions":4590,"interventions":4594},"NCT04665609","Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC",[88],"2022-12-31","2021-03-05",[18,4591,4592,4593],"Thermal Ablation","Anlotinib","PDL-1",[4574,4595],"TQB2450 solution",{"trials":4597,"activeCount":98},[],{"trials":4599,"activeCount":98},[],{"intervention":4595,"totalTrials":114,"cells":4601},{"EARLY_PHASE1":4602,"PHASE1":4604,"PHASE2":4606,"PHASE3":4608,"PHASE4":4614,"NA":4616},{"trials":4603,"activeCount":98},[],{"trials":4605,"activeCount":98},[],{"trials":4607,"activeCount":98},[],{"trials":4609,"activeCount":98},[4610],{"nctId":4585,"briefTitle":4586,"status":625,"phases":4611,"primaryCompletion":4588,"completion":1109,"start":4589,"enrollment":756,"conditions":4612,"interventions":4613},[88],[18,4591,4592,4593],[4574,4595],{"trials":4615,"activeCount":98},[],{"trials":4617,"activeCount":98},[],{"intervention":4274,"totalTrials":114,"cells":4619},{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4632,"NA":4634},{"trials":4621,"activeCount":98},[],{"trials":4623,"activeCount":98},[],{"trials":4625,"activeCount":98},[],{"trials":4627,"activeCount":98},[4628],{"nctId":4266,"briefTitle":4267,"status":625,"phases":4629,"primaryCompletion":4269,"completion":4269,"start":3602,"enrollment":2884,"conditions":4630,"interventions":4631},[87,88],[4271,4272],[977,4274],{"trials":4633,"activeCount":98},[],{"trials":4635,"activeCount":98},[],{"intervention":976,"totalTrials":2255,"cells":4637},{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4670,"PHASE4":4672,"NA":4674},{"trials":4639,"activeCount":98},[],{"trials":4641,"activeCount":98},[],{"trials":4643,"activeCount":98},[4644,4648,4652,4656,4666],{"nctId":967,"briefTitle":968,"status":625,"phases":4645,"primaryCompletion":970,"completion":971,"start":972,"enrollment":886,"conditions":4646,"interventions":4647},[87],[974],[976,957,977],{"nctId":4223,"briefTitle":4224,"status":625,"phases":4649,"primaryCompletion":4226,"completion":108,"start":4227,"enrollment":886,"conditions":4650,"interventions":4651},[86,87],[4229,4230],[976,977,4232],{"nctId":4234,"briefTitle":4235,"status":625,"phases":4653,"primaryCompletion":4237,"completion":4238,"start":4239,"enrollment":756,"conditions":4654,"interventions":4655},[86,87],[4241],[976,977,4243,4244],{"nctId":4657,"briefTitle":4658,"status":625,"phases":4659,"primaryCompletion":4660,"completion":2057,"start":4661,"enrollment":852,"conditions":4662,"interventions":4663},"NCT05370547","Chidamide Bridging for CAR-T Therapy",[86,87],"2024-06-30","2022-05-25",[551],[976,4664,4665],"Fludarabine and cyclophosphamide","Anti-CD19 CAR-T cells",{"nctId":979,"briefTitle":980,"status":625,"phases":4667,"primaryCompletion":982,"completion":983,"start":984,"enrollment":886,"conditions":4668,"interventions":4669},[86,87],[986],[976,977,957],{"trials":4671,"activeCount":98},[],{"trials":4673,"activeCount":98},[],{"trials":4675,"activeCount":98},[],{"intervention":2270,"totalTrials":2255,"cells":4677},{"EARLY_PHASE1":4678,"PHASE1":4680,"PHASE2":4686,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4679,"activeCount":98},[],{"trials":4681,"activeCount":98},[4682],{"nctId":2262,"briefTitle":2263,"status":625,"phases":4683,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":16,"conditions":4684,"interventions":4685},[86],[23,34],[2270,514,2271],{"trials":4687,"activeCount":98},[4688,4692,4702,4706],{"nctId":2283,"briefTitle":2284,"status":625,"phases":4689,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":861,"conditions":4690,"interventions":4691},[86,87],[29],[2270,2291,2292,530],{"nctId":4693,"briefTitle":4694,"status":625,"phases":4695,"primaryCompletion":4696,"completion":4697,"start":4698,"enrollment":522,"conditions":4699,"interventions":4700},"NCT04873440","An Open-label, Phase I\u002FII Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma",[86,87],"2022-05-31","2023-05-31","2021-05-06",[23,34],[2270,4701],"Chemo-immunotherapy",{"nctId":2294,"briefTitle":2295,"status":625,"phases":4703,"primaryCompletion":2297,"completion":2298,"start":2288,"enrollment":16,"conditions":4704,"interventions":4705},[86,87],[2300],[2270,2291,2292,530],{"nctId":4707,"briefTitle":4708,"status":824,"phases":4709,"primaryCompletion":4710,"completion":4711,"start":4712,"enrollment":4713,"conditions":4714,"interventions":4716},"NCT03989336","A Study of the Pan-immunotherapy in Patients With Relapsed\u002FRefractory Ovarian Cancer",[87],"2022-05-22","2023-12-10","2020-12-23",84,[4715],"Ovarian Cancer",[2270,2291,4717,4718],"Platinum chemotherapy","Sintilimab",{"trials":4720,"activeCount":98},[],{"trials":4722,"activeCount":98},[],{"trials":4724,"activeCount":98},[],{"intervention":2292,"totalTrials":767,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4731,"PHASE3":4748,"PHASE4":4750,"NA":4752},{"trials":4728,"activeCount":98},[],{"trials":4730,"activeCount":98},[],{"trials":4732,"activeCount":98},[4733,4740,4744],{"nctId":4734,"briefTitle":4735,"status":625,"phases":4736,"primaryCompletion":3159,"completion":3533,"start":2558,"enrollment":539,"conditions":4737,"interventions":4738},"NCT02135822","Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer",[87],[1041],[1043,4739],"gemcitabine",{"nctId":2283,"briefTitle":2284,"status":625,"phases":4741,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":861,"conditions":4742,"interventions":4743},[86,87],[29],[2270,2291,2292,530],{"nctId":2294,"briefTitle":2295,"status":625,"phases":4745,"primaryCompletion":2297,"completion":2298,"start":2288,"enrollment":16,"conditions":4746,"interventions":4747},[86,87],[2300],[2270,2291,2292,530],{"trials":4749,"activeCount":98},[],{"trials":4751,"activeCount":98},[],{"trials":4753,"activeCount":98},[],{"intervention":2291,"totalTrials":767,"cells":4755},{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4760,"PHASE3":4774,"PHASE4":4776,"NA":4778},{"trials":4757,"activeCount":98},[],{"trials":4759,"activeCount":98},[],{"trials":4761,"activeCount":98},[4762,4766,4770],{"nctId":2283,"briefTitle":2284,"status":625,"phases":4763,"primaryCompletion":2286,"completion":2287,"start":2288,"enrollment":861,"conditions":4764,"interventions":4765},[86,87],[29],[2270,2291,2292,530],{"nctId":2294,"briefTitle":2295,"status":625,"phases":4767,"primaryCompletion":2297,"completion":2298,"start":2288,"enrollment":16,"conditions":4768,"interventions":4769},[86,87],[2300],[2270,2291,2292,530],{"nctId":4707,"briefTitle":4708,"status":824,"phases":4771,"primaryCompletion":4710,"completion":4711,"start":4712,"enrollment":4713,"conditions":4772,"interventions":4773},[87],[4715],[2270,2291,4717,4718],{"trials":4775,"activeCount":98},[],{"trials":4777,"activeCount":98},[],{"trials":4779,"activeCount":98},[],{"intervention":1008,"totalTrials":767,"cells":4781},{"EARLY_PHASE1":4782,"PHASE1":4784,"PHASE2":4786,"PHASE3":4805,"PHASE4":4807,"NA":4809},{"trials":4783,"activeCount":98},[],{"trials":4785,"activeCount":98},[],{"trials":4787,"activeCount":98},[4788,4792,4801],{"nctId":1045,"briefTitle":1046,"status":625,"phases":4789,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":16,"conditions":4790,"interventions":4791},[87],[20],[1052,1008,1017],{"nctId":4793,"briefTitle":4794,"status":625,"phases":4795,"primaryCompletion":4361,"completion":3077,"start":4796,"enrollment":671,"conditions":4797,"interventions":4798},"NCT02250209","T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy",[87],"2014-07",[20],[4799,4800,1008],"Trastuzumab","Capecitabine",{"nctId":999,"briefTitle":1000,"status":625,"phases":4802,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":1005,"conditions":4803,"interventions":4804},[87],[20],[957,1008,1009],{"trials":4806,"activeCount":98},[],{"trials":4808,"activeCount":98},[],{"trials":4810,"activeCount":98},[],{"intervention":4217,"totalTrials":94,"cells":4812},{"EARLY_PHASE1":4813,"PHASE1":4815,"PHASE2":4817,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4814,"activeCount":98},[],{"trials":4816,"activeCount":98},[],{"trials":4818,"activeCount":98},[4819,4823],{"nctId":4208,"briefTitle":4209,"status":625,"phases":4820,"primaryCompletion":2288,"completion":4211,"start":4212,"enrollment":539,"conditions":4821,"interventions":4822},[86,87],[4214],[977,4216,4217],{"nctId":4246,"briefTitle":4247,"status":625,"phases":4824,"primaryCompletion":4249,"completion":4250,"start":4251,"enrollment":4252,"conditions":4825,"interventions":4826},[87],[974],[4217,977],{"trials":4828,"activeCount":98},[],{"trials":4830,"activeCount":98},[],{"trials":4832,"activeCount":98},[],{"intervention":1043,"totalTrials":94,"cells":4834},{"EARLY_PHASE1":4835,"PHASE1":4837,"PHASE2":4839,"PHASE3":4849,"PHASE4":4851,"NA":4853},{"trials":4836,"activeCount":98},[],{"trials":4838,"activeCount":98},[],{"trials":4840,"activeCount":98},[4841,4845],{"nctId":1033,"briefTitle":1034,"status":625,"phases":4842,"primaryCompletion":1036,"completion":1037,"start":1038,"enrollment":1039,"conditions":4843,"interventions":4844},[87],[1041],[1043,1017],{"nctId":4734,"briefTitle":4735,"status":625,"phases":4846,"primaryCompletion":3159,"completion":3533,"start":2558,"enrollment":539,"conditions":4847,"interventions":4848},[87],[1041],[1043,4739],{"trials":4850,"activeCount":98},[],{"trials":4852,"activeCount":98},[],{"trials":4854,"activeCount":98},[],{"intervention":4856,"totalTrials":94,"cells":4857},"Mesenchymal stem cells",{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4870,"PHASE3":4879,"PHASE4":4881,"NA":4883},{"trials":4859,"activeCount":98},[],{"trials":4861,"activeCount":98},[4862],{"nctId":4863,"briefTitle":4864,"status":625,"phases":4865,"primaryCompletion":3533,"completion":3077,"start":2742,"enrollment":16,"conditions":4866,"interventions":4869},"NCT02304588","Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot",[86],[4867,4868],"Diabetic Foot","Lower Limb Ischemia",[4856],{"trials":4871,"activeCount":98},[4872],{"nctId":4873,"briefTitle":4874,"status":625,"phases":4875,"primaryCompletion":4876,"completion":4588,"start":1111,"enrollment":756,"conditions":4877,"interventions":4878},"NCT04194671","Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury",[86,87],"2022-10-31",[863,2746],[4856],{"trials":4880,"activeCount":98},[],{"trials":4882,"activeCount":98},[],{"trials":4884,"activeCount":98},[],{"intervention":1052,"totalTrials":94,"cells":4886},{"EARLY_PHASE1":4887,"PHASE1":4889,"PHASE2":4891,"PHASE3":4905,"PHASE4":4907,"NA":4909},{"trials":4888,"activeCount":98},[],{"trials":4890,"activeCount":98},[],{"trials":4892,"activeCount":98},[4893,4901],{"nctId":4894,"briefTitle":4895,"status":625,"phases":4896,"primaryCompletion":4897,"completion":4897,"start":4898,"enrollment":756,"conditions":4899,"interventions":4900},"NCT02596256","Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)",[87],"2019-02","2016-04",[20],[1052,4426],{"nctId":1045,"briefTitle":1046,"status":625,"phases":4902,"primaryCompletion":1048,"completion":1048,"start":1049,"enrollment":16,"conditions":4903,"interventions":4904},[87],[20],[1052,1008,1017],{"trials":4906,"activeCount":98},[],{"trials":4908,"activeCount":98},[],{"trials":4910,"activeCount":98},[],{"intervention":4426,"totalTrials":94,"cells":4912},{"EARLY_PHASE1":4913,"PHASE1":4915,"PHASE2":4917,"PHASE3":4927,"PHASE4":4929,"NA":4931},{"trials":4914,"activeCount":98},[],{"trials":4916,"activeCount":98},[],{"trials":4918,"activeCount":98},[4919,4923],{"nctId":4894,"briefTitle":4895,"status":625,"phases":4920,"primaryCompletion":4897,"completion":4897,"start":4898,"enrollment":756,"conditions":4921,"interventions":4922},[87],[20],[1052,4426],{"nctId":4415,"briefTitle":4416,"status":625,"phases":4924,"primaryCompletion":4302,"completion":4385,"start":4418,"enrollment":1039,"conditions":4925,"interventions":4926},[87],[4420,4421,4422,4423],[4425,4426,4333,4426,4333,4425],{"trials":4928,"activeCount":98},[],{"trials":4930,"activeCount":98},[],{"trials":4932,"activeCount":98},[],{"intervention":4718,"totalTrials":94,"cells":4934},{"EARLY_PHASE1":4935,"PHASE1":4937,"PHASE2":4939,"PHASE3":4956,"PHASE4":4958,"NA":4960},{"trials":4936,"activeCount":98},[],{"trials":4938,"activeCount":98},[],{"trials":4940,"activeCount":98},[4941,4952],{"nctId":4942,"briefTitle":4943,"status":625,"phases":4944,"primaryCompletion":4945,"completion":4946,"start":4947,"enrollment":539,"conditions":4948,"interventions":4950},"NCT04179084","Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer",[87],"2020-03-01","2020-05-01","2019-08-28",[4949],"Metastasis Colorectal Cancer",[4951,4718],"fruquintinib",{"nctId":4707,"briefTitle":4708,"status":824,"phases":4953,"primaryCompletion":4710,"completion":4711,"start":4712,"enrollment":4713,"conditions":4954,"interventions":4955},[87],[4715],[2270,2291,4717,4718],{"trials":4957,"activeCount":98},[],{"trials":4959,"activeCount":98},[],{"trials":4961,"activeCount":98},[],{"intervention":4963,"totalTrials":114,"cells":4964},"Chidamide; Decitabine; Camrelizumab",{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4966,"activeCount":98},[],{"trials":4968,"activeCount":98},[],{"trials":4970,"activeCount":98},[4971],{"nctId":4972,"briefTitle":4973,"status":625,"phases":4974,"primaryCompletion":4975,"completion":173,"start":4976,"enrollment":335,"conditions":4977,"interventions":4979},"NCT04514081","The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.",[87],"2022-08-01","2020-08-01",[974,4978],"Anti-PD-1 Antibody Resistant",[4963,4980],"Decitabine+Camrelizumab",{"trials":4982,"activeCount":98},[],{"trials":4984,"activeCount":98},[],{"trials":4986,"activeCount":98},[],{"intervention":4980,"totalTrials":114,"cells":4988},{"EARLY_PHASE1":4989,"PHASE1":4991,"PHASE2":4993,"PHASE3":4999,"PHASE4":5001,"NA":5003},{"trials":4990,"activeCount":98},[],{"trials":4992,"activeCount":98},[],{"trials":4994,"activeCount":98},[4995],{"nctId":4972,"briefTitle":4973,"status":625,"phases":4996,"primaryCompletion":4975,"completion":173,"start":4976,"enrollment":335,"conditions":4997,"interventions":4998},[87],[974,4978],[4963,4980],{"trials":5000,"activeCount":98},[],{"trials":5002,"activeCount":98},[],{"trials":5004,"activeCount":98},[],{"intervention":5006,"totalTrials":114,"cells":5007},"Combination: Fruquintinib + FOLFIRI",{"EARLY_PHASE1":5008,"PHASE1":5010,"PHASE2":5012,"PHASE3":5024,"PHASE4":5026,"NA":5028},{"trials":5009,"activeCount":98},[],{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[5014],{"nctId":5015,"briefTitle":5016,"status":625,"phases":5017,"primaryCompletion":5018,"completion":3948,"start":5019,"enrollment":5020,"conditions":5021,"interventions":5023},"NCT05522738","Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer",[86,87],"2024-12","2022-08-10",46,[5022],"Metastatic Colorectal Cancer",[5006],{"trials":5025,"activeCount":98},[],{"trials":5027,"activeCount":98},[],{"trials":5029,"activeCount":98},[],{"intervention":4216,"totalTrials":114,"cells":5031},{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5042,"PHASE4":5044,"NA":5046},{"trials":5033,"activeCount":98},[],{"trials":5035,"activeCount":98},[],{"trials":5037,"activeCount":98},[5038],{"nctId":4208,"briefTitle":4209,"status":625,"phases":5039,"primaryCompletion":2288,"completion":4211,"start":4212,"enrollment":539,"conditions":5040,"interventions":5041},[86,87],[4214],[977,4216,4217],{"trials":5043,"activeCount":98},[],{"trials":5045,"activeCount":98},[],{"trials":5047,"activeCount":98},[],{"intervention":5049,"totalTrials":114,"cells":5050},"nanoparticle albumin-bound paclitaxel, S-1",{"EARLY_PHASE1":5051,"PHASE1":5053,"PHASE2":5055,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5052,"activeCount":98},[],{"trials":5054,"activeCount":98},[],{"trials":5056,"activeCount":98},[5057],{"nctId":5058,"briefTitle":5059,"status":824,"phases":5060,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":5064,"conditions":5065,"interventions":5067},"NCT03051373","Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and\u002For Metastatic Transitional Cell Carcinoma of Urothelial Tract",[87],"2019-04-30","2020-04-30","2017-04-01",108,[5066],"Carcinoma, Transitional Cell",[5049,5068],"Gemcitabine, cisplatin",{"trials":5070,"activeCount":98},[],{"trials":5072,"activeCount":98},[],{"trials":5074,"activeCount":98},[],{"intervention":5068,"totalTrials":114,"cells":5076},{"EARLY_PHASE1":5077,"PHASE1":5079,"PHASE2":5081,"PHASE3":5087,"PHASE4":5089,"NA":5091},{"trials":5078,"activeCount":98},[],{"trials":5080,"activeCount":98},[],{"trials":5082,"activeCount":98},[5083],{"nctId":5058,"briefTitle":5059,"status":824,"phases":5084,"primaryCompletion":5061,"completion":5062,"start":5063,"enrollment":5064,"conditions":5085,"interventions":5086},[87],[5066],[5049,5068],{"trials":5088,"activeCount":98},[],{"trials":5090,"activeCount":98},[],{"trials":5092,"activeCount":98},[],{"intervention":5094,"totalTrials":114,"cells":5095},"PD-1 inhibitor + Gemcitabine + Cisplatin",{"EARLY_PHASE1":5096,"PHASE1":5098,"PHASE2":5100,"PHASE3":5108,"PHASE4":5110,"NA":5112},{"trials":5097,"activeCount":98},[],{"trials":5099,"activeCount":98},[],{"trials":5101,"activeCount":98},[5102],{"nctId":5103,"briefTitle":5104,"status":625,"phases":5105,"primaryCompletion":39,"completion":4146,"start":4212,"enrollment":539,"conditions":5106,"interventions":5107},"NCT03311789","Study of PD-1 Inhibitor in Combination With Gemcitabine\u002FCisplatin for Advancer BTCs",[86,87],[1139],[5094],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[],{"trials":5113,"activeCount":98},[],{"intervention":5115,"totalTrials":114,"cells":5116},"Crizotinib, bevacizumab",{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5121,"PHASE3":5131,"PHASE4":5133,"NA":5135},{"trials":5118,"activeCount":98},[],{"trials":5120,"activeCount":98},[],{"trials":5122,"activeCount":98},[5123],{"nctId":5124,"briefTitle":5125,"status":625,"phases":5126,"primaryCompletion":3076,"completion":5127,"start":755,"enrollment":1039,"conditions":5128,"interventions":5130},"NCT02946359","A+C in Metastatic Lung Adenocarcinoma Cancer",[87],"2018-07",[5129],"Lung Adenocarcinoma Metastatic",[5115],{"trials":5132,"activeCount":98},[],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"intervention":5138,"totalTrials":114,"cells":5139},"Metoprolol",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5157,"PHASE4":5159,"NA":5161},{"trials":5141,"activeCount":98},[],{"trials":5143,"activeCount":98},[],{"trials":5145,"activeCount":98},[5146],{"nctId":5147,"briefTitle":5148,"status":625,"phases":5149,"primaryCompletion":5150,"completion":5151,"start":5152,"enrollment":539,"conditions":5153,"interventions":5155},"NCT04082910","Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells",[86,87],"2022-12-30","2023-12-30","2019-09-15",[23,5154],"Hematological Malignancy",[5138,5156],"metoprolol, infliximab, etanercept, tocilizumab and\u002For other agents",{"trials":5158,"activeCount":98},[],{"trials":5160,"activeCount":98},[],{"trials":5162,"activeCount":98},[],{"intervention":5156,"totalTrials":114,"cells":5164},{"EARLY_PHASE1":5165,"PHASE1":5167,"PHASE2":5169,"PHASE3":5175,"PHASE4":5177,"NA":5179},{"trials":5166,"activeCount":98},[],{"trials":5168,"activeCount":98},[],{"trials":5170,"activeCount":98},[5171],{"nctId":5147,"briefTitle":5148,"status":625,"phases":5172,"primaryCompletion":5150,"completion":5151,"start":5152,"enrollment":539,"conditions":5173,"interventions":5174},[86,87],[23,5154],[5138,5156],{"trials":5176,"activeCount":98},[],{"trials":5178,"activeCount":98},[],{"trials":5180,"activeCount":98},[],{"intervention":5182,"totalTrials":114,"cells":5183},"CD19-PD1-CART Cell",{"EARLY_PHASE1":5184,"PHASE1":5186,"PHASE2":5188,"PHASE3":5199,"PHASE4":5201,"NA":5203},{"trials":5185,"activeCount":98},[],{"trials":5187,"activeCount":98},[],{"trials":5189,"activeCount":98},[5190],{"nctId":5191,"briefTitle":5192,"status":625,"phases":5193,"primaryCompletion":2776,"completion":5194,"start":5195,"enrollment":539,"conditions":5196,"interventions":5198},"NCT04163302","Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed\u002FRefractory B Cell Lymphoma",[87],"2022-07-01","2019-07-07",[5197],"Lymphoma, B-Cell",[5182],{"trials":5200,"activeCount":98},[],{"trials":5202,"activeCount":98},[],{"trials":5204,"activeCount":98},[],{"intervention":5206,"totalTrials":114,"cells":5207},"SHR2150",{"EARLY_PHASE1":5208,"PHASE1":5210,"PHASE2":5212,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5209,"activeCount":98},[],{"trials":5211,"activeCount":98},[],{"trials":5213,"activeCount":98},[5214],{"nctId":5215,"briefTitle":5216,"status":625,"phases":5217,"primaryCompletion":5218,"completion":5219,"start":5220,"enrollment":861,"conditions":5221,"interventions":5222},"NCT04588324","Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable\u002F Metastatic Solid Tumors",[86,87],"2021-11-30","2022-11-30","2020-10-10",[23],[5206,5223,5206],"Anti-Cancer Agent",{"trials":5225,"activeCount":98},[],{"trials":5227,"activeCount":98},[],{"trials":5229,"activeCount":98},[],{"intervention":5223,"totalTrials":114,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5236,"PHASE3":5242,"PHASE4":5244,"NA":5246},{"trials":5233,"activeCount":98},[],{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[5238],{"nctId":5215,"briefTitle":5216,"status":625,"phases":5239,"primaryCompletion":5218,"completion":5219,"start":5220,"enrollment":861,"conditions":5240,"interventions":5241},[86,87],[23],[5206,5223,5206],{"trials":5243,"activeCount":98},[],{"trials":5245,"activeCount":98},[],{"trials":5247,"activeCount":98},[],{"intervention":5249,"totalTrials":114,"cells":5250},"Prophylactic DLI",{"EARLY_PHASE1":5251,"PHASE1":5253,"PHASE2":5255,"PHASE3":5267,"PHASE4":5269,"NA":5271},{"trials":5252,"activeCount":98},[],{"trials":5254,"activeCount":98},[],{"trials":5256,"activeCount":98},[5257],{"nctId":5258,"briefTitle":5259,"status":625,"phases":5260,"primaryCompletion":2741,"completion":5261,"start":3288,"enrollment":671,"conditions":5262,"interventions":5266},"NCT03771222","Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies",[87],"2021-12",[5263,1660,5264,5265,977],"Donor Lymphocyte Infusion","Relapse","Graft-versus-host Disease",[5249],{"trials":5268,"activeCount":98},[],{"trials":5270,"activeCount":98},[],{"trials":5272,"activeCount":98},[],{"intervention":4297,"totalTrials":114,"cells":5274},{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5285,"PHASE4":5287,"NA":5289},{"trials":5276,"activeCount":98},[],{"trials":5278,"activeCount":98},[],{"trials":5280,"activeCount":98},[5281],{"nctId":4289,"briefTitle":4290,"status":824,"phases":5282,"primaryCompletion":4292,"completion":4292,"start":3997,"enrollment":4293,"conditions":5283,"interventions":5284},[86,87],[4295],[4280,4297],{"trials":5286,"activeCount":98},[],{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[],{"intervention":5292,"totalTrials":114,"cells":5293},"Tislelizumab",{"EARLY_PHASE1":5294,"PHASE1":5296,"PHASE2":5298,"PHASE3":5313,"PHASE4":5315,"NA":5317},{"trials":5295,"activeCount":98},[],{"trials":5297,"activeCount":98},[],{"trials":5299,"activeCount":98},[5300],{"nctId":5301,"briefTitle":5302,"status":625,"phases":5303,"primaryCompletion":5304,"completion":5305,"start":5306,"enrollment":5307,"conditions":5308,"interventions":5312},"NCT04541277","Combined Inhibition of PD-1 and DNA Hypomethylating Agent +\u002F- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy",[87],"2021-08-30","2022-08-30","2020-09-01",55,[5309,5310,5311],"Acute Myeloid Leukemia, in Relapsed or Refractory","Acute Myeloid Leukemia, Elderly, Unfit","Acute Myeloid Leukemia With Positive Minimal Residual Disease",[5292],{"trials":5314,"activeCount":98},[],{"trials":5316,"activeCount":98},[],{"trials":5318,"activeCount":98},[],{"intervention":5320,"totalTrials":114,"cells":5321},"anti-CD19\u002F20-CAR vector-transduced T cells",{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5326,"PHASE3":5359,"PHASE4":5361,"NA":5363},{"trials":5323,"activeCount":98},[],{"trials":5325,"activeCount":98},[],{"trials":5327,"activeCount":98},[5328],{"nctId":5329,"briefTitle":5330,"status":824,"phases":5331,"primaryCompletion":5332,"completion":5333,"start":5063,"enrollment":886,"conditions":5334,"interventions":5358},"NCT03097770","Treatment of Relapsed and\u002For Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20",[86,87],"2019-05-10","2020-01-31",[5335,5336,5337,5338,5339,5340,5341,5342,5343,5344,5345,5346,5347,5348,5349,5350,5351,5352,5353,5354,5355,5356,5357],"Hematopoietic\u002FLymphoid Cancer","Adult Acute Lymphoblastic Leukemia in Remission","B-cell Adult Acute Lymphoblastic Leukemia","B-cell Chronic Lymphocytic Leukemia","Prolymphocytic Leukemia","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Refractory Chronic Lymphocytic Leukemia","Stage III Adult Diffuse Large Cell Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Adult Diffuse Large Cell Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Mantle Cell Lymphoma",[5320],{"trials":5360,"activeCount":98},[],{"trials":5362,"activeCount":98},[],{"trials":5364,"activeCount":98},[],{"intervention":5366,"totalTrials":114,"cells":5367},"CART-HER-2",{"EARLY_PHASE1":5368,"PHASE1":5370,"PHASE2":5372,"PHASE3":5384,"PHASE4":5386,"NA":5388},{"trials":5369,"activeCount":98},[],{"trials":5371,"activeCount":98},[],{"trials":5373,"activeCount":98},[5374],{"nctId":5375,"briefTitle":5376,"status":625,"phases":5377,"primaryCompletion":3509,"completion":5378,"start":3603,"enrollment":522,"conditions":5379,"interventions":5383},"NCT01935843","Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors",[86,87],"2017-09",[5380,5381,5382],"Advanced HER-2 Positive Solid Tumors","Chemotherapy Refactory","HER-2 Antibody Inhibitor Therapy Refactory",[5366],{"trials":5385,"activeCount":98},[],{"trials":5387,"activeCount":98},[],{"trials":5389,"activeCount":98},[],{"intervention":5391,"totalTrials":114,"cells":5392},"anti-CD133-CAR vector-transduced T cells",{"EARLY_PHASE1":5393,"PHASE1":5395,"PHASE2":5397,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5394,"activeCount":98},[],{"trials":5396,"activeCount":98},[],{"trials":5398,"activeCount":98},[5399],{"nctId":5400,"briefTitle":5401,"status":824,"phases":5402,"primaryCompletion":5403,"completion":5403,"start":4385,"enrollment":16,"conditions":5404,"interventions":5409},"NCT02541370","Treatment of Relapsed and\u002For Chemotherapy Refractory Advanced Malignancies by CART133",[86,87],"2019-06",[5405,29,5406,2574,5407,1266,5408],"Liver Cancer","Brain Tumor","Ovarian Tumor","Acute Myeloid and Lymphoid Leukemias",[5391],{"trials":5411,"activeCount":98},[],{"trials":5413,"activeCount":98},[],{"trials":5415,"activeCount":98},[],{"intervention":5417,"totalTrials":114,"cells":5418},"Nab-paclitaxel plus Gemcitabine",{"EARLY_PHASE1":5419,"PHASE1":5421,"PHASE2":5423,"PHASE3":5437,"PHASE4":5439,"NA":5441},{"trials":5420,"activeCount":98},[],{"trials":5422,"activeCount":98},[],{"trials":5424,"activeCount":98},[5425],{"nctId":5426,"briefTitle":5427,"status":625,"phases":5428,"primaryCompletion":5429,"completion":5430,"start":5431,"enrollment":1183,"conditions":5432,"interventions":5434},"NCT03278015","Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients",[87],"2018-03-31","2018-09-30","2017-10-01",[5433],"Cancer of Pancreas",[5417,5435,5436],"Gemcitabine monotherapy","S-1 monotherapy",{"trials":5438,"activeCount":98},[],{"trials":5440,"activeCount":98},[],{"trials":5442,"activeCount":98},[],{"intervention":5435,"totalTrials":114,"cells":5444},{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5455,"PHASE4":5457,"NA":5459},{"trials":5446,"activeCount":98},[],{"trials":5448,"activeCount":98},[],{"trials":5450,"activeCount":98},[5451],{"nctId":5426,"briefTitle":5427,"status":625,"phases":5452,"primaryCompletion":5429,"completion":5430,"start":5431,"enrollment":1183,"conditions":5453,"interventions":5454},[87],[5433],[5417,5435,5436],{"trials":5456,"activeCount":98},[],{"trials":5458,"activeCount":98},[],{"trials":5460,"activeCount":98},[],{"intervention":5436,"totalTrials":114,"cells":5462},{"EARLY_PHASE1":5463,"PHASE1":5465,"PHASE2":5467,"PHASE3":5473,"PHASE4":5475,"NA":5477},{"trials":5464,"activeCount":98},[],{"trials":5466,"activeCount":98},[],{"trials":5468,"activeCount":98},[5469],{"nctId":5426,"briefTitle":5427,"status":625,"phases":5470,"primaryCompletion":5429,"completion":5430,"start":5431,"enrollment":1183,"conditions":5471,"interventions":5472},[87],[5433],[5417,5435,5436],{"trials":5474,"activeCount":98},[],{"trials":5476,"activeCount":98},[],{"trials":5478,"activeCount":98},[],{"intervention":5480,"totalTrials":114,"cells":5481},"Decitabine 20 mg\u002Fm²\u002Fday for 5 days",{"EARLY_PHASE1":5482,"PHASE1":5484,"PHASE2":5486,"PHASE3":5497,"PHASE4":5499,"NA":5501},{"trials":5483,"activeCount":98},[],{"trials":5485,"activeCount":98},[],{"trials":5487,"activeCount":98},[5488],{"nctId":5489,"briefTitle":5490,"status":824,"phases":5491,"primaryCompletion":5492,"completion":5493,"start":5494,"enrollment":539,"conditions":5495,"interventions":5496},"NCT02662647","Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML",[87],"2018-06","2019-03","2015-04",[3165],[5480],{"trials":5498,"activeCount":98},[],{"trials":5500,"activeCount":98},[],{"trials":5502,"activeCount":98},[],{"intervention":5504,"totalTrials":114,"cells":5505},"CAPOX combined with bevacizumab and Tislelizumab",{"EARLY_PHASE1":5506,"PHASE1":5508,"PHASE2":5510,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5507,"activeCount":98},[],{"trials":5509,"activeCount":98},[],{"trials":5511,"activeCount":98},[5512],{"nctId":5513,"briefTitle":5514,"status":824,"phases":5515,"primaryCompletion":5516,"completion":5516,"start":5517,"enrollment":5518,"conditions":5519,"interventions":5522},"NCT05299476","CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS \u003C 5 Locally Advanced or Metastatic GEA",[87],"2025-01-20","2022-04-25",32,[1030,5520,5521],"First-line Therapy","PDL1 CPS \u003C 5",[5504],{"trials":5524,"activeCount":98},[],{"trials":5526,"activeCount":98},[],{"trials":5528,"activeCount":98},[],{"intervention":5530,"totalTrials":114,"cells":5531},"CART-138 cells",{"EARLY_PHASE1":5532,"PHASE1":5534,"PHASE2":5536,"PHASE3":5544,"PHASE4":5546,"NA":5548},{"trials":5533,"activeCount":98},[],{"trials":5535,"activeCount":98},[],{"trials":5537,"activeCount":98},[5538],{"nctId":5539,"briefTitle":5540,"status":625,"phases":5541,"primaryCompletion":3422,"completion":3422,"start":4302,"enrollment":522,"conditions":5542,"interventions":5543},"NCT01886976","Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138",[86,87],[2236],[5530],{"trials":5545,"activeCount":98},[],{"trials":5547,"activeCount":98},[],{"trials":5549,"activeCount":98},[],{"intervention":4308,"totalTrials":114,"cells":5551},{"EARLY_PHASE1":5552,"PHASE1":5554,"PHASE2":5556,"PHASE3":5562,"PHASE4":5564,"NA":5566},{"trials":5553,"activeCount":98},[],{"trials":5555,"activeCount":98},[],{"trials":5557,"activeCount":98},[5558],{"nctId":4299,"briefTitle":4300,"status":625,"phases":5559,"primaryCompletion":4302,"start":4303,"enrollment":4304,"conditions":5560,"interventions":5561},[87],[4306],[4280,4308],{"trials":5563,"activeCount":98},[],{"trials":5565,"activeCount":98},[],{"trials":5567,"activeCount":98},[],{"intervention":5569,"totalTrials":114,"cells":5570},"modified By\u002FCy conditioning regimen intensified by Ruxolitinib and Decitabine",{"EARLY_PHASE1":5571,"PHASE1":5573,"PHASE2":5575,"PHASE3":5584,"PHASE4":5586,"NA":5588},{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":98},[5577],{"nctId":5578,"briefTitle":5579,"status":625,"phases":5580,"primaryCompletion":5581,"completion":2800,"start":5306,"enrollment":1039,"conditions":5582,"interventions":5583},"NCT04582604","Ruxolitinib and Decitabine for High Risk Hematological Malignancies",[86,87],"2023-09-01",[1660],[5569],{"trials":5585,"activeCount":98},[],{"trials":5587,"activeCount":98},[],{"trials":5589,"activeCount":98},[],{"intervention":5591,"totalTrials":114,"cells":5592},"Dual Specificity CD38 and bcma CAR-T Cells",{"EARLY_PHASE1":5593,"PHASE1":5595,"PHASE2":5597,"PHASE3":5607,"PHASE4":5609,"NA":5611},{"trials":5594,"activeCount":98},[],{"trials":5596,"activeCount":98},[],{"trials":5598,"activeCount":98},[5599],{"nctId":5600,"briefTitle":5601,"status":625,"phases":5602,"primaryCompletion":5603,"completion":5603,"start":5604,"enrollment":756,"conditions":5605,"interventions":5606},"NCT03767751","A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma",[86,87],"2022-12-05","2018-12-05",[2236],[5591],{"trials":5608,"activeCount":98},[],{"trials":5610,"activeCount":98},[],{"trials":5612,"activeCount":98},[],{"intervention":5614,"totalTrials":114,"cells":5615},"Ex-vivo expanded γδ T cell",{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5633,"PHASE4":5635,"NA":5637},{"trials":5617,"activeCount":98},[],{"trials":5619,"activeCount":98},[],{"trials":5621,"activeCount":98},[5622],{"nctId":5623,"briefTitle":5624,"status":625,"phases":5625,"primaryCompletion":5626,"completion":5627,"start":5628,"enrollment":16,"conditions":5629,"interventions":5632},"NCT04764513","Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT",[86,87],"2023-04","2025-04","2021-09-12",[817,5630,5631,34],"Acute Lymphoblastic Leukemia","Myelodysplastic Syndromes",[5614],{"trials":5634,"activeCount":98},[],{"trials":5636,"activeCount":98},[],{"trials":5638,"activeCount":98},[],{"intervention":4232,"totalTrials":114,"cells":5640},{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5645,"PHASE3":5651,"PHASE4":5653,"NA":5655},{"trials":5642,"activeCount":98},[],{"trials":5644,"activeCount":98},[],{"trials":5646,"activeCount":98},[5647],{"nctId":4223,"briefTitle":4224,"status":625,"phases":5648,"primaryCompletion":4226,"completion":108,"start":4227,"enrollment":886,"conditions":5649,"interventions":5650},[86,87],[4229,4230],[976,977,4232],{"trials":5652,"activeCount":98},[],{"trials":5654,"activeCount":98},[],{"trials":5656,"activeCount":98},[],{"intervention":5658,"totalTrials":114,"cells":5659},"Chidamide plus DCAG regimen",{"EARLY_PHASE1":5660,"PHASE1":5662,"PHASE2":5664,"PHASE3":5672,"PHASE4":5674,"NA":5676},{"trials":5661,"activeCount":98},[],{"trials":5663,"activeCount":98},[],{"trials":5665,"activeCount":98},[5666],{"nctId":5667,"briefTitle":5668,"status":625,"phases":5669,"primaryCompletion":5492,"completion":5403,"start":3422,"enrollment":886,"conditions":5670,"interventions":5671},"NCT02886559","Chidamide Plus DCAG for Relapsed\u002FRefractory AML",[86,87],[3165,5264],[5658],{"trials":5673,"activeCount":98},[],{"trials":5675,"activeCount":98},[],{"trials":5677,"activeCount":98},[],{"intervention":5679,"totalTrials":114,"cells":5680},"recombinant human endostatin",{"EARLY_PHASE1":5681,"PHASE1":5683,"PHASE2":5685,"PHASE3":5696,"PHASE4":5698,"NA":5700},{"trials":5682,"activeCount":98},[],{"trials":5684,"activeCount":98},[],{"trials":5686,"activeCount":98},[5687],{"nctId":5688,"briefTitle":5689,"status":625,"phases":5690,"primaryCompletion":5691,"completion":2265,"start":5692,"enrollment":5693,"conditions":5694,"interventions":5695},"NCT03208335","Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)",[87],"2018-12-31","2017-01-01",61,[18],[5679],{"trials":5697,"activeCount":98},[],{"trials":5699,"activeCount":98},[],{"trials":5701,"activeCount":98},[],{"intervention":5703,"totalTrials":114,"cells":5704},"Low-Dose Decitabine plus anti-PD-1",{"EARLY_PHASE1":5705,"PHASE1":5707,"PHASE2":5709,"PHASE3":5722,"PHASE4":5724,"NA":5726},{"trials":5706,"activeCount":98},[],{"trials":5708,"activeCount":98},[],{"trials":5710,"activeCount":98},[5711],{"nctId":5712,"briefTitle":5713,"status":625,"phases":5714,"primaryCompletion":3629,"completion":1264,"start":5715,"enrollment":16,"conditions":5716,"interventions":5721},"NCT05816746","Decitabine and Anti-PD-1 in R\u002FR DLBCL",[87],"2023-05-15",[5717,5718,5719,5720],"Diffuse Large B Cell Lymphoma","Relapse\u002FRecurrence","Extranodal Extension","Central Nervous System Lymphoma",[5703],{"trials":5723,"activeCount":98},[],{"trials":5725,"activeCount":98},[],{"trials":5727,"activeCount":98},[],{"intervention":5729,"totalTrials":114,"cells":5730},"azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte",{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5746,"PHASE4":5748,"NA":5750},{"trials":5732,"activeCount":98},[],{"trials":5734,"activeCount":98},[],{"trials":5736,"activeCount":98},[5737],{"nctId":5738,"briefTitle":5739,"status":824,"phases":5740,"primaryCompletion":5741,"completion":5742,"start":5743,"enrollment":539,"conditions":5744,"interventions":5745},"NCT05659992","Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia",[87],"2023-08-14","2024-08-14","2022-12-25",[817],[5729],{"trials":5747,"activeCount":98},[],{"trials":5749,"activeCount":98},[],{"trials":5751,"activeCount":98},[],{"intervention":4318,"totalTrials":114,"cells":5753},{"EARLY_PHASE1":5754,"PHASE1":5756,"PHASE2":5758,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5755,"activeCount":98},[],{"trials":5757,"activeCount":98},[],{"trials":5759,"activeCount":98},[5760],{"nctId":4310,"briefTitle":4311,"status":625,"phases":5761,"primaryCompletion":4313,"completion":4313,"start":4314,"enrollment":1005,"conditions":5762,"interventions":5763},[87],[4316],[4280,4318,4319],{"trials":5765,"activeCount":98},[],{"trials":5767,"activeCount":98},[],{"trials":5769,"activeCount":98},[],{"intervention":4319,"totalTrials":114,"cells":5771},{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5782,"PHASE4":5784,"NA":5786},{"trials":5773,"activeCount":98},[],{"trials":5775,"activeCount":98},[],{"trials":5777,"activeCount":98},[5778],{"nctId":4310,"briefTitle":4311,"status":625,"phases":5779,"primaryCompletion":4313,"completion":4313,"start":4314,"enrollment":1005,"conditions":5780,"interventions":5781},[87],[4316],[4280,4318,4319],{"trials":5783,"activeCount":98},[],{"trials":5785,"activeCount":98},[],{"trials":5787,"activeCount":98},[],{"intervention":5789,"totalTrials":114,"cells":5790},"Drug: S-1 and oxaliplatin",{"EARLY_PHASE1":5791,"PHASE1":5793,"PHASE2":5795,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5792,"activeCount":98},[],{"trials":5794,"activeCount":98},[],{"trials":5796,"activeCount":98},[5797],{"nctId":5798,"briefTitle":5799,"status":625,"phases":5800,"primaryCompletion":5801,"completion":3533,"start":5802,"enrollment":815,"conditions":5803,"interventions":5804},"NCT01090505","Study of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer",[87],"2012-12","2009-11",[20],[5789],{"trials":5806,"activeCount":98},[],{"trials":5808,"activeCount":98},[],{"trials":5810,"activeCount":98},[],{"intervention":5812,"totalTrials":114,"cells":5813},"Allogeneic γδ T cells",{"EARLY_PHASE1":5814,"PHASE1":5816,"PHASE2":5818,"PHASE3":5828,"PHASE4":5830,"NA":5832},{"trials":5815,"activeCount":98},[],{"trials":5817,"activeCount":98},[],{"trials":5819,"activeCount":98},[5820],{"nctId":5821,"briefTitle":5822,"status":625,"phases":5823,"primaryCompletion":1109,"completion":5824,"start":4398,"enrollment":1039,"conditions":5825,"interventions":5827},"NCT04765462","Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors",[86,87],"2024-12-31",[5826],"Malignant Solid Tumours",[5812],{"trials":5829,"activeCount":98},[],{"trials":5831,"activeCount":98},[],{"trials":5833,"activeCount":98},[],{"intervention":5835,"totalTrials":114,"cells":5836},"Deciatbine",{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5850,"PHASE4":5852,"NA":5854},{"trials":5838,"activeCount":98},[],{"trials":5840,"activeCount":98},[],{"trials":5842,"activeCount":98},[5843],{"nctId":5844,"briefTitle":5845,"status":625,"phases":5846,"primaryCompletion":4361,"completion":5492,"start":5801,"enrollment":539,"conditions":5847,"interventions":5849},"NCT01758367","Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation",[86,87],[5848],"Recurrent Adult Acute Myeloid Leukemia",[5835],{"trials":5851,"activeCount":98},[],{"trials":5853,"activeCount":98},[],{"trials":5855,"activeCount":98},[],{"intervention":4243,"totalTrials":114,"cells":5857},{"EARLY_PHASE1":5858,"PHASE1":5860,"PHASE2":5862,"PHASE3":5868,"PHASE4":5870,"NA":5872},{"trials":5859,"activeCount":98},[],{"trials":5861,"activeCount":98},[],{"trials":5863,"activeCount":98},[5864],{"nctId":4234,"briefTitle":4235,"status":625,"phases":5865,"primaryCompletion":4237,"completion":4238,"start":4239,"enrollment":756,"conditions":5866,"interventions":5867},[86,87],[4241],[976,977,4243,4244],{"trials":5869,"activeCount":98},[],{"trials":5871,"activeCount":98},[],{"trials":5873,"activeCount":98},[],{"intervention":4244,"totalTrials":114,"cells":5875},{"EARLY_PHASE1":5876,"PHASE1":5878,"PHASE2":5880,"PHASE3":5886,"PHASE4":5888,"NA":5890},{"trials":5877,"activeCount":98},[],{"trials":5879,"activeCount":98},[],{"trials":5881,"activeCount":98},[5882],{"nctId":4234,"briefTitle":4235,"status":625,"phases":5883,"primaryCompletion":4237,"completion":4238,"start":4239,"enrollment":756,"conditions":5884,"interventions":5885},[86,87],[4241],[976,977,4243,4244],{"trials":5887,"activeCount":98},[],{"trials":5889,"activeCount":98},[],{"trials":5891,"activeCount":98},[],{"intervention":5893,"totalTrials":114,"cells":5894},"Nivolumab plus SOX",{"EARLY_PHASE1":5895,"PHASE1":5897,"PHASE2":5899,"PHASE3":5909,"PHASE4":5911,"NA":5913},{"trials":5896,"activeCount":98},[],{"trials":5898,"activeCount":98},[],{"trials":5900,"activeCount":98},[5901],{"nctId":5902,"briefTitle":5903,"status":625,"phases":5904,"primaryCompletion":1109,"completion":826,"start":5905,"enrollment":539,"conditions":5906,"interventions":5907},"NCT04782791","Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer",[87],"2022-05-01",[20,484],[5893,5908],"Nivolumab",{"trials":5910,"activeCount":98},[],{"trials":5912,"activeCount":98},[],{"trials":5914,"activeCount":98},[],{"intervention":5908,"totalTrials":114,"cells":5916},{"EARLY_PHASE1":5917,"PHASE1":5919,"PHASE2":5921,"PHASE3":5927,"PHASE4":5929,"NA":5931},{"trials":5918,"activeCount":98},[],{"trials":5920,"activeCount":98},[],{"trials":5922,"activeCount":98},[5923],{"nctId":5902,"briefTitle":5903,"status":625,"phases":5924,"primaryCompletion":1109,"completion":826,"start":5905,"enrollment":539,"conditions":5925,"interventions":5926},[87],[20,484],[5893,5908],{"trials":5928,"activeCount":98},[],{"trials":5930,"activeCount":98},[],{"trials":5932,"activeCount":98},[],{"intervention":5934,"totalTrials":114,"cells":5935},"Expanded Activated Lymphocytes",{"EARLY_PHASE1":5936,"PHASE1":5938,"PHASE2":5940,"PHASE3":5950,"PHASE4":5952,"NA":5954},{"trials":5937,"activeCount":98},[],{"trials":5939,"activeCount":98},[],{"trials":5941,"activeCount":98},[5942],{"nctId":5943,"briefTitle":5944,"status":625,"phases":5945,"primaryCompletion":3102,"completion":1134,"start":5946,"enrollment":5947,"conditions":5948,"interventions":5949},"NCT05213637","Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection",[87],"2018-04-25",430,[2001],[5934],{"trials":5951,"activeCount":98},[],{"trials":5953,"activeCount":98},[],{"trials":5955,"activeCount":98},[],{"intervention":4664,"totalTrials":114,"cells":5957},{"EARLY_PHASE1":5958,"PHASE1":5960,"PHASE2":5962,"PHASE3":5968,"PHASE4":5970,"NA":5972},{"trials":5959,"activeCount":98},[],{"trials":5961,"activeCount":98},[],{"trials":5963,"activeCount":98},[5964],{"nctId":4657,"briefTitle":4658,"status":625,"phases":5965,"primaryCompletion":4660,"completion":2057,"start":4661,"enrollment":852,"conditions":5966,"interventions":5967},[86,87],[551],[976,4664,4665],{"trials":5969,"activeCount":98},[],{"trials":5971,"activeCount":98},[],{"trials":5973,"activeCount":98},[],{"intervention":4665,"totalTrials":114,"cells":5975},{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5980,"PHASE3":5986,"PHASE4":5988,"NA":5990},{"trials":5977,"activeCount":98},[],{"trials":5979,"activeCount":98},[],{"trials":5981,"activeCount":98},[5982],{"nctId":4657,"briefTitle":4658,"status":625,"phases":5983,"primaryCompletion":4660,"completion":2057,"start":4661,"enrollment":852,"conditions":5984,"interventions":5985},[86,87],[551],[976,4664,4665],{"trials":5987,"activeCount":98},[],{"trials":5989,"activeCount":98},[],{"trials":5991,"activeCount":98},[],{"intervention":5993,"totalTrials":114,"cells":5994},"Ruxolitinib",{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":5999,"PHASE3":6010,"PHASE4":6012,"NA":6014},{"trials":5996,"activeCount":98},[],{"trials":5998,"activeCount":98},[],{"trials":6000,"activeCount":98},[6001],{"nctId":6002,"briefTitle":6003,"status":824,"phases":6004,"primaryCompletion":4975,"completion":629,"start":6005,"enrollment":6006,"conditions":6007,"interventions":6008},"NCT04061876","First Line Therapy for High Risk Acute GVHD",[87],"2019-08-25",198,[4068,2062],[5993,6009],"Corticosteroid",{"trials":6011,"activeCount":98},[],{"trials":6013,"activeCount":98},[],{"trials":6015,"activeCount":98},[],{"intervention":6017,"totalTrials":114,"cells":6018},"Camrelizumab, Apatinib and Nab-paclitaxel",{"EARLY_PHASE1":6019,"PHASE1":6021,"PHASE2":6023,"PHASE3":6036,"PHASE4":6038,"NA":6040},{"trials":6020,"activeCount":98},[],{"trials":6022,"activeCount":98},[],{"trials":6024,"activeCount":98},[6025],{"nctId":6026,"briefTitle":6027,"status":625,"phases":6028,"primaryCompletion":6029,"completion":6030,"start":6031,"enrollment":6032,"conditions":6033,"interventions":6035},"NCT04182724","Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer",[86,87],"2021-05-12","2022-05-12","2019-11-12",57,[6034],"Advanced Gastric Cancer",[6017],{"trials":6037,"activeCount":98},[],{"trials":6039,"activeCount":98},[],{"trials":6041,"activeCount":98},[],{"intervention":6043,"totalTrials":114,"cells":6044},"SHR2554+SHR1701",{"EARLY_PHASE1":6045,"PHASE1":6047,"PHASE2":6049,"PHASE3":6058,"PHASE4":6060,"NA":6062},{"trials":6046,"activeCount":98},[],{"trials":6048,"activeCount":98},[],{"trials":6050,"activeCount":98},[6051],{"nctId":6052,"briefTitle":6053,"status":625,"phases":6054,"primaryCompletion":3114,"completion":128,"start":5306,"enrollment":886,"conditions":6055,"interventions":6056},"NCT04407741","Phase Ⅰ\u002FⅡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas",[86,87],[23,34],[6043,6057],"SHR1701",{"trials":6059,"activeCount":98},[],{"trials":6061,"activeCount":98},[],{"trials":6063,"activeCount":98},[],{"intervention":6057,"totalTrials":114,"cells":6065},{"EARLY_PHASE1":6066,"PHASE1":6068,"PHASE2":6070,"PHASE3":6076,"PHASE4":6078,"NA":6080},{"trials":6067,"activeCount":98},[],{"trials":6069,"activeCount":98},[],{"trials":6071,"activeCount":98},[6072],{"nctId":6052,"briefTitle":6053,"status":625,"phases":6073,"primaryCompletion":3114,"completion":128,"start":5306,"enrollment":886,"conditions":6074,"interventions":6075},[86,87],[23,34],[6043,6057],{"trials":6077,"activeCount":98},[],{"trials":6079,"activeCount":98},[],{"trials":6081,"activeCount":98},[],{"intervention":6083,"totalTrials":114,"cells":6084},"CART33 cells",{"EARLY_PHASE1":6085,"PHASE1":6087,"PHASE2":6089,"PHASE3":6103,"PHASE4":6105,"NA":6107},{"trials":6086,"activeCount":98},[],{"trials":6088,"activeCount":98},[],{"trials":6090,"activeCount":98},[6091],{"nctId":6092,"briefTitle":6093,"status":625,"phases":6094,"primaryCompletion":4898,"completion":6095,"start":6096,"enrollment":522,"conditions":6097,"interventions":6100},"NCT01864902","Treatment of Relapsed and\u002For Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33",[86,87],"2017-04","2013-04",[6098,6099],"Relapsed Adult Myeloid Leukemia","Chemotherapy Refractory Adult Myeloid Leukemia",[6083,6101,6102],"anti-CD33 CART","anti-CD33 CAR T cells",{"trials":6104,"activeCount":98},[],{"trials":6106,"activeCount":98},[],{"trials":6108,"activeCount":98},[],{"intervention":6101,"totalTrials":114,"cells":6110},{"EARLY_PHASE1":6111,"PHASE1":6113,"PHASE2":6115,"PHASE3":6121,"PHASE4":6123,"NA":6125},{"trials":6112,"activeCount":98},[],{"trials":6114,"activeCount":98},[],{"trials":6116,"activeCount":98},[6117],{"nctId":6092,"briefTitle":6093,"status":625,"phases":6118,"primaryCompletion":4898,"completion":6095,"start":6096,"enrollment":522,"conditions":6119,"interventions":6120},[86,87],[6098,6099],[6083,6101,6102],{"trials":6122,"activeCount":98},[],{"trials":6124,"activeCount":98},[],{"trials":6126,"activeCount":98},[],{"intervention":6102,"totalTrials":114,"cells":6128},{"EARLY_PHASE1":6129,"PHASE1":6131,"PHASE2":6133,"PHASE3":6139,"PHASE4":6141,"NA":6143},{"trials":6130,"activeCount":98},[],{"trials":6132,"activeCount":98},[],{"trials":6134,"activeCount":98},[6135],{"nctId":6092,"briefTitle":6093,"status":625,"phases":6136,"primaryCompletion":4898,"completion":6095,"start":6096,"enrollment":522,"conditions":6137,"interventions":6138},[86,87],[6098,6099],[6083,6101,6102],{"trials":6140,"activeCount":98},[],{"trials":6142,"activeCount":98},[],{"trials":6144,"activeCount":98},[],{"intervention":6146,"totalTrials":114,"cells":6147},"autologous gp96 vaccination",{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6152,"PHASE3":6163,"PHASE4":6165,"NA":6167},{"trials":6149,"activeCount":98},[],{"trials":6151,"activeCount":98},[],{"trials":6153,"activeCount":98},[6154],{"nctId":6155,"briefTitle":6156,"status":625,"phases":6157,"primaryCompletion":3077,"completion":3077,"start":3534,"enrollment":6158,"conditions":6159,"interventions":6161},"NCT02317471","Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96",[86,87],45,[6160],"Gastric Carcinoma",[6146,6162],"Oxaliplatin+S-1",{"trials":6164,"activeCount":98},[],{"trials":6166,"activeCount":98},[],{"trials":6168,"activeCount":98},[],{"intervention":6162,"totalTrials":114,"cells":6170},{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6175,"PHASE3":6181,"PHASE4":6183,"NA":6185},{"trials":6172,"activeCount":98},[],{"trials":6174,"activeCount":98},[],{"trials":6176,"activeCount":98},[6177],{"nctId":6155,"briefTitle":6156,"status":625,"phases":6178,"primaryCompletion":3077,"completion":3077,"start":3534,"enrollment":6158,"conditions":6179,"interventions":6180},[86,87],[6160],[6146,6162],{"trials":6182,"activeCount":98},[],{"trials":6184,"activeCount":98},[],{"trials":6186,"activeCount":98},[],{"intervention":1141,"totalTrials":114,"cells":6188},{"EARLY_PHASE1":6189,"PHASE1":6191,"PHASE2":6193,"PHASE3":6199,"PHASE4":6201,"NA":6203},{"trials":6190,"activeCount":98},[],{"trials":6192,"activeCount":98},[],{"trials":6194,"activeCount":98},[6195],{"nctId":1131,"briefTitle":1132,"status":625,"phases":6196,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":6197,"interventions":6198},[86,87],[29,1139],[1141,1142,676],{"trials":6200,"activeCount":98},[],{"trials":6202,"activeCount":98},[],{"trials":6204,"activeCount":98},[],{"intervention":1142,"totalTrials":114,"cells":6206},{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6208,"activeCount":98},[],{"trials":6210,"activeCount":98},[],{"trials":6212,"activeCount":98},[6213],{"nctId":1131,"briefTitle":1132,"status":625,"phases":6214,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":6215,"interventions":6216},[86,87],[29,1139],[1141,1142,676],{"trials":6218,"activeCount":98},[],{"trials":6220,"activeCount":98},[],{"trials":6222,"activeCount":98},[],{"intervention":6224,"totalTrials":114,"cells":6225},"Ruxolitinib 10 mg twice a day combined with Corticosteroids",{"EARLY_PHASE1":6226,"PHASE1":6228,"PHASE2":6230,"PHASE3":6243,"PHASE4":6245,"NA":6247},{"trials":6227,"activeCount":98},[],{"trials":6229,"activeCount":98},[],{"trials":6231,"activeCount":98},[6232],{"nctId":6233,"briefTitle":6234,"status":824,"phases":6235,"primaryCompletion":6236,"completion":2058,"start":6237,"enrollment":630,"conditions":6238,"interventions":6239},"NCT04397367","Low Dose Ruxolitinib in Combination With Methylprednisolone",[86,87],"2020-07-01","2019-01-01",[4068,2062],[6224,6240,6241,6242],"Ruxolitinib 5 mg twice a day combined with Corticosteroids","Ruxolitinib 5 mg once a day combined with Corticosteroids","Ruxolitinib 2.5 mg once a day combined with Corticosteroids",{"trials":6244,"activeCount":98},[],{"trials":6246,"activeCount":98},[],{"trials":6248,"activeCount":98},[],{"intervention":6240,"totalTrials":114,"cells":6250},{"EARLY_PHASE1":6251,"PHASE1":6253,"PHASE2":6255,"PHASE3":6261,"PHASE4":6263,"NA":6265},{"trials":6252,"activeCount":98},[],{"trials":6254,"activeCount":98},[],{"trials":6256,"activeCount":98},[6257],{"nctId":6233,"briefTitle":6234,"status":824,"phases":6258,"primaryCompletion":6236,"completion":2058,"start":6237,"enrollment":630,"conditions":6259,"interventions":6260},[86,87],[4068,2062],[6224,6240,6241,6242],{"trials":6262,"activeCount":98},[],{"trials":6264,"activeCount":98},[],{"trials":6266,"activeCount":98},[],{"intervention":6241,"totalTrials":114,"cells":6268},{"EARLY_PHASE1":6269,"PHASE1":6271,"PHASE2":6273,"PHASE3":6279,"PHASE4":6281,"NA":6283},{"trials":6270,"activeCount":98},[],{"trials":6272,"activeCount":98},[],{"trials":6274,"activeCount":98},[6275],{"nctId":6233,"briefTitle":6234,"status":824,"phases":6276,"primaryCompletion":6236,"completion":2058,"start":6237,"enrollment":630,"conditions":6277,"interventions":6278},[86,87],[4068,2062],[6224,6240,6241,6242],{"trials":6280,"activeCount":98},[],{"trials":6282,"activeCount":98},[],{"trials":6284,"activeCount":98},[],{"intervention":6242,"totalTrials":114,"cells":6286},{"EARLY_PHASE1":6287,"PHASE1":6289,"PHASE2":6291,"PHASE3":6297,"PHASE4":6299,"NA":6301},{"trials":6288,"activeCount":98},[],{"trials":6290,"activeCount":98},[],{"trials":6292,"activeCount":98},[6293],{"nctId":6233,"briefTitle":6234,"status":824,"phases":6294,"primaryCompletion":6236,"completion":2058,"start":6237,"enrollment":630,"conditions":6295,"interventions":6296},[86,87],[4068,2062],[6224,6240,6241,6242],{"trials":6298,"activeCount":98},[],{"trials":6300,"activeCount":98},[],{"trials":6302,"activeCount":98},[],{"intervention":3167,"totalTrials":114,"cells":6304},{"EARLY_PHASE1":6305,"PHASE1":6307,"PHASE2":6309,"PHASE3":6315,"PHASE4":6317,"NA":6319},{"trials":6306,"activeCount":98},[],{"trials":6308,"activeCount":98},[],{"trials":6310,"activeCount":98},[6311],{"nctId":3156,"briefTitle":3157,"status":824,"phases":6312,"primaryCompletion":3159,"completion":3160,"start":3161,"enrollment":3162,"conditions":6313,"interventions":6314},[86,87],[3164,3165],[977,761,3167,3168],{"trials":6316,"activeCount":98},[],{"trials":6318,"activeCount":98},[],{"trials":6320,"activeCount":98},[],{"intervention":6322,"totalTrials":114,"cells":6323},"BCMA-PD1-CART Cell",{"EARLY_PHASE1":6324,"PHASE1":6326,"PHASE2":6328,"PHASE3":6338,"PHASE4":6340,"NA":6342},{"trials":6325,"activeCount":98},[],{"trials":6327,"activeCount":98},[],{"trials":6329,"activeCount":98},[6330],{"nctId":6331,"briefTitle":6332,"status":625,"phases":6333,"primaryCompletion":6334,"completion":6335,"start":5195,"enrollment":539,"conditions":6336,"interventions":6337},"NCT04162119","Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed\u002FRefractory Multiple Myeloma",[87],"2021-10-10","2022-10-10",[2236],[6322],{"trials":6339,"activeCount":98},[],{"trials":6341,"activeCount":98},[],{"trials":6343,"activeCount":98},[],{"intervention":6345,"totalTrials":114,"cells":6346},"Apatinib Mesylate",{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6363,"PHASE4":6365,"NA":6367},{"trials":6348,"activeCount":98},[],{"trials":6350,"activeCount":98},[],{"trials":6352,"activeCount":98},[6353],{"nctId":6354,"briefTitle":6355,"status":625,"phases":6356,"primaryCompletion":6357,"completion":6358,"start":3630,"enrollment":1183,"conditions":6359,"interventions":6362},"NCT04204577","The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer",[87],"2021-11","2023-11",[6360,6361],"BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma",[6345],{"trials":6364,"activeCount":98},[],{"trials":6366,"activeCount":98},[],{"trials":6368,"activeCount":98},[],{"intervention":6370,"totalTrials":114,"cells":6371},"UCART019",{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6376,"PHASE3":6385,"PHASE4":6387,"NA":6389},{"trials":6373,"activeCount":98},[],{"trials":6375,"activeCount":98},[],{"trials":6377,"activeCount":98},[6378],{"nctId":6379,"briefTitle":6380,"status":625,"phases":6381,"primaryCompletion":1002,"completion":1002,"start":4361,"enrollment":756,"conditions":6382,"interventions":6384},"NCT03166878","A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma",[86,87],[6383,604],"B Cell Leukemia",[6370],{"trials":6386,"activeCount":98},[],{"trials":6388,"activeCount":98},[],{"trials":6390,"activeCount":98},[],{"intervention":6392,"totalTrials":114,"cells":6393},"Rabbit ATG",{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6408,"PHASE4":6410,"NA":6412},{"trials":6395,"activeCount":98},[],{"trials":6397,"activeCount":98},[],{"trials":6399,"activeCount":98},[6400],{"nctId":6401,"briefTitle":6402,"status":625,"phases":6403,"primaryCompletion":4975,"completion":4975,"start":6404,"enrollment":1039,"conditions":6405,"interventions":6407},"NCT05214066","Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT",[87],"2019-02-01",[4068,6406],"cGVHD",[6392],{"trials":6409,"activeCount":98},[],{"trials":6411,"activeCount":98},[],{"trials":6413,"activeCount":98},[],{"intervention":2748,"totalTrials":114,"cells":6415},{"EARLY_PHASE1":6416,"PHASE1":6418,"PHASE2":6420,"PHASE3":6426,"PHASE4":6428,"NA":6430},{"trials":6417,"activeCount":98},[],{"trials":6419,"activeCount":98},[],{"trials":6421,"activeCount":98},[6422],{"nctId":2738,"briefTitle":2739,"status":824,"phases":6423,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":2743,"conditions":6424,"interventions":6425},[87],[2745,2746],[2542,2748],{"trials":6427,"activeCount":98},[],{"trials":6429,"activeCount":98},[],{"trials":6431,"activeCount":98},[],{"intervention":4701,"totalTrials":114,"cells":6433},{"EARLY_PHASE1":6434,"PHASE1":6436,"PHASE2":6438,"PHASE3":6444,"PHASE4":6446,"NA":6448},{"trials":6435,"activeCount":98},[],{"trials":6437,"activeCount":98},[],{"trials":6439,"activeCount":98},[6440],{"nctId":4693,"briefTitle":4694,"status":625,"phases":6441,"primaryCompletion":4696,"completion":4697,"start":4698,"enrollment":522,"conditions":6442,"interventions":6443},[86,87],[23,34],[2270,4701],{"trials":6445,"activeCount":98},[],{"trials":6447,"activeCount":98},[],{"trials":6449,"activeCount":98},[],{"intervention":6451,"totalTrials":114,"cells":6452},"raltitrexed combined with apatinib",{"EARLY_PHASE1":6453,"PHASE1":6455,"PHASE2":6457,"PHASE3":6467,"PHASE4":6469,"NA":6471},{"trials":6454,"activeCount":98},[],{"trials":6456,"activeCount":98},[],{"trials":6458,"activeCount":98},[6459],{"nctId":6460,"briefTitle":6461,"status":625,"phases":6462,"primaryCompletion":6237,"completion":6463,"start":6464,"enrollment":539,"conditions":6465,"interventions":6466},"NCT03344614","A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer",[87],"2019-07-01","2017-07-01",[1266],[6451],{"trials":6468,"activeCount":98},[],{"trials":6470,"activeCount":98},[],{"trials":6472,"activeCount":98},[],{"intervention":6474,"totalTrials":114,"cells":6475},"AK104+anlotinib",{"EARLY_PHASE1":6476,"PHASE1":6478,"PHASE2":6480,"PHASE3":6492,"PHASE4":6494,"NA":6496},{"trials":6477,"activeCount":98},[],{"trials":6479,"activeCount":98},[],{"trials":6481,"activeCount":98},[6482],{"nctId":6483,"briefTitle":6484,"status":625,"phases":6485,"primaryCompletion":6486,"completion":6487,"start":6488,"enrollment":539,"conditions":6489,"interventions":6491},"NCT04544644","A Study of Combination Therapy in NSCLC",[87],"2022-09","2023-09","2020-09",[6490],"Non-small Cell Lung Cancer",[6474],{"trials":6493,"activeCount":98},[],{"trials":6495,"activeCount":98},[],{"trials":6497,"activeCount":98},[],{"intervention":633,"totalTrials":114,"cells":6499},{"EARLY_PHASE1":6500,"PHASE1":6502,"PHASE2":6504,"PHASE3":6510,"PHASE4":6512,"NA":6514},{"trials":6501,"activeCount":98},[],{"trials":6503,"activeCount":98},[],{"trials":6505,"activeCount":98},[6506],{"nctId":623,"briefTitle":624,"status":625,"phases":6507,"primaryCompletion":627,"completion":628,"start":629,"enrollment":630,"conditions":6508,"interventions":6509},[86,87],[561],[633,545,491],{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[],{"trials":6515,"activeCount":98},[],{"intervention":6517,"totalTrials":114,"cells":6518},"anti-CD20-CAR vector-transduced autologous T cells",{"EARLY_PHASE1":6519,"PHASE1":6521,"PHASE2":6523,"PHASE3":6531,"PHASE4":6533,"NA":6535},{"trials":6520,"activeCount":98},[],{"trials":6522,"activeCount":98},[],{"trials":6524,"activeCount":98},[6525],{"nctId":6526,"briefTitle":6527,"status":625,"phases":6528,"primaryCompletion":1037,"completion":39,"start":2742,"enrollment":861,"conditions":6529,"interventions":6530},"NCT01735604","Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy",[86,87],[5335,5336,5337,5338,5339,5340,5341,5342,5343,5344,5345,5346,5347,5348,5349,5350,5351,5352,5353,5354,5355,5356,5357],[6517],{"trials":6532,"activeCount":98},[],{"trials":6534,"activeCount":98},[],{"trials":6536,"activeCount":98},[],{"intervention":6538,"totalTrials":114,"cells":6539},"Specificity CD38 CAR-T Cells",{"EARLY_PHASE1":6540,"PHASE1":6542,"PHASE2":6544,"PHASE3":6555,"PHASE4":6557,"NA":6559},{"trials":6541,"activeCount":98},[],{"trials":6543,"activeCount":98},[],{"trials":6545,"activeCount":98},[6546],{"nctId":6547,"briefTitle":6548,"status":625,"phases":6549,"primaryCompletion":6550,"completion":6550,"start":6551,"enrollment":756,"conditions":6552,"interventions":6554},"NCT03754764","A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy",[86,87],"2022-11-23","2018-11-23",[6553],"Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI",[6538],{"trials":6556,"activeCount":98},[],{"trials":6558,"activeCount":98},[],{"trials":6560,"activeCount":98},[],{"intervention":6562,"totalTrials":114,"cells":6563},"Cisplatin\u002FNedaplatin, albumin paclitaxel",{"EARLY_PHASE1":6564,"PHASE1":6566,"PHASE2":6568,"PHASE3":6578,"PHASE4":6580,"NA":6582},{"trials":6565,"activeCount":98},[],{"trials":6567,"activeCount":98},[],{"trials":6569,"activeCount":98},[6570],{"nctId":6571,"briefTitle":6572,"status":625,"phases":6573,"primaryCompletion":6574,"completion":6574,"start":2776,"enrollment":539,"conditions":6575,"interventions":6577},"NCT05860335","Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer",[87],"2025-06-01",[6576],"Hypopharyngeal Cancer",[6562],{"trials":6579,"activeCount":98},[],{"trials":6581,"activeCount":98},[],{"trials":6583,"activeCount":98},[],{"intervention":6585,"totalTrials":114,"cells":6586},"ulinastatin",{"EARLY_PHASE1":6587,"PHASE1":6589,"PHASE2":6591,"PHASE3":6602,"PHASE4":6604,"NA":6606},{"trials":6588,"activeCount":98},[],{"trials":6590,"activeCount":98},[],{"trials":6592,"activeCount":98},[6593],{"nctId":6594,"briefTitle":6595,"status":625,"phases":6596,"primaryCompletion":5801,"completion":2742,"start":6597,"enrollment":852,"conditions":6598,"interventions":6600},"NCT01287806","Ulinastatin in Inhalation Lung Injury",[87],"2011-02",[6599],"Inhalation Injury",[6585,6601],"blank group",{"trials":6603,"activeCount":98},[],{"trials":6605,"activeCount":98},[],{"trials":6607,"activeCount":98},[],{"intervention":6601,"totalTrials":114,"cells":6609},{"EARLY_PHASE1":6610,"PHASE1":6612,"PHASE2":6614,"PHASE3":6620,"PHASE4":6622,"NA":6624},{"trials":6611,"activeCount":98},[],{"trials":6613,"activeCount":98},[],{"trials":6615,"activeCount":98},[6616],{"nctId":6594,"briefTitle":6595,"status":625,"phases":6617,"primaryCompletion":5801,"completion":2742,"start":6597,"enrollment":852,"conditions":6618,"interventions":6619},[87],[6599],[6585,6601],{"trials":6621,"activeCount":98},[],{"trials":6623,"activeCount":98},[],{"trials":6625,"activeCount":98},[],{"intervention":4425,"totalTrials":114,"cells":6627},{"EARLY_PHASE1":6628,"PHASE1":6630,"PHASE2":6632,"PHASE3":6638,"PHASE4":6640,"NA":6642},{"trials":6629,"activeCount":98},[],{"trials":6631,"activeCount":98},[],{"trials":6633,"activeCount":98},[6634],{"nctId":4415,"briefTitle":4416,"status":625,"phases":6635,"primaryCompletion":4302,"completion":4385,"start":4418,"enrollment":1039,"conditions":6636,"interventions":6637},[87],[4420,4421,4422,4423],[4425,4426,4333,4426,4333,4425],{"trials":6639,"activeCount":98},[],{"trials":6641,"activeCount":98},[],{"trials":6643,"activeCount":98},[],{"intervention":6645,"totalTrials":114,"cells":6646},"oxaliplatin+capecitabine+bevacizumab+PD-1 antibody",{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6663,"PHASE4":6665,"NA":6667},{"trials":6648,"activeCount":98},[],{"trials":6650,"activeCount":98},[],{"trials":6652,"activeCount":98},[6653],{"nctId":6654,"briefTitle":6655,"status":625,"phases":6656,"primaryCompletion":5018,"completion":3948,"start":6657,"enrollment":671,"conditions":6658,"interventions":6662},"NCT06206096","PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC",[87],"2021-05-26",[1266,6659,6660,6661],"RAS Mutation","Colorectal Neoplasms","Microsatellite Stable Colorectal Carcinoma",[6645],{"trials":6664,"activeCount":98},[],{"trials":6666,"activeCount":98},[],{"trials":6668,"activeCount":98},[],{"intervention":4799,"totalTrials":114,"cells":6670},{"EARLY_PHASE1":6671,"PHASE1":6673,"PHASE2":6675,"PHASE3":6681,"PHASE4":6683,"NA":6685},{"trials":6672,"activeCount":98},[],{"trials":6674,"activeCount":98},[],{"trials":6676,"activeCount":98},[6677],{"nctId":4793,"briefTitle":4794,"status":625,"phases":6678,"primaryCompletion":4361,"completion":3077,"start":4796,"enrollment":671,"conditions":6679,"interventions":6680},[87],[20],[4799,4800,1008],{"trials":6682,"activeCount":98},[],{"trials":6684,"activeCount":98},[],{"trials":6686,"activeCount":98},[],{"intervention":4800,"totalTrials":114,"cells":6688},{"EARLY_PHASE1":6689,"PHASE1":6691,"PHASE2":6693,"PHASE3":6699,"PHASE4":6701,"NA":6703},{"trials":6690,"activeCount":98},[],{"trials":6692,"activeCount":98},[],{"trials":6694,"activeCount":98},[6695],{"nctId":4793,"briefTitle":4794,"status":625,"phases":6696,"primaryCompletion":4361,"completion":3077,"start":4796,"enrollment":671,"conditions":6697,"interventions":6698},[87],[20],[4799,4800,1008],{"trials":6700,"activeCount":98},[],{"trials":6702,"activeCount":98},[],{"trials":6704,"activeCount":98},[],{"intervention":6706,"totalTrials":114,"cells":6707},"Perfluorocarbon",{"EARLY_PHASE1":6708,"PHASE1":6710,"PHASE2":6712,"PHASE3":6724,"PHASE4":6726,"NA":6728},{"trials":6709,"activeCount":98},[],{"trials":6711,"activeCount":98},[],{"trials":6713,"activeCount":98},[6714],{"nctId":6715,"briefTitle":6716,"status":625,"phases":6717,"primaryCompletion":6096,"completion":5494,"start":6718,"enrollment":335,"conditions":6719,"interventions":6722},"NCT01391481","Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury\u002FAcute Respiratory Distress Syndrome",[87],"2011-08",[6720,6721],"Respiratory Distress Syndrome, Adult","Acute Lung Injury",[6706,6723],"Sterile Water for",{"trials":6725,"activeCount":98},[],{"trials":6727,"activeCount":98},[],{"trials":6729,"activeCount":98},[],{"intervention":6723,"totalTrials":114,"cells":6731},{"EARLY_PHASE1":6732,"PHASE1":6734,"PHASE2":6736,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6733,"activeCount":98},[],{"trials":6735,"activeCount":98},[],{"trials":6737,"activeCount":98},[6738],{"nctId":6715,"briefTitle":6716,"status":625,"phases":6739,"primaryCompletion":6096,"completion":5494,"start":6718,"enrollment":335,"conditions":6740,"interventions":6741},[87],[6720,6721],[6706,6723],{"trials":6743,"activeCount":98},[],{"trials":6745,"activeCount":98},[],{"trials":6747,"activeCount":98},[],{"intervention":6749,"totalTrials":114,"cells":6750},"Azacytidine, Bendamustine and Piamprizumab",{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6766,"PHASE4":6768,"NA":6770},{"trials":6752,"activeCount":98},[],{"trials":6754,"activeCount":98},[],{"trials":6756,"activeCount":98},[6757],{"nctId":6758,"briefTitle":6759,"status":625,"phases":6760,"primaryCompletion":6761,"completion":6762,"start":6763,"enrollment":539,"conditions":6764,"interventions":6765},"NCT04897477","Azacytidine, Bendamustine, Piamprizumab in Refractory\u002FRelapsed B-cell Non-Hodgkin's Lymphoma",[86,87],"2022-04-23","2023-04-23","2021-04-22",[561],[6749],{"trials":6767,"activeCount":98},[],{"trials":6769,"activeCount":98},[],{"trials":6771,"activeCount":98},[],{"intervention":6773,"totalTrials":114,"cells":6774},"anti-CD19\u002F22-CAR vector-transduced T cells",{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6789,"PHASE4":6791,"NA":6793},{"trials":6776,"activeCount":98},[],{"trials":6778,"activeCount":98},[],{"trials":6780,"activeCount":98},[6781],{"nctId":6782,"briefTitle":6783,"status":625,"phases":6784,"primaryCompletion":6785,"completion":4976,"start":3334,"enrollment":539,"conditions":6786,"interventions":6788},"NCT03185494","Treatment of Relapsed and\u002For Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22",[86,87],"2019-08-01",[5335,5336,5337,6787,5339,5340,5341,5342,5343,5344,5345,5346,5347,5348,5349,5350,5351,5352,5353,5354,5355,5356,5357],"B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)",[6773],{"trials":6790,"activeCount":98},[],{"trials":6792,"activeCount":98},[],{"trials":6794,"activeCount":98},[],{"intervention":6796,"totalTrials":114,"cells":6797},"SHR2554+ SHR1701",{"EARLY_PHASE1":6798,"PHASE1":6800,"PHASE2":6802,"PHASE3":6813,"PHASE4":6815,"NA":6817},{"trials":6799,"activeCount":98},[],{"trials":6801,"activeCount":98},[],{"trials":6803,"activeCount":98},[6804],{"nctId":6805,"briefTitle":6806,"status":625,"phases":6807,"primaryCompletion":6574,"completion":2214,"start":6808,"enrollment":886,"conditions":6809,"interventions":6811},"NCT05896046","SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma",[86,87],"2023-06-14",[6810],"Relapsed or Refractory Hodgkin Lymphoma",[6796,6812],"SHR-1701",{"trials":6814,"activeCount":98},[],{"trials":6816,"activeCount":98},[],{"trials":6818,"activeCount":98},[],{"intervention":6812,"totalTrials":114,"cells":6820},{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6825,"PHASE3":6831,"PHASE4":6833,"NA":6835},{"trials":6822,"activeCount":98},[],{"trials":6824,"activeCount":98},[],{"trials":6826,"activeCount":98},[6827],{"nctId":6805,"briefTitle":6806,"status":625,"phases":6828,"primaryCompletion":6574,"completion":2214,"start":6808,"enrollment":886,"conditions":6829,"interventions":6830},[86,87],[6810],[6796,6812],{"trials":6832,"activeCount":98},[],{"trials":6834,"activeCount":98},[],{"trials":6836,"activeCount":98},[],{"intervention":1009,"totalTrials":114,"cells":6838},{"EARLY_PHASE1":6839,"PHASE1":6841,"PHASE2":6843,"PHASE3":6849,"PHASE4":6851,"NA":6853},{"trials":6840,"activeCount":98},[],{"trials":6842,"activeCount":98},[],{"trials":6844,"activeCount":98},[6845],{"nctId":999,"briefTitle":1000,"status":625,"phases":6846,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":1005,"conditions":6847,"interventions":6848},[87],[20],[957,1008,1009],{"trials":6850,"activeCount":98},[],{"trials":6852,"activeCount":98},[],{"trials":6854,"activeCount":98},[],{"intervention":1115,"totalTrials":114,"cells":6856},{"EARLY_PHASE1":6857,"PHASE1":6859,"PHASE2":6861,"PHASE3":6867,"PHASE4":6869,"NA":6871},{"trials":6858,"activeCount":98},[],{"trials":6860,"activeCount":98},[],{"trials":6862,"activeCount":98},[6863],{"nctId":1106,"briefTitle":1107,"status":625,"phases":6864,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":671,"conditions":6865,"interventions":6866},[87],[1113],[1115,1082],{"trials":6868,"activeCount":98},[],{"trials":6870,"activeCount":98},[],{"trials":6872,"activeCount":98},[],{"intervention":6874,"totalTrials":114,"cells":6875},"Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells",{"EARLY_PHASE1":6876,"PHASE1":6878,"PHASE2":6880,"PHASE3":6890,"PHASE4":6892,"NA":6894},{"trials":6877,"activeCount":98},[],{"trials":6879,"activeCount":98},[],{"trials":6881,"activeCount":98},[6882],{"nctId":6883,"briefTitle":6884,"status":625,"phases":6885,"primaryCompletion":6886,"completion":6886,"start":6887,"enrollment":756,"conditions":6888,"interventions":6889},"NCT03398967","A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma",[86,87],"2022-05-20","2018-01-02",[6383,604],[6874],{"trials":6891,"activeCount":98},[],{"trials":6893,"activeCount":98},[],{"trials":6895,"activeCount":98},[],{"intervention":6897,"totalTrials":114,"cells":6898},"CART-EGFR",{"EARLY_PHASE1":6899,"PHASE1":6901,"PHASE2":6903,"PHASE3":6913,"PHASE4":6915,"NA":6917},{"trials":6900,"activeCount":98},[],{"trials":6902,"activeCount":98},[],{"trials":6904,"activeCount":98},[6905],{"nctId":6906,"briefTitle":6907,"status":625,"phases":6908,"primaryCompletion":1036,"completion":3077,"start":6909,"enrollment":1039,"conditions":6910,"interventions":6912},"NCT01869166","Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)",[86,87],"2013-05",[6911],"Advanced EGFR-positive Solid Tumors",[6897],{"trials":6914,"activeCount":98},[],{"trials":6916,"activeCount":98},[],{"trials":6918,"activeCount":98},[],{"intervention":4390,"totalTrials":114,"cells":6920},{"EARLY_PHASE1":6921,"PHASE1":6923,"PHASE2":6925,"PHASE3":6931,"PHASE4":6933,"NA":6935},{"trials":6922,"activeCount":98},[],{"trials":6924,"activeCount":98},[],{"trials":6926,"activeCount":98},[6927],{"nctId":4382,"briefTitle":4383,"status":824,"phases":6928,"primaryCompletion":4361,"completion":4361,"start":4385,"enrollment":522,"conditions":6929,"interventions":6930},[86,87],[4387,4388],[4388,4390],{"trials":6932,"activeCount":98},[],{"trials":6934,"activeCount":98},[],{"trials":6936,"activeCount":98},[],{"intervention":4951,"totalTrials":114,"cells":6938},{"EARLY_PHASE1":6939,"PHASE1":6941,"PHASE2":6943,"PHASE3":6949,"PHASE4":6951,"NA":6953},{"trials":6940,"activeCount":98},[],{"trials":6942,"activeCount":98},[],{"trials":6944,"activeCount":98},[6945],{"nctId":4942,"briefTitle":4943,"status":625,"phases":6946,"primaryCompletion":4945,"completion":4946,"start":4947,"enrollment":539,"conditions":6947,"interventions":6948},[87],[4949],[4951,4718],{"trials":6950,"activeCount":98},[],{"trials":6952,"activeCount":98},[],{"trials":6954,"activeCount":98},[],{"intervention":4717,"totalTrials":114,"cells":6956},{"EARLY_PHASE1":6957,"PHASE1":6959,"PHASE2":6961,"PHASE3":6967,"PHASE4":6969,"NA":6971},{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[],{"trials":6962,"activeCount":98},[6963],{"nctId":4707,"briefTitle":4708,"status":824,"phases":6964,"primaryCompletion":4710,"completion":4711,"start":4712,"enrollment":4713,"conditions":6965,"interventions":6966},[87],[4715],[2270,2291,4717,4718],{"trials":6968,"activeCount":98},[],{"trials":6970,"activeCount":98},[],{"trials":6972,"activeCount":98},[],{"intervention":6974,"totalTrials":114,"cells":6975},"Modified By\u002FCy conditioning regimen intensified by Ruxolitinib and Chidamide",{"EARLY_PHASE1":6976,"PHASE1":6978,"PHASE2":6980,"PHASE3":6989,"PHASE4":6991,"NA":6993},{"trials":6977,"activeCount":98},[],{"trials":6979,"activeCount":98},[],{"trials":6981,"activeCount":98},[6982],{"nctId":6983,"briefTitle":6984,"status":625,"phases":6985,"primaryCompletion":885,"completion":6574,"start":6986,"enrollment":861,"conditions":6987,"interventions":6988},"NCT05075681","Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia\u002F Lymphoblastic Lymphoma",[86,87],"2021-11-01",[1660],[6974],{"trials":6990,"activeCount":98},[],{"trials":6992,"activeCount":98},[],{"trials":6994,"activeCount":98},[],{"intervention":6996,"totalTrials":94,"cells":6997},"CD19 CART",{"EARLY_PHASE1":6998,"PHASE1":7000,"PHASE2":7020,"PHASE3":7022,"PHASE4":7024,"NA":7026},{"trials":6999,"activeCount":98},[],{"trials":7001,"activeCount":98},[7002,7012],{"nctId":7003,"briefTitle":7004,"status":625,"phases":7005,"primaryCompletion":7006,"completion":7007,"start":3867,"enrollment":21,"conditions":7008,"interventions":7011},"NCT04012879","Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia",[86],"2021-04-30","2021-06-30",[7009,7010],"Relapsed Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia",[6996],{"nctId":7013,"briefTitle":7014,"status":625,"phases":7015,"primaryCompletion":7006,"completion":4040,"start":3867,"enrollment":21,"conditions":7016,"interventions":7019},"NCT04012892","Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma",[86],[7017,7018],"Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma",[6996],{"trials":7021,"activeCount":98},[],{"trials":7023,"activeCount":98},[],{"trials":7025,"activeCount":98},[],{"trials":7027,"activeCount":98},[],{"intervention":7029,"totalTrials":94,"cells":7030},"mesenchymal stem cell conditioned medium-derived pleiotropic factor",{"EARLY_PHASE1":7031,"PHASE1":7033,"PHASE2":7053,"PHASE3":7055,"PHASE4":7057,"NA":7059},{"trials":7032,"activeCount":98},[],{"trials":7034,"activeCount":98},[7035,7044],{"nctId":7036,"briefTitle":7037,"status":625,"phases":7038,"primaryCompletion":7039,"completion":7007,"start":7040,"enrollment":16,"conditions":7041,"interventions":7043},"NCT04234750","Mesenchymal Stem Cell-derived Pleiotropic Factor in the Treatment of Donor Sites",[86],"2020-12-30","2019-10-17",[7042],"Evaluate the Safety and Effectiveness of Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Donor Sites",[7029],{"nctId":7045,"briefTitle":7046,"status":625,"phases":7047,"primaryCompletion":7039,"completion":7007,"start":7048,"enrollment":539,"conditions":7049,"interventions":7051},"NCT04235296","Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Residual Burn Wound",[86],"2019-11-17",[7050],"Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Residual Burn Wound",[7052,7029],"epidermal growth factor",{"trials":7054,"activeCount":98},[],{"trials":7056,"activeCount":98},[],{"trials":7058,"activeCount":98},[],{"trials":7060,"activeCount":98},[],{"intervention":7062,"totalTrials":114,"cells":7063},"UC-MSCs Gel group",{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7076,"PHASE3":7078,"PHASE4":7080,"NA":7082},{"trials":7065,"activeCount":98},[],{"trials":7067,"activeCount":98},[7068],{"nctId":7069,"briefTitle":7070,"status":824,"phases":7071,"primaryCompletion":3533,"completion":3533,"start":7072,"enrollment":16,"conditions":7073,"interventions":7075},"NCT02685722","UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers",[86],"2012-01",[7074],"Difficult to Healing of Skin Ulcers",[7062],{"trials":7077,"activeCount":98},[],{"trials":7079,"activeCount":98},[],{"trials":7081,"activeCount":98},[],{"trials":7083,"activeCount":98},[],{"intervention":7085,"totalTrials":114,"cells":7086},"Corticosteroids & tanCART19\u002F20",{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7102,"PHASE3":7104,"PHASE4":7106,"NA":7108},{"trials":7088,"activeCount":98},[],{"trials":7090,"activeCount":98},[7091],{"nctId":7092,"briefTitle":7093,"status":7094,"phases":7095,"primaryCompletion":7096,"completion":7097,"start":7098,"enrollment":98,"conditions":7099,"interventions":7101},"NCT03605238","Treatment of Relapsed and\u002For Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20","WITHDRAWN",[86],"2019-08-15","2020-08-15","2018-08-15",[7100],"Neuromyelitis Optica Spectrum Disorder",[7085],{"trials":7103,"activeCount":98},[],{"trials":7105,"activeCount":98},[],{"trials":7107,"activeCount":98},[],{"trials":7109,"activeCount":98},[],{"intervention":7111,"totalTrials":114,"cells":7112},"The pleiotropic factor derived from mesenchymal stem cells",{"EARLY_PHASE1":7113,"PHASE1":7115,"PHASE2":7127,"PHASE3":7129,"PHASE4":7131,"NA":7133},{"trials":7114,"activeCount":98},[],{"trials":7116,"activeCount":98},[7117],{"nctId":7118,"briefTitle":7119,"status":625,"phases":7120,"primaryCompletion":7121,"completion":7122,"start":7123,"enrollment":861,"conditions":7124,"interventions":7126},"NCT04538885","Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Poorly Healed Wounds of Postoperative Incision",[86],"2021-03-31","2021-05-30","2020-09-10",[7125],"MSCs-PFs in Treating Poorly Healed Wounds of Postoperative Incision",[7111],{"trials":7128,"activeCount":98},[],{"trials":7130,"activeCount":98},[],{"trials":7132,"activeCount":98},[],{"trials":7134,"activeCount":98},[],{"intervention":7136,"totalTrials":114,"cells":7137},"Stem cell-derived derived pleiotropic factor",{"EARLY_PHASE1":7138,"PHASE1":7140,"PHASE2":7153,"PHASE3":7155,"PHASE4":7157,"NA":7159},{"trials":7139,"activeCount":98},[],{"trials":7141,"activeCount":98},[7142],{"nctId":7143,"briefTitle":7144,"status":625,"phases":7145,"primaryCompletion":7146,"completion":7147,"start":7148,"enrollment":539,"conditions":7149,"interventions":7151},"NCT04235868","Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds",[86],"2020-08-30","2020-10-30","2019-10-20",[7150],"Mesenchymal Stem Cell-derived Bioactivator for Treating Chronic Wounds",[7136,7152],"fibroblast growth factor",{"trials":7154,"activeCount":98},[],{"trials":7156,"activeCount":98},[],{"trials":7158,"activeCount":98},[],{"trials":7160,"activeCount":98},[],{"intervention":7152,"totalTrials":114,"cells":7162},{"EARLY_PHASE1":7163,"PHASE1":7165,"PHASE2":7171,"PHASE3":7173,"PHASE4":7175,"NA":7177},{"trials":7164,"activeCount":98},[],{"trials":7166,"activeCount":98},[7167],{"nctId":7143,"briefTitle":7144,"status":625,"phases":7168,"primaryCompletion":7146,"completion":7147,"start":7148,"enrollment":539,"conditions":7169,"interventions":7170},[86],[7150],[7136,7152],{"trials":7172,"activeCount":98},[],{"trials":7174,"activeCount":98},[],{"trials":7176,"activeCount":98},[],{"trials":7178,"activeCount":98},[],{"intervention":7180,"totalTrials":114,"cells":7181},"CMV-TCR-T cells",{"EARLY_PHASE1":7182,"PHASE1":7184,"PHASE2":7194,"PHASE3":7196,"PHASE4":7198,"NA":7200},{"trials":7183,"activeCount":98},[],{"trials":7185,"activeCount":98},[7186],{"nctId":7187,"briefTitle":7188,"status":625,"phases":7189,"primaryCompletion":5824,"completion":5824,"start":7190,"enrollment":21,"conditions":7191,"interventions":7193},"NCT05140187","CMV-TCR-T Cells for CMV Infection After Allogenic HSCT",[86],"2021-10-15",[7192],"CMV Infection After Allogenic HSCT",[7180],{"trials":7195,"activeCount":98},[],{"trials":7197,"activeCount":98},[],{"trials":7199,"activeCount":98},[],{"trials":7201,"activeCount":98},[],{"intervention":7203,"totalTrials":114,"cells":7204},"TB4",{"EARLY_PHASE1":7205,"PHASE1":7207,"PHASE2":7216,"PHASE3":7218,"PHASE4":7220,"NA":7222},{"trials":7206,"activeCount":98},[],{"trials":7208,"activeCount":98},[7209],{"nctId":7210,"briefTitle":7211,"status":824,"phases":7212,"primaryCompletion":3533,"completion":3533,"start":7072,"enrollment":16,"conditions":7213,"interventions":7215},"NCT02668055","Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds",[86],[7214],"Wounds",[7203],{"trials":7217,"activeCount":98},[],{"trials":7219,"activeCount":98},[],{"trials":7221,"activeCount":98},[],{"trials":7223,"activeCount":98},[],{"intervention":2780,"totalTrials":114,"cells":7225},{"EARLY_PHASE1":7226,"PHASE1":7228,"PHASE2":7234,"PHASE3":7236,"PHASE4":7238,"NA":7240},{"trials":7227,"activeCount":98},[],{"trials":7229,"activeCount":98},[7230],{"nctId":2772,"briefTitle":2773,"status":824,"phases":7231,"primaryCompletion":2775,"completion":2775,"start":2776,"enrollment":2777,"conditions":7232,"interventions":7233},[86],[23,663],[2756,2780],{"trials":7235,"activeCount":98},[],{"trials":7237,"activeCount":98},[],{"trials":7239,"activeCount":98},[],{"trials":7241,"activeCount":98},[],{"intervention":7243,"totalTrials":114,"cells":7244},"Mesothelin-directed CAR-T cells",{"EARLY_PHASE1":7245,"PHASE1":7247,"PHASE2":7256,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7246,"activeCount":98},[],{"trials":7248,"activeCount":98},[7249],{"nctId":7250,"briefTitle":7251,"status":625,"phases":7252,"primaryCompletion":7253,"completion":1004,"start":1048,"enrollment":522,"conditions":7254,"interventions":7255},"NCT03747965","Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors",[86],"2019-11",[506],[7243],{"trials":7257,"activeCount":98},[],{"trials":7259,"activeCount":98},[],{"trials":7261,"activeCount":98},[],{"trials":7263,"activeCount":98},[],{"intervention":7265,"totalTrials":114,"cells":7266},"anti-meso-CAR vector transduced T cells",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7268,"activeCount":98},[],{"trials":7270,"activeCount":98},[7271],{"nctId":7272,"briefTitle":7273,"status":625,"phases":7274,"primaryCompletion":7275,"completion":1048,"start":7276,"enrollment":16,"conditions":7277,"interventions":7282},"NCT02580747","Treatment of Relapsed and\u002For Chemotherapy Refractory Advanced Malignancies by CART-meso",[86],"2017-11","2015-10",[7278,29,5407,7279,7280,7281],"Malignant Mesothelioma","Triple Negative Breast Cancer","Endometrial Cancer","Other Mesothelin Positive Tumors",[7265],{"trials":7284,"activeCount":98},[],{"trials":7286,"activeCount":98},[],{"trials":7288,"activeCount":98},[],{"trials":7290,"activeCount":98},[],{"intervention":7292,"totalTrials":114,"cells":7293},"anti-mesothelin CAR-T cells",{"EARLY_PHASE1":7294,"PHASE1":7296,"PHASE2":7305,"PHASE3":7307,"PHASE4":7309,"NA":7311},{"trials":7295,"activeCount":98},[],{"trials":7297,"activeCount":98},[7298],{"nctId":7299,"briefTitle":7300,"status":625,"phases":7301,"primaryCompletion":7147,"completion":7039,"start":7302,"enrollment":522,"conditions":7303,"interventions":7304},"NCT03545815","Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.",[86],"2018-03-19",[506],[7292],{"trials":7306,"activeCount":98},[],{"trials":7308,"activeCount":98},[],{"trials":7310,"activeCount":98},[],{"trials":7312,"activeCount":98},[],{"intervention":7314,"totalTrials":114,"cells":7315},"UCB Mesenchymal Stem Cells treatment",{"EARLY_PHASE1":7316,"PHASE1":7318,"PHASE2":7327,"PHASE3":7329,"PHASE4":7331,"NA":7333},{"trials":7317,"activeCount":98},[],{"trials":7319,"activeCount":98},[7320],{"nctId":7321,"briefTitle":7322,"status":625,"phases":7323,"primaryCompletion":3077,"completion":3077,"start":2742,"enrollment":861,"conditions":7324,"interventions":7326},"NCT02304562","Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair",[86],[7325],"Sweat Gland Diseases",[7314],{"trials":7328,"activeCount":98},[],{"trials":7330,"activeCount":98},[],{"trials":7332,"activeCount":98},[],{"trials":7334,"activeCount":98},[],{"intervention":7336,"totalTrials":114,"cells":7337},"MSCs Derived Pleiotropic Factors",{"EARLY_PHASE1":7338,"PHASE1":7340,"PHASE2":7351,"PHASE3":7353,"PHASE4":7355,"NA":7357},{"trials":7339,"activeCount":98},[],{"trials":7341,"activeCount":98},[7342],{"nctId":7343,"briefTitle":7344,"status":625,"phases":7345,"primaryCompletion":7346,"completion":7347,"start":5220,"enrollment":861,"conditions":7348,"interventions":7350},"NCT04536233","Effects of MSCs Derived Pleiotropic Factors on Wound Healing in Endonasal Surgeries",[86],"2021-01-31","2021-03-30",[7349],"MSCs Derived Pleiotropic Factors on Wound Healing in Endonasal Surgeries",[7336],{"trials":7352,"activeCount":98},[],{"trials":7354,"activeCount":98},[],{"trials":7356,"activeCount":98},[],{"trials":7358,"activeCount":98},[],{"intervention":7360,"totalTrials":114,"cells":7361},"donor-derived CD19\u002F22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT",{"EARLY_PHASE1":7362,"PHASE1":7364,"PHASE2":7373,"PHASE3":7375,"PHASE4":7377,"NA":7379},{"trials":7363,"activeCount":98},[],{"trials":7365,"activeCount":98},[7366],{"nctId":7367,"briefTitle":7368,"status":625,"phases":7369,"primaryCompletion":5403,"completion":3508,"start":7370,"enrollment":522,"conditions":7371,"interventions":7372},"NCT03463928","A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia",[86],"2017-10-08",[6383],[7360],{"trials":7374,"activeCount":98},[],{"trials":7376,"activeCount":98},[],{"trials":7378,"activeCount":98},[],{"trials":7380,"activeCount":98},[],{"intervention":7382,"totalTrials":114,"cells":7383},"2-4 mCi 68Ga\u002F64Cu-FAPI-XT117",{"EARLY_PHASE1":7384,"PHASE1":7386,"PHASE2":7399,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7385,"activeCount":98},[],{"trials":7387,"activeCount":98},[7388],{"nctId":7389,"briefTitle":7390,"status":824,"phases":7391,"primaryCompletion":2775,"completion":7392,"start":7393,"enrollment":685,"conditions":7394,"interventions":7396},"NCT05814835","First in Human Study of 68Ga\u002F64Cu-FAPI-XT117 PET\u002FCT in Patients With Malignant Solid Tumors",[86],"2023-12-18","2022-12-07",[7395],"Malignant Solid Tumors",[7382,7397,7398],"4-6 mCi 68Ga\u002F64Cu-FAPI-XT117","6-8 mCi 68Ga\u002F64Cu-FAPI-XT117",{"trials":7400,"activeCount":98},[],{"trials":7402,"activeCount":98},[],{"trials":7404,"activeCount":98},[],{"trials":7406,"activeCount":98},[],{"intervention":7397,"totalTrials":114,"cells":7408},{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7417,"PHASE3":7419,"PHASE4":7421,"NA":7423},{"trials":7410,"activeCount":98},[],{"trials":7412,"activeCount":98},[7413],{"nctId":7389,"briefTitle":7390,"status":824,"phases":7414,"primaryCompletion":2775,"completion":7392,"start":7393,"enrollment":685,"conditions":7415,"interventions":7416},[86],[7395],[7382,7397,7398],{"trials":7418,"activeCount":98},[],{"trials":7420,"activeCount":98},[],{"trials":7422,"activeCount":98},[],{"trials":7424,"activeCount":98},[],{"intervention":7398,"totalTrials":114,"cells":7426},{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7435,"PHASE3":7437,"PHASE4":7439,"NA":7441},{"trials":7428,"activeCount":98},[],{"trials":7430,"activeCount":98},[7431],{"nctId":7389,"briefTitle":7390,"status":824,"phases":7432,"primaryCompletion":2775,"completion":7392,"start":7393,"enrollment":685,"conditions":7433,"interventions":7434},[86],[7395],[7382,7397,7398],{"trials":7436,"activeCount":98},[],{"trials":7438,"activeCount":98},[],{"trials":7440,"activeCount":98},[],{"trials":7442,"activeCount":98},[],{"intervention":7444,"totalTrials":114,"cells":7445},"TGFβR-KO CAR-EGFR T Cells",{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7459,"PHASE3":7461,"PHASE4":7463,"NA":7465},{"trials":7447,"activeCount":98},[],{"trials":7449,"activeCount":98},[7450],{"nctId":7451,"briefTitle":7452,"status":625,"phases":7453,"primaryCompletion":7454,"completion":5824,"start":7455,"enrollment":539,"conditions":7456,"interventions":7458},"NCT04976218","TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors",[86],"2023-12-20","2022-03-15",[506,7457],"EGFR Overexpression",[7444],{"trials":7460,"activeCount":98},[],{"trials":7462,"activeCount":98},[],{"trials":7464,"activeCount":98},[],{"trials":7466,"activeCount":98},[],{"intervention":2271,"totalTrials":114,"cells":7468},{"EARLY_PHASE1":7469,"PHASE1":7471,"PHASE2":7477,"PHASE3":7479,"PHASE4":7481,"NA":7483},{"trials":7470,"activeCount":98},[],{"trials":7472,"activeCount":98},[7473],{"nctId":2262,"briefTitle":2263,"status":625,"phases":7474,"primaryCompletion":2265,"completion":2266,"start":2267,"enrollment":16,"conditions":7475,"interventions":7476},[86],[23,34],[2270,514,2271],{"trials":7478,"activeCount":98},[],{"trials":7480,"activeCount":98},[],{"trials":7482,"activeCount":98},[],{"trials":7484,"activeCount":98},[],{"intervention":7052,"totalTrials":114,"cells":7486},{"EARLY_PHASE1":7487,"PHASE1":7489,"PHASE2":7495,"PHASE3":7497,"PHASE4":7499,"NA":7501},{"trials":7488,"activeCount":98},[],{"trials":7490,"activeCount":98},[7491],{"nctId":7045,"briefTitle":7046,"status":625,"phases":7492,"primaryCompletion":7039,"completion":7007,"start":7048,"enrollment":539,"conditions":7493,"interventions":7494},[86],[7050],[7052,7029],{"trials":7496,"activeCount":98},[],{"trials":7498,"activeCount":98},[],{"trials":7500,"activeCount":98},[],{"trials":7502,"activeCount":98},[],{"intervention":7504,"totalTrials":114,"cells":7505},"CAR-T-19 Cells",{"EARLY_PHASE1":7506,"PHASE1":7508,"PHASE2":7520,"PHASE3":7522,"PHASE4":7524,"NA":7526},{"trials":7507,"activeCount":98},[],{"trials":7509,"activeCount":98},[7510],{"nctId":7511,"briefTitle":7512,"status":625,"phases":7513,"primaryCompletion":7514,"completion":7515,"start":7516,"enrollment":24,"conditions":7517,"interventions":7519},"NCT05270772","CAR-T-19 Cells for Patients With CD19+ Relapse\u002FRefractory B-ALL",[86],"2022-07-15","2024-09-16","2021-02-25",[7518],"CD19+ Relapse\u002FRefractory B-ALL",[7504],{"trials":7521,"activeCount":98},[],{"trials":7523,"activeCount":98},[],{"trials":7525,"activeCount":98},[],{"trials":7527,"activeCount":98},[],{"intervention":7529,"totalTrials":114,"cells":7530},"MSCs",{"EARLY_PHASE1":7531,"PHASE1":7533,"PHASE2":7541,"PHASE3":7543,"PHASE4":7545,"NA":7547},{"trials":7532,"activeCount":98},[],{"trials":7534,"activeCount":98},[7535],{"nctId":7536,"briefTitle":7537,"status":824,"phases":7538,"primaryCompletion":3533,"completion":3533,"start":7072,"enrollment":16,"conditions":7539,"interventions":7540},"NCT02669199","MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound",[86],[7529],[7529],{"trials":7542,"activeCount":98},[],{"trials":7544,"activeCount":98},[],{"trials":7546,"activeCount":98},[],{"trials":7548,"activeCount":98},[],{"intervention":7550,"totalTrials":114,"cells":7551},"liveness tissue skin",{"EARLY_PHASE1":7552,"PHASE1":7554,"PHASE2":7563,"PHASE3":7565,"PHASE4":7567,"NA":7569},{"trials":7553,"activeCount":98},[],{"trials":7555,"activeCount":98},[7556],{"nctId":7557,"briefTitle":7558,"status":824,"phases":7559,"primaryCompletion":3533,"completion":3533,"start":7072,"enrollment":16,"conditions":7560,"interventions":7562},"NCT02668042","The Activity of Tissue Engineering Skin Substitutes",[86],[7561],"Difficult to Heal Wounds",[7550],{"trials":7564,"activeCount":98},[],{"trials":7566,"activeCount":98},[],{"trials":7568,"activeCount":98},[],{"trials":7570,"activeCount":98},[],{"intervention":7572,"totalTrials":114,"cells":7573},"Neoantigen Vaccines",{"EARLY_PHASE1":7574,"PHASE1":7576,"PHASE2":7588,"PHASE3":7590,"PHASE4":7592,"NA":7594},{"trials":7575,"activeCount":98},[],{"trials":7577,"activeCount":98},[7578],{"nctId":7579,"briefTitle":7580,"status":625,"phases":7581,"primaryCompletion":7582,"completion":7583,"start":7584,"enrollment":661,"conditions":7585,"interventions":7587},"NCT03674073","A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma",[86],"2020-10-15","2020-12-15","2018-10-15",[18,7586],"Liver Cancer, Adult",[7572],{"trials":7589,"activeCount":98},[],{"trials":7591,"activeCount":98},[],{"trials":7593,"activeCount":98},[],{"trials":7595,"activeCount":98},[],{"intervention":3580,"totalTrials":2255,"cells":7597},{"EARLY_PHASE1":7598,"PHASE1":7600,"PHASE2":7602,"PHASE3":7604,"PHASE4":7606,"NA":7616},{"trials":7599,"activeCount":98},[],{"trials":7601,"activeCount":98},[],{"trials":7603,"activeCount":98},[],{"trials":7605,"activeCount":98},[],{"trials":7607,"activeCount":98},[7608,7612],{"nctId":3215,"briefTitle":3216,"status":824,"phases":7609,"primaryCompletion":3218,"completion":3218,"start":3219,"enrollment":1005,"conditions":7610,"interventions":7611},[89],[3221],[3223,3202],{"nctId":3572,"briefTitle":3573,"status":824,"phases":7613,"primaryCompletion":3575,"completion":3576,"start":3577,"enrollment":335,"conditions":7614,"interventions":7615},[89],[3579,3580],[3580,3559],{"trials":7617,"activeCount":98},[7618,7626,7636],{"nctId":7619,"briefTitle":7620,"status":625,"phases":7621,"primaryCompletion":4226,"completion":4226,"start":7622,"enrollment":2590,"conditions":7623,"interventions":7625},"NCT05274789","Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Robot-assisted Pancreaticoduodenectomy: a Randomized Controlled Study",[90],"2022-04-15",[7624],"Delirium in Old Age",[3580],{"nctId":7627,"briefTitle":7628,"status":824,"phases":7629,"primaryCompletion":7630,"completion":7631,"start":3101,"enrollment":7632,"conditions":7633,"interventions":7635},"NCT06362408","Effect of Dexmedetomidine on Postoperative Mental Disorders and Long-term Survival in Elderly Patients",[],"2023-05-25","2023-06-01",6000,[7634],"Cohort Studies",[3580],{"nctId":7637,"briefTitle":7638,"status":824,"phases":7639,"primaryCompletion":3114,"completion":650,"start":5194,"enrollment":7640,"conditions":7641,"interventions":7642},"NCT05436964","Effect of Intraoperative Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing Major Abdominal Surgery",[90],268,[7624],[3580],{"intervention":7644,"totalTrials":94,"cells":7645},"anti-CD19-CAR vector-transduced T cells",{"EARLY_PHASE1":7646,"PHASE1":7648,"PHASE2":7650,"PHASE3":7660,"PHASE4":7662,"NA":7664},{"trials":7647,"activeCount":98},[],{"trials":7649,"activeCount":98},[],{"trials":7651,"activeCount":98},[7652],{"nctId":7653,"briefTitle":7654,"status":625,"phases":7655,"primaryCompletion":3507,"completion":3508,"start":7656,"enrollment":94,"conditions":7657,"interventions":7659},"NCT02081937","CART-19 Immunotherapy in Mantle Cell Lymphoma",[86,87],"2014-03",[5335,561,7658],"Mantle Cell Lymphoma",[7644],{"trials":7661,"activeCount":98},[],{"trials":7663,"activeCount":98},[],{"trials":7665,"activeCount":98},[7666],{"nctId":7667,"briefTitle":7668,"status":625,"phases":7669,"primaryCompletion":6095,"completion":6095,"start":6096,"enrollment":21,"conditions":7670,"interventions":7671},"NCT01864889","Treatment of Relapsed and\u002For Chemotherapy Refractory B-cell Malignancy by CART19",[90],[5335,5336,5337,5338,5339,5340,5341,5342,5343,5344,5345,5346,5347,5348,5349,5350,5351,5352,5353,5354,5355,5356,5357],[7644],{"intervention":7673,"totalTrials":94,"cells":7674},"Piperacillin-tazobactam combination product",{"EARLY_PHASE1":7675,"PHASE1":7677,"PHASE2":7679,"PHASE3":7681,"PHASE4":7683,"NA":7685},{"trials":7676,"activeCount":98},[],{"trials":7678,"activeCount":98},[],{"trials":7680,"activeCount":98},[],{"trials":7682,"activeCount":98},[],{"trials":7684,"activeCount":98},[],{"trials":7686,"activeCount":98},[7687,7697],{"nctId":7688,"briefTitle":7689,"status":625,"phases":7690,"primaryCompletion":3376,"completion":3534,"start":7691,"enrollment":242,"conditions":7692,"interventions":7695},"NCT01714557","Prophylactic Piperacillin\u002FTazobactam in Hematopoietic Stem Cell Transplantation",[90],"2012-09",[7693,7694],"Neutropenia","Hematopoietic Stem Cell Transplantation",[7696,7673],"Piperacillin",{"nctId":7698,"briefTitle":7699,"status":824,"phases":7700,"primaryCompletion":7656,"completion":1038,"start":3161,"enrollment":7701,"conditions":7702,"interventions":7704},"NCT01714570","Piperacillin\u002FTazobactam for Empirical Therapy of Febrile Neutropenia",[90],123,[7703,7693,7694],"Febrile",[7673,7705],"Imipenem",{"intervention":7707,"totalTrials":94,"cells":7708},"Visipaque",{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7713,"PHASE3":7715,"PHASE4":7717,"NA":7719},{"trials":7710,"activeCount":98},[],{"trials":7712,"activeCount":98},[],{"trials":7714,"activeCount":98},[],{"trials":7716,"activeCount":98},[],{"trials":7718,"activeCount":98},[],{"trials":7720,"activeCount":98},[7721,7731],{"nctId":7722,"briefTitle":7723,"status":824,"phases":7724,"primaryCompletion":7725,"completion":7725,"start":3601,"enrollment":7726,"conditions":7727,"interventions":7729},"NCT02405377","Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy",[90],"2015-02",264,[7728],"Cardio-Renal Syndrome",[7707,7730],"0.9% sodium chloride fluid administration",{"nctId":7732,"briefTitle":7733,"status":625,"phases":7734,"primaryCompletion":7735,"completion":6095,"start":3289,"enrollment":7736,"conditions":7737,"interventions":7738},"NCT02718521","Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN",[90],"2017-03",400,[7728],[7707,7730,7739],"isosorbide dinitrate",{"intervention":7730,"totalTrials":94,"cells":7741},{"EARLY_PHASE1":7742,"PHASE1":7744,"PHASE2":7746,"PHASE3":7748,"PHASE4":7750,"NA":7752},{"trials":7743,"activeCount":98},[],{"trials":7745,"activeCount":98},[],{"trials":7747,"activeCount":98},[],{"trials":7749,"activeCount":98},[],{"trials":7751,"activeCount":98},[],{"trials":7753,"activeCount":98},[7754,7758],{"nctId":7722,"briefTitle":7723,"status":824,"phases":7755,"primaryCompletion":7725,"completion":7725,"start":3601,"enrollment":7726,"conditions":7756,"interventions":7757},[90],[7728],[7707,7730],{"nctId":7732,"briefTitle":7733,"status":625,"phases":7759,"primaryCompletion":7735,"completion":6095,"start":3289,"enrollment":7736,"conditions":7760,"interventions":7761},[90],[7728],[7707,7730,7739],{"intervention":6009,"totalTrials":94,"cells":7763},{"EARLY_PHASE1":7764,"PHASE1":7766,"PHASE2":7768,"PHASE3":7774,"PHASE4":7776,"NA":7778},{"trials":7765,"activeCount":98},[],{"trials":7767,"activeCount":98},[],{"trials":7769,"activeCount":98},[7770],{"nctId":6002,"briefTitle":6003,"status":824,"phases":7771,"primaryCompletion":4975,"completion":629,"start":6005,"enrollment":6006,"conditions":7772,"interventions":7773},[87],[4068,2062],[5993,6009],{"trials":7775,"activeCount":98},[],{"trials":7777,"activeCount":98},[],{"trials":7779,"activeCount":98},[7780],{"nctId":7781,"briefTitle":7782,"status":625,"phases":7783,"primaryCompletion":1111,"completion":1111,"start":7784,"enrollment":2614,"conditions":7785,"interventions":7787},"NCT03586557","Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis",[90],"2018-09-01",[7786],"Optic Neuritis",[6009],{"intervention":7789,"totalTrials":94,"cells":7790},"liraglutide",{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7792,"activeCount":98},[],{"trials":7794,"activeCount":98},[],{"trials":7796,"activeCount":98},[],{"trials":7798,"activeCount":98},[],{"trials":7800,"activeCount":98},[],{"trials":7802,"activeCount":98},[7803,7810],{"nctId":7804,"briefTitle":7805,"status":625,"phases":7806,"primaryCompletion":755,"completion":755,"start":3741,"enrollment":861,"conditions":7807,"interventions":7809},"NCT02490176","Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters",[90],[7808],"Heart Failure",[7789],{"nctId":7811,"briefTitle":7812,"status":625,"phases":7813,"primaryCompletion":7814,"completion":7815,"start":3509,"enrollment":7736,"conditions":7816,"interventions":7818},"NCT02930265","Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy",[90],"2018-02","2018-03",[7817],"Ischemic Cardiomyopathy",[7819],"Liraglutide",{"intervention":7821,"totalTrials":114,"cells":7822},"Anti-PD-1\u002FPD-L1 antibodies",{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7829,"PHASE4":7831,"NA":7833},{"trials":7824,"activeCount":98},[],{"trials":7826,"activeCount":98},[],{"trials":7828,"activeCount":98},[],{"trials":7830,"activeCount":98},[],{"trials":7832,"activeCount":98},[],{"trials":7834,"activeCount":98},[7835],{"nctId":7836,"briefTitle":7837,"status":625,"phases":7838,"primaryCompletion":7839,"completion":7839,"start":7840,"enrollment":7736,"conditions":7841,"interventions":7842},"NCT03787953","A Real World Study of Anti-PD-1\u002FPD-L1 Antibodies for the Treatment of Advanced Solid Tumors",[],"2019-09-30","2018-12-30",[4230],[7821],{"intervention":2564,"totalTrials":114,"cells":7844},{"EARLY_PHASE1":7845,"PHASE1":7847,"PHASE2":7849,"PHASE3":7851,"PHASE4":7853,"NA":7855},{"trials":7846,"activeCount":98},[],{"trials":7848,"activeCount":98},[],{"trials":7850,"activeCount":98},[],{"trials":7852,"activeCount":98},[],{"trials":7854,"activeCount":98},[],{"trials":7856,"activeCount":98},[7857],{"nctId":2555,"briefTitle":2556,"status":824,"phases":7858,"primaryCompletion":2558,"completion":2559,"start":2560,"enrollment":861,"conditions":7859,"interventions":7860},[90],[2562],[2564,2527],{"intervention":7862,"totalTrials":114,"cells":7863},"SOX plus PD-1 inhibitor",{"EARLY_PHASE1":7864,"PHASE1":7866,"PHASE2":7868,"PHASE3":7870,"PHASE4":7872,"NA":7874},{"trials":7865,"activeCount":98},[],{"trials":7867,"activeCount":98},[],{"trials":7869,"activeCount":98},[],{"trials":7871,"activeCount":98},[],{"trials":7873,"activeCount":98},[],{"trials":7875,"activeCount":98},[7876],{"nctId":7877,"briefTitle":7878,"status":625,"phases":7879,"primaryCompletion":4660,"completion":7880,"start":5194,"enrollment":7881,"conditions":7882,"interventions":7884},"NCT06202781","Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy",[],"2024-07-31",28,[20,7883,1889,3066],"Tumor Microenvironment",[7862],{"intervention":7886,"totalTrials":114,"cells":7887},"biomimetic cartilage matrix + autologous chondrocytes",{"EARLY_PHASE1":7888,"PHASE1":7890,"PHASE2":7892,"PHASE3":7894,"PHASE4":7896,"NA":7898},{"trials":7889,"activeCount":98},[],{"trials":7891,"activeCount":98},[],{"trials":7893,"activeCount":98},[],{"trials":7895,"activeCount":98},[],{"trials":7897,"activeCount":98},[],{"trials":7899,"activeCount":98},[7900],{"nctId":7901,"briefTitle":7902,"status":625,"phases":7903,"primaryCompletion":7904,"completion":3422,"start":2560,"enrollment":886,"conditions":7905,"interventions":7907},"NCT02770209","Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions",[90],"2013-08",[7906],"Cartilage Diseases",[7886],{"intervention":7909,"totalTrials":114,"cells":7910},"Nicardipine",{"EARLY_PHASE1":7911,"PHASE1":7913,"PHASE2":7915,"PHASE3":7917,"PHASE4":7919,"NA":7921},{"trials":7912,"activeCount":98},[],{"trials":7914,"activeCount":98},[],{"trials":7916,"activeCount":98},[],{"trials":7918,"activeCount":98},[],{"trials":7920,"activeCount":98},[],{"trials":7922,"activeCount":98},[7923],{"nctId":7924,"briefTitle":7925,"status":824,"phases":7926,"primaryCompletion":7927,"completion":7928,"start":7929,"enrollment":7930,"conditions":7931,"interventions":7933},"NCT03497351","Effects of Different Kinds of Hypotensive Drugs on Dynamic Hemodynamic Changing in Patients Under Surgeries",[90],"2019-01-31","2019-02-15","2018-04-15",59,[7932],"General Surgery",[7909,7934],"Urapidil",{"intervention":7934,"totalTrials":114,"cells":7936},{"EARLY_PHASE1":7937,"PHASE1":7939,"PHASE2":7941,"PHASE3":7943,"PHASE4":7945,"NA":7947},{"trials":7938,"activeCount":98},[],{"trials":7940,"activeCount":98},[],{"trials":7942,"activeCount":98},[],{"trials":7944,"activeCount":98},[],{"trials":7946,"activeCount":98},[],{"trials":7948,"activeCount":98},[7949],{"nctId":7924,"briefTitle":7925,"status":824,"phases":7950,"primaryCompletion":7927,"completion":7928,"start":7929,"enrollment":7930,"conditions":7951,"interventions":7952},[90],[7932],[7909,7934],{"intervention":7954,"totalTrials":114,"cells":7955},"Systemic anti-tumor therapy",{"EARLY_PHASE1":7956,"PHASE1":7958,"PHASE2":7960,"PHASE3":7962,"PHASE4":7964,"NA":7966},{"trials":7957,"activeCount":98},[],{"trials":7959,"activeCount":98},[],{"trials":7961,"activeCount":98},[],{"trials":7963,"activeCount":98},[],{"trials":7965,"activeCount":98},[],{"trials":7967,"activeCount":98},[7968],{"nctId":7969,"briefTitle":7970,"status":625,"phases":7971,"primaryCompletion":2741,"completion":2741,"start":3532,"enrollment":335,"conditions":7972,"interventions":7974},"NCT02701231","Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer",[90],[7973],"Lung Neoplasms",[7954],{"intervention":7976,"totalTrials":114,"cells":7977},"GLSE compound",{"EARLY_PHASE1":7978,"PHASE1":7980,"PHASE2":7982,"PHASE3":7984,"PHASE4":7986,"NA":7988},{"trials":7979,"activeCount":98},[],{"trials":7981,"activeCount":98},[],{"trials":7983,"activeCount":98},[],{"trials":7985,"activeCount":98},[],{"trials":7987,"activeCount":98},[],{"trials":7989,"activeCount":98},[7990],{"nctId":7991,"briefTitle":7992,"status":824,"phases":7993,"primaryCompletion":1049,"completion":7994,"start":3532,"enrollment":270,"conditions":7995,"interventions":7997},"NCT02603016","Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma",[90],"2017-02",[7973,7996],"Breast Neoplasms",[7976,7998,7999],"Maitake mushroom extract compound","Ginseng compound",{"intervention":7998,"totalTrials":114,"cells":8001},{"EARLY_PHASE1":8002,"PHASE1":8004,"PHASE2":8006,"PHASE3":8008,"PHASE4":8010,"NA":8012},{"trials":8003,"activeCount":98},[],{"trials":8005,"activeCount":98},[],{"trials":8007,"activeCount":98},[],{"trials":8009,"activeCount":98},[],{"trials":8011,"activeCount":98},[],{"trials":8013,"activeCount":98},[8014],{"nctId":7991,"briefTitle":7992,"status":824,"phases":8015,"primaryCompletion":1049,"completion":7994,"start":3532,"enrollment":270,"conditions":8016,"interventions":8017},[90],[7973,7996],[7976,7998,7999],{"intervention":7999,"totalTrials":114,"cells":8019},{"EARLY_PHASE1":8020,"PHASE1":8022,"PHASE2":8024,"PHASE3":8026,"PHASE4":8028,"NA":8030},{"trials":8021,"activeCount":98},[],{"trials":8023,"activeCount":98},[],{"trials":8025,"activeCount":98},[],{"trials":8027,"activeCount":98},[],{"trials":8029,"activeCount":98},[],{"trials":8031,"activeCount":98},[8032],{"nctId":7991,"briefTitle":7992,"status":824,"phases":8033,"primaryCompletion":1049,"completion":7994,"start":3532,"enrollment":270,"conditions":8034,"interventions":8035},[90],[7973,7996],[7976,7998,7999],{"intervention":8037,"totalTrials":114,"cells":8038},"probiotics",{"EARLY_PHASE1":8039,"PHASE1":8041,"PHASE2":8043,"PHASE3":8045,"PHASE4":8047,"NA":8049},{"trials":8040,"activeCount":98},[],{"trials":8042,"activeCount":98},[],{"trials":8044,"activeCount":98},[],{"trials":8046,"activeCount":98},[],{"trials":8048,"activeCount":98},[],{"trials":8050,"activeCount":98},[8051],{"nctId":8052,"briefTitle":8053,"status":625,"phases":8054,"primaryCompletion":5691,"completion":8055,"start":8056,"enrollment":8057,"conditions":8058,"interventions":8060},"NCT03377946","Effect of Probiotics on Pre-diabetes and Diabetes in China",[90],"2019-08-31","2017-12-21",220,[8059],"Type 2 Diabetes Mellitus",[8037],{"intervention":7696,"totalTrials":114,"cells":8062},{"EARLY_PHASE1":8063,"PHASE1":8065,"PHASE2":8067,"PHASE3":8069,"PHASE4":8071,"NA":8073},{"trials":8064,"activeCount":98},[],{"trials":8066,"activeCount":98},[],{"trials":8068,"activeCount":98},[],{"trials":8070,"activeCount":98},[],{"trials":8072,"activeCount":98},[],{"trials":8074,"activeCount":98},[8075],{"nctId":7688,"briefTitle":7689,"status":625,"phases":8076,"primaryCompletion":3376,"completion":3534,"start":7691,"enrollment":242,"conditions":8077,"interventions":8078},[90],[7693,7694],[7696,7673],{"intervention":8080,"totalTrials":114,"cells":8081},"detection of driver mutation",{"EARLY_PHASE1":8082,"PHASE1":8084,"PHASE2":8086,"PHASE3":8088,"PHASE4":8090,"NA":8092},{"trials":8083,"activeCount":98},[],{"trials":8085,"activeCount":98},[],{"trials":8087,"activeCount":98},[],{"trials":8089,"activeCount":98},[],{"trials":8091,"activeCount":98},[],{"trials":8093,"activeCount":98},[8094],{"nctId":8095,"briefTitle":8096,"status":625,"phases":8097,"primaryCompletion":3507,"completion":8098,"start":7276,"enrollment":335,"conditions":8099,"interventions":8101},"NCT02778854","Liquid Biopsy for Detection of Driver Mutation in NSCLC",[],"2020-11",[8100],"Non Small Cell Lung Cancer",[8080],{"intervention":8103,"totalTrials":114,"cells":8104},"melatonin",{"EARLY_PHASE1":8105,"PHASE1":8107,"PHASE2":8109,"PHASE3":8111,"PHASE4":8113,"NA":8115},{"trials":8106,"activeCount":98},[],{"trials":8108,"activeCount":98},[],{"trials":8110,"activeCount":98},[],{"trials":8112,"activeCount":98},[],{"trials":8114,"activeCount":98},[],{"trials":8116,"activeCount":98},[8117],{"nctId":8118,"briefTitle":8119,"status":625,"phases":8120,"primaryCompletion":3630,"completion":3630,"start":8121,"enrollment":8122,"conditions":8123,"interventions":8125},"NCT03303378","Effects of Melatonin on Reperfusion Injury",[90],"2017-11-01",190,[8124],"Reperfusion Injury, Myocardial",[8103,8126],"Placebos",{"intervention":8126,"totalTrials":114,"cells":8128},{"EARLY_PHASE1":8129,"PHASE1":8131,"PHASE2":8133,"PHASE3":8135,"PHASE4":8137,"NA":8139},{"trials":8130,"activeCount":98},[],{"trials":8132,"activeCount":98},[],{"trials":8134,"activeCount":98},[],{"trials":8136,"activeCount":98},[],{"trials":8138,"activeCount":98},[],{"trials":8140,"activeCount":98},[8141],{"nctId":8118,"briefTitle":8119,"status":625,"phases":8142,"primaryCompletion":3630,"completion":3630,"start":8121,"enrollment":8122,"conditions":8143,"interventions":8144},[90],[8124],[8103,8126],{"intervention":8146,"totalTrials":114,"cells":8147},"Omeprazole",{"EARLY_PHASE1":8148,"PHASE1":8150,"PHASE2":8152,"PHASE3":8154,"PHASE4":8156,"NA":8158},{"trials":8149,"activeCount":98},[],{"trials":8151,"activeCount":98},[],{"trials":8153,"activeCount":98},[],{"trials":8155,"activeCount":98},[],{"trials":8157,"activeCount":98},[],{"trials":8159,"activeCount":98},[8160],{"nctId":8161,"briefTitle":8162,"status":824,"phases":8163,"primaryCompletion":5492,"completion":5492,"start":3160,"enrollment":8164,"conditions":8165,"interventions":8169},"NCT02685150","Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease",[90],157,[8166,8167,8168],"Gastroesophageal Reflux Disease","Dyspepsia","Bile Reflux",[8146],{"intervention":8171,"totalTrials":114,"cells":8172},"Trimetazidine",{"EARLY_PHASE1":8173,"PHASE1":8175,"PHASE2":8177,"PHASE3":8179,"PHASE4":8181,"NA":8183},{"trials":8174,"activeCount":98},[],{"trials":8176,"activeCount":98},[],{"trials":8178,"activeCount":98},[],{"trials":8180,"activeCount":98},[],{"trials":8182,"activeCount":98},[],{"trials":8184,"activeCount":98},[8185],{"nctId":8186,"briefTitle":8187,"status":625,"phases":8188,"primaryCompletion":8189,"start":755,"enrollment":174,"conditions":8190,"interventions":8191},"NCT02826616","Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction",[90],"2017-08",[3632],[8171],{"intervention":7705,"totalTrials":114,"cells":8193},{"EARLY_PHASE1":8194,"PHASE1":8196,"PHASE2":8198,"PHASE3":8200,"PHASE4":8202,"NA":8204},{"trials":8195,"activeCount":98},[],{"trials":8197,"activeCount":98},[],{"trials":8199,"activeCount":98},[],{"trials":8201,"activeCount":98},[],{"trials":8203,"activeCount":98},[],{"trials":8205,"activeCount":98},[8206],{"nctId":7698,"briefTitle":7699,"status":824,"phases":8207,"primaryCompletion":7656,"completion":1038,"start":3161,"enrollment":7701,"conditions":8208,"interventions":8209},[90],[7703,7693,7694],[7673,7705],{"intervention":8211,"totalTrials":114,"cells":8212},"vitamin D3",{"EARLY_PHASE1":8213,"PHASE1":8215,"PHASE2":8217,"PHASE3":8219,"PHASE4":8221,"NA":8223},{"trials":8214,"activeCount":98},[],{"trials":8216,"activeCount":98},[],{"trials":8218,"activeCount":98},[],{"trials":8220,"activeCount":98},[],{"trials":8222,"activeCount":98},[],{"trials":8224,"activeCount":98},[8225],{"nctId":8226,"briefTitle":8227,"status":625,"phases":8228,"primaryCompletion":8229,"completion":8229,"start":3741,"enrollment":8230,"conditions":8231,"interventions":8233},"NCT02489240","Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy",[90],"2017-07",306,[8232],"Contrast-induced Nephropathy",[8211],{"intervention":8235,"totalTrials":114,"cells":8236},"volatile anaesthetic",{"EARLY_PHASE1":8237,"PHASE1":8239,"PHASE2":8241,"PHASE3":8243,"PHASE4":8245,"NA":8247},{"trials":8238,"activeCount":98},[],{"trials":8240,"activeCount":98},[],{"trials":8242,"activeCount":98},[],{"trials":8244,"activeCount":98},[],{"trials":8246,"activeCount":98},[],{"trials":8248,"activeCount":98},[8249],{"nctId":8250,"briefTitle":8251,"status":824,"phases":8252,"primaryCompletion":8253,"completion":2519,"start":2521,"enrollment":8254,"conditions":8255,"interventions":8256},"NCT06307717","Effects of Volatile Anaesthetics on Incidence of Postoperative Depression and Anxiety in Elderly Patients",[],"2021-10-31",8000,[7634],[8235],{"intervention":7739,"totalTrials":114,"cells":8258},{"EARLY_PHASE1":8259,"PHASE1":8261,"PHASE2":8263,"PHASE3":8265,"PHASE4":8267,"NA":8269},{"trials":8260,"activeCount":98},[],{"trials":8262,"activeCount":98},[],{"trials":8264,"activeCount":98},[],{"trials":8266,"activeCount":98},[],{"trials":8268,"activeCount":98},[],{"trials":8270,"activeCount":98},[8271],{"nctId":7732,"briefTitle":7733,"status":625,"phases":8272,"primaryCompletion":7735,"completion":6095,"start":3289,"enrollment":7736,"conditions":8273,"interventions":8274},[90],[7728],[7707,7730,7739],{"intervention":8276,"totalTrials":114,"cells":8277},"Ticagrelor",{"EARLY_PHASE1":8278,"PHASE1":8280,"PHASE2":8282,"PHASE3":8284,"PHASE4":8286,"NA":8288},{"trials":8279,"activeCount":98},[],{"trials":8281,"activeCount":98},[],{"trials":8283,"activeCount":98},[],{"trials":8285,"activeCount":98},[],{"trials":8287,"activeCount":98},[],{"trials":8289,"activeCount":98},[8290],{"nctId":8291,"briefTitle":8292,"status":625,"phases":8293,"primaryCompletion":1036,"completion":1036,"start":2559,"enrollment":174,"conditions":8294,"interventions":8295},"NCT02798874","Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction",[90],[3632],[8276,8296],"Clopidogrel",{"intervention":8296,"totalTrials":114,"cells":8298},{"EARLY_PHASE1":8299,"PHASE1":8301,"PHASE2":8303,"PHASE3":8305,"PHASE4":8307,"NA":8309},{"trials":8300,"activeCount":98},[],{"trials":8302,"activeCount":98},[],{"trials":8304,"activeCount":98},[],{"trials":8306,"activeCount":98},[],{"trials":8308,"activeCount":98},[],{"trials":8310,"activeCount":98},[8311],{"nctId":8291,"briefTitle":8292,"status":625,"phases":8312,"primaryCompletion":1036,"completion":1036,"start":2559,"enrollment":174,"conditions":8313,"interventions":8314},[90],[3632],[8276,8296],{"intervention":8316,"totalTrials":114,"cells":8317},"Ezetimibe with simvastatin",{"EARLY_PHASE1":8318,"PHASE1":8320,"PHASE2":8322,"PHASE3":8324,"PHASE4":8326,"NA":8328},{"trials":8319,"activeCount":98},[],{"trials":8321,"activeCount":98},[],{"trials":8323,"activeCount":98},[],{"trials":8325,"activeCount":98},[],{"trials":8327,"activeCount":98},[],{"trials":8329,"activeCount":98},[8330],{"nctId":8331,"briefTitle":8332,"status":625,"phases":8333,"primaryCompletion":8334,"completion":2265,"start":3064,"enrollment":174,"conditions":8335,"interventions":8337},"NCT03771053","The Effect of Simvastatin Combined With Ezetimibe in Patients With Stable Angina and Diabetes",[90],"2019-03-31",[8336],"Coronary Heart Disease",[8316,8338],"Simvastatin",{"intervention":8338,"totalTrials":114,"cells":8340},{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8345,"PHASE3":8347,"PHASE4":8349,"NA":8351},{"trials":8342,"activeCount":98},[],{"trials":8344,"activeCount":98},[],{"trials":8346,"activeCount":98},[],{"trials":8348,"activeCount":98},[],{"trials":8350,"activeCount":98},[],{"trials":8352,"activeCount":98},[8353],{"nctId":8331,"briefTitle":8332,"status":625,"phases":8354,"primaryCompletion":8334,"completion":2265,"start":3064,"enrollment":174,"conditions":8355,"interventions":8356},[90],[8336],[8316,8338],{"intervention":8358,"totalTrials":114,"cells":8359},"rabeprazole",{"EARLY_PHASE1":8360,"PHASE1":8362,"PHASE2":8364,"PHASE3":8366,"PHASE4":8368,"NA":8370},{"trials":8361,"activeCount":98},[],{"trials":8363,"activeCount":98},[],{"trials":8365,"activeCount":98},[],{"trials":8367,"activeCount":98},[],{"trials":8369,"activeCount":98},[],{"trials":8371,"activeCount":98},[8372],{"nctId":8373,"briefTitle":8374,"status":625,"phases":8375,"primaryCompletion":4326,"completion":1036,"start":8376,"enrollment":8377,"conditions":8378,"interventions":8379},"NCT01504971","Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease",[],"2011-01",95,[8166],[8358],{"intervention":2604,"totalTrials":114,"cells":8381},{"EARLY_PHASE1":8382,"PHASE1":8384,"PHASE2":8386,"PHASE3":8388,"PHASE4":8390,"NA":8392},{"trials":8383,"activeCount":98},[],{"trials":8385,"activeCount":98},[],{"trials":8387,"activeCount":98},[],{"trials":8389,"activeCount":98},[],{"trials":8391,"activeCount":98},[],{"trials":8393,"activeCount":98},[8394],{"nctId":2597,"briefTitle":2598,"status":625,"phases":8395,"primaryCompletion":2600,"completion":2559,"start":2560,"enrollment":886,"conditions":8396,"interventions":8397},[90],[2602],[2604,2605,2606,2543],{"intervention":2605,"totalTrials":114,"cells":8399},{"EARLY_PHASE1":8400,"PHASE1":8402,"PHASE2":8404,"PHASE3":8406,"PHASE4":8408,"NA":8410},{"trials":8401,"activeCount":98},[],{"trials":8403,"activeCount":98},[],{"trials":8405,"activeCount":98},[],{"trials":8407,"activeCount":98},[],{"trials":8409,"activeCount":98},[],{"trials":8411,"activeCount":98},[8412],{"nctId":2597,"briefTitle":2598,"status":625,"phases":8413,"primaryCompletion":2600,"completion":2559,"start":2560,"enrollment":886,"conditions":8414,"interventions":8415},[90],[2602],[2604,2605,2606,2543],{"intervention":2606,"totalTrials":114,"cells":8417},{"EARLY_PHASE1":8418,"PHASE1":8420,"PHASE2":8422,"PHASE3":8424,"PHASE4":8426,"NA":8428},{"trials":8419,"activeCount":98},[],{"trials":8421,"activeCount":98},[],{"trials":8423,"activeCount":98},[],{"trials":8425,"activeCount":98},[],{"trials":8427,"activeCount":98},[],{"trials":8429,"activeCount":98},[8430],{"nctId":2597,"briefTitle":2598,"status":625,"phases":8431,"primaryCompletion":2600,"completion":2559,"start":2560,"enrollment":886,"conditions":8432,"interventions":8433},[90],[2602],[2604,2605,2606,2543],{"intervention":8435,"totalTrials":114,"cells":8436},"dinitrophenyl",{"EARLY_PHASE1":8437,"PHASE1":8439,"PHASE2":8441,"PHASE3":8443,"PHASE4":8445,"NA":8447},{"trials":8438,"activeCount":98},[],{"trials":8440,"activeCount":98},[],{"trials":8442,"activeCount":98},[],{"trials":8444,"activeCount":98},[],{"trials":8446,"activeCount":98},[],{"trials":8448,"activeCount":98},[8449],{"nctId":8450,"briefTitle":8451,"status":824,"phases":8452,"primaryCompletion":8453,"completion":2558,"start":8454,"enrollment":4329,"conditions":8455,"interventions":8457},"NCT02372708","Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy",[],"2012-05","2008-08",[8456],"Melanoma",[8435],{"intervention":8459,"totalTrials":114,"cells":8460},"Perflubutane Microspheres for",{"EARLY_PHASE1":8461,"PHASE1":8463,"PHASE2":8465,"PHASE3":8467,"PHASE4":8469,"NA":8471},{"trials":8462,"activeCount":98},[],{"trials":8464,"activeCount":98},[],{"trials":8466,"activeCount":98},[],{"trials":8468,"activeCount":98},[],{"trials":8470,"activeCount":98},[],{"trials":8472,"activeCount":98},[8473],{"nctId":8474,"briefTitle":8475,"status":625,"phases":8476,"primaryCompletion":8477,"completion":8477,"start":8478,"enrollment":8479,"conditions":8480,"interventions":8482},"NCT04961775","A Prospective Multi-center Study on Using Sonazoid Diagnose Early Stage Endometrial Cancer",[],"2021-08-01","2020-10-01",277,[8481],"Endometrial Carcinoma Stage I",[8459],{"intervention":8484,"totalTrials":114,"cells":8485},"Repaglinide",{"EARLY_PHASE1":8486,"PHASE1":8488,"PHASE2":8490,"PHASE3":8492,"PHASE4":8494,"NA":8496},{"trials":8487,"activeCount":98},[],{"trials":8489,"activeCount":98},[],{"trials":8491,"activeCount":98},[],{"trials":8493,"activeCount":98},[],{"trials":8495,"activeCount":98},[],{"trials":8497,"activeCount":98},[8498],{"nctId":8499,"briefTitle":8500,"status":625,"phases":8501,"primaryCompletion":8502,"completion":4399,"start":8503,"enrollment":1039,"conditions":8504,"interventions":8505},"NCT00832481","Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions",[90],"2009-10","2009-01",[2745],[8484,8506],"Metformin",{"intervention":8506,"totalTrials":114,"cells":8508},{"EARLY_PHASE1":8509,"PHASE1":8511,"PHASE2":8513,"PHASE3":8515,"PHASE4":8517,"NA":8519},{"trials":8510,"activeCount":98},[],{"trials":8512,"activeCount":98},[],{"trials":8514,"activeCount":98},[],{"trials":8516,"activeCount":98},[],{"trials":8518,"activeCount":98},[],{"trials":8520,"activeCount":98},[8521],{"nctId":8499,"briefTitle":8500,"status":625,"phases":8522,"primaryCompletion":8502,"completion":4399,"start":8503,"enrollment":1039,"conditions":8523,"interventions":8524},[90],[2745],[8484,8506],{"intervention":8526,"totalTrials":114,"cells":8527},"NKT cells",{"EARLY_PHASE1":8528,"PHASE1":8530,"PHASE2":8532,"PHASE3":8534,"PHASE4":8536,"NA":8538},{"trials":8529,"activeCount":98},[],{"trials":8531,"activeCount":98},[],{"trials":8533,"activeCount":98},[],{"trials":8535,"activeCount":98},[],{"trials":8537,"activeCount":98},[],{"trials":8539,"activeCount":98},[8540],{"nctId":8541,"briefTitle":8542,"status":625,"phases":8543,"primaryCompletion":2559,"completion":4361,"start":2742,"enrollment":2590,"conditions":8544,"interventions":8550},"NCT01801852","Autologous Natural Killer T Cells Infusion for the Treatment of Cancer",[90],[2574,8545,8546,8547,29,8548,8549],"Glioma","Hepatocellular Cancer","Squamous Cell Lung Cancer","Colon Cancer","Prostate Cancer",[8526],{"intervention":2619,"totalTrials":114,"cells":8552},{"EARLY_PHASE1":8553,"PHASE1":8555,"PHASE2":8557,"PHASE3":8559,"PHASE4":8561,"NA":8563},{"trials":8554,"activeCount":98},[],{"trials":8556,"activeCount":98},[],{"trials":8558,"activeCount":98},[],{"trials":8560,"activeCount":98},[],{"trials":8562,"activeCount":98},[],{"trials":8564,"activeCount":98},[8565],{"nctId":2608,"briefTitle":2609,"status":824,"phases":8566,"primaryCompletion":2611,"completion":2612,"start":2613,"enrollment":2614,"conditions":8567,"interventions":8568},[90],[2616,2617,2573],[2619,2527],{"intervention":8570,"totalTrials":114,"cells":8571},"Empagliflozin",{"EARLY_PHASE1":8572,"PHASE1":8574,"PHASE2":8576,"PHASE3":8578,"PHASE4":8580,"NA":8582},{"trials":8573,"activeCount":98},[],{"trials":8575,"activeCount":98},[],{"trials":8577,"activeCount":98},[],{"trials":8579,"activeCount":98},[],{"trials":8581,"activeCount":98},[],{"trials":8583,"activeCount":98},[8584],{"nctId":8585,"briefTitle":8586,"status":625,"phases":8587,"primaryCompletion":7927,"completion":4506,"start":3869,"enrollment":8588,"conditions":8589,"interventions":8590},"NCT03591991","Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI",[90],128,[8124],[8570],{"intervention":8592,"totalTrials":114,"cells":8593},"5-Alpha Reductase Inhibitors",{"EARLY_PHASE1":8594,"PHASE1":8596,"PHASE2":8598,"PHASE3":8600,"PHASE4":8602,"NA":8604},{"trials":8595,"activeCount":98},[],{"trials":8597,"activeCount":98},[],{"trials":8599,"activeCount":98},[],{"trials":8601,"activeCount":98},[],{"trials":8603,"activeCount":98},[],{"trials":8605,"activeCount":98},[8606],{"nctId":8607,"briefTitle":8608,"status":824,"phases":8609,"primaryCompletion":4588,"completion":4588,"start":8610,"enrollment":8611,"conditions":8612,"interventions":8615},"NCT07196280","Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies",[],"2012-01-01",10000,[8613,8614],"Atherosclerotic Cardiovascular Disease (ASCVD)","Benign Prostatic Hypertrophy (BPH)",[8592],{"intervention":8617,"totalTrials":114,"cells":8618},"Nicotine patch",{"EARLY_PHASE1":8619,"PHASE1":8621,"PHASE2":8623,"PHASE3":8625,"PHASE4":8627,"NA":8629},{"trials":8620,"activeCount":98},[],{"trials":8622,"activeCount":98},[],{"trials":8624,"activeCount":98},[],{"trials":8626,"activeCount":98},[],{"trials":8628,"activeCount":98},[],{"trials":8630,"activeCount":98},[8631],{"nctId":8632,"briefTitle":8633,"status":625,"phases":8634,"primaryCompletion":3603,"completion":3507,"start":8635,"enrollment":8636,"conditions":8637,"interventions":8639},"NCT01935505","Study on the Model of Smoking Cessation Intervention and Service Ability Improvement",[],"2008-10",2000,[8638],"Smoking Cessation",[8617],{"intervention":8641,"totalTrials":114,"cells":8642},"GLP-1",{"EARLY_PHASE1":8643,"PHASE1":8645,"PHASE2":8647,"PHASE3":8649,"PHASE4":8651,"NA":8653},{"trials":8644,"activeCount":98},[],{"trials":8646,"activeCount":98},[],{"trials":8648,"activeCount":98},[],{"trials":8650,"activeCount":98},[],{"trials":8652,"activeCount":98},[],{"trials":8654,"activeCount":98},[8655],{"nctId":8656,"briefTitle":8657,"status":625,"phases":8658,"primaryCompletion":3717,"completion":3717,"start":7276,"enrollment":1183,"conditions":8659,"interventions":8660},"NCT02577848","GLP-1 on Non-ST-Segment Elevation Myocardial Infarction",[90],[3266],[8641],{"intervention":8662,"totalTrials":114,"cells":8663},"Jin Youli",{"EARLY_PHASE1":8664,"PHASE1":8666,"PHASE2":8668,"PHASE3":8670,"PHASE4":8672,"NA":8674},{"trials":8665,"activeCount":98},[],{"trials":8667,"activeCount":98},[],{"trials":8669,"activeCount":98},[],{"trials":8671,"activeCount":98},[],{"trials":8673,"activeCount":98},[],{"trials":8675,"activeCount":98},[8676],{"nctId":8677,"briefTitle":8678,"status":625,"phases":8679,"primaryCompletion":8680,"completion":8681,"start":8682,"enrollment":16,"conditions":8683,"interventions":8685},"NCT04518800","PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer",[90],"2021-08-18","2022-02-18","2020-08-18",[8684,29],"PEG-rhG-CSF",[8662],{"intervention":8687,"totalTrials":114,"cells":8688},"Administration of methylprednisolone sodium succinate during general anesthesia induction",{"EARLY_PHASE1":8689,"PHASE1":8691,"PHASE2":8693,"PHASE3":8695,"PHASE4":8697,"NA":8699},{"trials":8690,"activeCount":98},[],{"trials":8692,"activeCount":98},[],{"trials":8694,"activeCount":98},[],{"trials":8696,"activeCount":98},[],{"trials":8698,"activeCount":98},[],{"trials":8700,"activeCount":98},[8701],{"nctId":8702,"briefTitle":8703,"status":824,"phases":8704,"primaryCompletion":8705,"completion":3262,"start":3869,"enrollment":8706,"conditions":8707,"interventions":8709},"NCT07271394","The Impact of Methylprednisolone Sodium Succinate on Postoperative Delirium in Elderly Patients Undergoing Abdominal Surgery: A Target Trial Emulation Study",[],"2020-09-30",25800,[8708],"Postoperative Delirium (POD)",[8687,8710],"No administration of methylprednisolone sodium succinate during general anesthesia induction",{"intervention":8710,"totalTrials":114,"cells":8712},{"EARLY_PHASE1":8713,"PHASE1":8715,"PHASE2":8717,"PHASE3":8719,"PHASE4":8721,"NA":8723},{"trials":8714,"activeCount":98},[],{"trials":8716,"activeCount":98},[],{"trials":8718,"activeCount":98},[],{"trials":8720,"activeCount":98},[],{"trials":8722,"activeCount":98},[],{"trials":8724,"activeCount":98},[8725],{"nctId":8702,"briefTitle":8703,"status":824,"phases":8726,"primaryCompletion":8705,"completion":3262,"start":3869,"enrollment":8706,"conditions":8727,"interventions":8728},[],[8708],[8687,8710]]